ClickCease
+1-915-850-0900 spinedoctors@gmail.com
Select Page
Chiropractic Care: 5 Reasons For Whiplash Sufferers

Chiropractic Care: 5 Reasons For Whiplash Sufferers

Chiropractic Care: Our neck is a busy body part. It holds up and turns our head, allowing us to see, hear, and speak in the direction we choose.

Although the neck is a real “team player” it’s a bit of a diva, meaning it’s fairly delicate. There are many ways everyday motion injures the neck, ending up causing pain, decreased mobility, and varying degrees of short and long-term misery.

Whiplash is a common neck injury caused by a sudden movement that jerks the neck forth and then back in a whipping motion. Automobile accidents frequently result in whiplash, as the vehicle is moving and then stopping rapidly.

This affects the neck’s ligaments and joints in various degrees, depending on the speed of the vehicle and the site of the impact. In severe cases, the discs and the nerves may also be damaged.

Symptoms of whiplash include varying degrees of pain, stiffness in the neck, headaches, and sometimes dizziness, blurred vision, and nausea. Some people only suffer with whiplash a few days, while others experience ongoing issues.

If you have been injured in an automobile crash, it’s in your best interest to immediately schedule an appointment with a chiropractor. There are a myriad of ways chiropractic care assists in managing the pain and minimizing the symptoms of whiplash.

Here Are The 5 Best Reasons For Chiropractic Care:

chiropractic care#1: Reduces Inflammation To Promote Healing

The first order of business for whiplash sufferers is to get the neck’s inflammation reduced, as this hinders proper healing. Your chiropractor will utilize chiropractic adjustments, along with other forms of treatment based on your specific injury. It�s essential to undergo this type of treatment as soon after the injury occurs as possible in order to reach optimum results.

#2: Minimizes Pain For Greater Comfort

Whiplash can be extremely painful, as so many of the neck’s components may be involved, and the neck is such a mobile body part. Every neck movement hurting is no way to live! Chiropractic care soothes the pain of whiplash through therapeutic techniques that promote healing of the damaged area.

#3: Returns Proper Body Alignment

When the inflammation and the pain of whiplash are reduced, the next step is to promote healing and alignment within the body. A chiropractor will perform a series of chiropractic adjustments that includes the neck and spine, but may also incorporate other parts of the body. Whiplash does a number on the body’s natural alignment, and it’s the chiropractor’s job to put it all back together in workable order.

#4: Offers Exercises To Increase Mobility

Contrary to old movies where the whiplash sufferer wears a cumbersome neck brace, it’s vital to the rehabilitation process to keep moving. During chiropractic visits, patients receive a regimen of exercises to perform regularly at home. These, combined with chiropractic care, lessen the time it takes to recover.

#5: Provides An Alternative To Surgery

The good news is that a whiplash injury rarely requires surgery. However, it’s best to not tempt fate and visit a chiropractor to make certain your injuries are treated and begin healing. A chiropractor monitors improvements and keeps you apprised of your progress, empowering you to get better and back to normal activity faster than simply suffering through the symptoms, hoping they go away.

If you are involved in a motor vehicle crash and end up with whiplash, don’t despair. A chiropractor will map out a treatment regimen that will decrease inflammation and pain, increase mobility, and promote healing. Remember, the sooner you see your chiropractor, the faster the treatment begins, and the sooner you see results. Don’t suffer needlessly!

Chiropractic Care & Headaches

This article is copyrighted by Blogging Chiros LLC for its Doctor of Chiropractic members and may not be copied or duplicated in any manner including printed or electronic media, regardless of whether for a fee or gratis without the prior written permission of Blogging Chiros, LLC.

Soccer Injuries: Avoid/Treat With Chiropractic Care

Soccer Injuries: Avoid/Treat With Chiropractic Care

Soccer is one of the most popular team sports in the United States, and offers an excellent form of exercise to children and adults alike. Unfortunately, the nature of the sport, the repeated movement and the chance of collision, add up to quite a few opportunities for injury.

Lower and upper extremity injuries, overuse injuries, and head, neck, and face injuries are commonplace. According to Stanford Children’s Health, “88,000 children 8-14 were treated in an emergency room for soccer-related injuries.”

Soccer players who take certain precautionary measures decrease their chances of injury. Let�s look at three ways you can avoid injury as a soccer player:

#1: Soccer: Use Proper Equipment

Donning proper fitting cleats, uniforms, and shin guards decrease the risk of being hurt in the first place. Make adjustments often, especially if the player is growing rapidly or fluctuates in weight.

#2: Get Checked Out By A Chiropractor Pre-Season

Soccer players who allow their fitness less to lapse increase the chance of injury. Visit a Doctor of Chiropractic to ensure there are no underlying issues with participating in strenuous activity. A chiropractor is also able to make sure the spine is aligned and muscles and joints are strong and functioning properly.

#3: Pay Attention To The Surroundings

A field that is not kept up well offers a greater chance of turning an ankle or falling. It’s vital to check out the playing area beforehand and note any uneven areas that could cause a player to trip.

In addition, consider the weather. Muddy, slick fields create extra issues, and particularly hot temperatures make players run the risk of dehydration or heat stroke. Prepare for weather issues in advance of the game.

If, even though you take all of these precautions, you still end up injured, there are several options for treatment. The injury is hopefully mild and heals on its own after a few days of rest. More serious injuries require a doctor visit, and one of these three treatments.

First, ice and elevate it: Keep weight off the injured area as much as possible, and elevate it with pillows. Use an ice bag wrapped in a towel to keep down swelling and inflammation. If the injury is painful, over the counter medication helps reduce discomfort.

Then, take a break: The last decision you want to make is to begin playing too soon and re-injure yourself. With more serious injuries, sitting out of a few games, or even an entire season, is a choice that promotes healing and health. Talk to your chiropractor about the timeframe the injury needs to be able to recover correctly, and follow his or her advice.

Finally, keep your chiropractic adjustments: Chiropractors are trained in treating the neuromusculoskeletal system as a whole. Many of the injuries suffered from soccer show an improvement after a few chiropractic visits.

soccer

Spinal and joint alignment, muscle healing, and tendon relaxation are all techniques chiropractors employ to promote and hasten healing. Additionally, chiropractors give insight on valuable ways to use nutrition and exercise to keep the body functioning at optimum capacity, to avoid re-injury.

Enjoying physical activity is essential to maintain a routine that provides a healthy, active lifestyle, and joining a soccer team is a great choice for children as well as adults. Knowing the advance precautions to put in place to avoid injury will help keep you strong and safe.

If, however, you or your child end up hurt, these forms of treatment will lessen healing time and get you back in the game at full speed. So give us a call to schedule your next appointment before you get back out on the pitch.

Chiropractic Treatment For Concussions

This article is copyrighted by Blogging Chiros LLC for its Doctor of Chiropractic members and may not be copied or duplicated in any manner including printed or electronic media, regardless of whether for a fee or gratis without the prior written permission of Blogging Chiros, LLC.

Comparison of Chiropractic & Hospital Outpatient Care for Back Pain

Comparison of Chiropractic & Hospital Outpatient Care for Back Pain

Back pain is one of the most common causes people visit their healthcare professional every year. A primary care physician is often the first doctor who can provide treatment for a variety of injuries and/or conditions, however, among those individuals seeking complementary and alternative treatment options for back pain, most people choose chiropractic care. Chiropractic care focuses on the diagnosis, treatment and prevention of trauma and disease of the musculoskeletal and nervous systems, by correcting misalignments of the spine through the use of spinal adjustments and manual manipulations.

 

Approximately 35% of individuals seek chiropractic treatment for back pain caused by automobile accidents, sports injuries, and a variety of muscle strains. When people suffer an trauma or injury as a result of an accident, however, they may first receive treatment for their symptoms of back pain in a hospital. Hospital outpatient care describes treatment which does not require an overnight stay at a medical facility. A research study conducted an analysis comparing the effects of chiropractic care and hospital outpatient management for back pain. The results are described in detail below.

 

Abstract

 

Objective: To compare the effectiveness over three years of chiropractic and hospital outpatient management for low back pain.

 

Design: Randomised allocation of patients to chiropractic or hospital outpatient management.

 

Setting: Chiropractic clinics and hospital outpatient departments within reasonable travelling distance of each other in I I centres.

 

Subjects: 741 men and women aged 18-64 years with low back pain in whom manipulation was not contraindicated.

 

Outcome measures: Change in total 0swestry questionnaire score and in score for pain and patient satisfaction with allocated treatment.

 

Results: According to total 0swestry scores improvement in all patients at three years was about 291/6 more in those treated by chiropractors than in those treated by the hospitals. The beneficial effect of chiropractic on pain was particularly clear. Those treated by chiropractors had more further treatments for back pain after the completion of trial treatment. Among both those initially referred from chiropractors and from hospitals more rated chiropractic helpful at three years than hospital management.

 

Conclusions: At three years the results confirm the findings of an earlier report that when chiropractic or hospital therapists treat patients with low back pain as they would in day to day practice those treated by chiropractic derive more benefit and long term satisfaction than those treated by hospitals.

 

Introduction

 

In 1990 we reported greater improvement in patients with low back pain treated by chiropractic compared with those receiving hospital outpatient management. The trial was “pragmatic” in allowing the therapists to treat patients as they would in day to day practice. At the time of our first report not all patients had been in the trial for more than six months. This paper presents the full results up to three years for all patients for whom follow up information from Oswestry questionnaires and for other outcomes was available for analysis. We also present data on pain from the questionnaire, which is by definition the main complaint prompting referral or self referral.

 

Image 1 Comparison of Chiropractic & Hospital Outpatient Care for Back Pain

 

Methods

 

Methods were fully described in our first report. Patients initially referred or presenting either to a chiropractic clinic or in hospital were randomly allocated to be treated either by chiropractic or in hospital. A total of 741 patients started treatment. Progress was measured with the Oswestry questionnaire on back pain, which gives scores for I 0 sections for example, intensity of pain and difficulty with lifting, walking, and travelling. The result is expressed on a scale ranging from 0 (no pain or difficulties) to 100 (highest score for pain and greatest difficulty on all items). For an individual item, such as pain, scores range from 0 to 10. The main outcome measures are the changes in Oswestry score from before treatment to each follow up. At one, two, and three years patients were also asked about further treatment since the completion of their trial treatment or since the previous annual questionnaire. At the three year follow up patients were asked whether they thought their allocated trial treatment had helped their back pain.

 

In the random allocation of treatment minimisation was used within each centre to establish groups for the analysis of results according to initial referral clinic, length of current episode (more or less than ‘a month), presence or absence of a history of back pain, and an Oswestry score at entry of > 40 or <=40%.

 

Results were analysed on an intention to treat basis (subject to the availability of data at follow up as well as at entry for individual patients). Differences between mean changes were tested by unpaired t tests, and X2 tests were used to test for differences in proportions between the two treatment groups.

 

dr-jimenez_white-coat_no-background.png

Dr. Alex Jimenez’s Insight

Chiropractic is a natural form of health care which purpose is to restore and maintain the function of the musculoskeletal and nervous systems, promoting spinal health and allowing the body to heal itself naturally. Our philosophy emphasizes on the treatment of the human body as a whole, rather than on the treatment of a single injury and/or condition. As an experienced chiropractor, my goal is to properly assess patients in order to determine which type of treatment will most effectively heal their individual type of health issue. From spinal adjustments and manual manipulations to physical activity, chiropractic care can help correct spinal misalignments that cause back pain.

 

Results

 

Follow up Oswestry questionnaires were returned by a consistently higher proportion of patients allocated to chiropractic than to hospital treatment. At six weeks, for example, they were returned by 95% and 89% of chiropractic and hospital patients, respectively and at three years by 77% and 70%.

 

Mean (SD) scores before treatment were 29-8 (14-2) and 28-5 (14-1) in the chiropractic and hospital treatment groups, respectively. Table I shows the differences between the mean changes in total Oswestry scores according to randomly allocated treatment group. The difference at each follow up is the mean change for the chiropractic group minus the mean change for the hospital group.

 

Table 1 Differences Between Mean Changes in Oswestry Scores

 

Positive differences therefore reflect more improvement (due to a greater change in score) in those treated by chiropractic than in hospital (negative differences the reverse). The 3-18 percentage point difference at three years in table I represents a 29% greater improvement in patients treated with chiropractic compared with hospital treatment, the absolute improvement in the two groups at this time being 14-1 and 10-9 percentage points, respectively. As in the first report those with short current episodes, a history of back pain, and initially high Oswestry scores tended to derive most benefit from chiropractic. Those referred by chiropractors consistently derived more benefit from chiropractic than those referred by hospitals.

 

Table II shows changes between the scores on pain intensity before treatment and the corresponding scores at the various follow up intervals. All these changes were positive that is, indicated improvement but were all significantly greater in those treated by chiropractic, including the changes early on that is, at six weeks and six months, when the proportions returning questionnaires were high. As with the results based on the full Oswestry score the improvement due to chiropractic was greatest in those initially referred by chiropractors, although there was also a non-significant improvement (ranging from 9% at six months to 34% at three years) due to chiropractic at each follow up interval in those referred by hospitals.

 

Table 2 Changes in Scores from Section on Pain Intensity in Oswestry Questionnaire

 

Other scores for individual items on the Oswestry index to show significant improvement attributable to chiropractic were ability to sit for more than a short time and sleeping (P=0’004 and 0 03, respectively, at three years), though the differences were not as consistent as for pain. Other scores (personal care, lifting, walking, standing, sex life, social life, and travelling) also nearly all improved more in the patients treated with chiropractic, though most of the differences were small compared with the differences for pain.

 

Higher proportions of patients allocated to chiropractic sought further treatment (of any kind) for back pain after completion of trial treatment than those managed in hospital. For example, between one and two years after trial entry 122/292 (42%) patients treated with chiropractic compared with 80/258 (3 1%) of hospital treated patients did so (Xl=6 8, P=0 0 1).

 

Table III shows the proportions of patients at three years who thought their allocated trial treatment had helped their back pain. Among those initially referred by hospitals as well as among those initially referred by chiropractors higher proportions treated by chiropractic considered that treatment had helped compared with those treated in hospital.

 

Table 3 Number of Patients at Three Year Follow Up

 

Key Messages

 

  • Back pain often remits spontaneously
  • Effective treatments for non-remitting episodes need to be more clearly identified
  • Chiropractic seems to be more effective than hospital management, possibly because more treatments are spread over longer time periods
  • A growing number of NHS purchasers are making complementary treatments, including chiropractic, available
  • Further trials to identify the effective components of chiropractic are needed

 

Discussion

 

The results at six weeks and six months shown in table I are identical with those in our first report, as all patients had then been followed up for six months. The findings at one year are similar as many patients had also been followed up then. The considerably larger numbers of patients with data now available at two and three years show smaller benefits at these intervals than previously, though these still significantly favour chiropractic. The substantial benefit of chiropractic on intensity of pain is evident early on and then persists. The consistently larger proportions lost to follow up throughout the trial in those treated in hospital than in those treated by chiropractic suggests greater satisfaction with chiropractic. This conclusion is supported (table III) by the higher proportions in each referral group considering chiropractic helpful by comparison with hospital treatment.

 

Image of medical researchers recording clinical findings on the results of low back pain treatment.

 

The main criticism of the trial after our first report centred on its “pragmatic” nature, particularly the larger number of chiropractic than hospital treatments and the longer period over which the chiropractic treatments were spread and which were deliberately allowed. These considerations and any consequences of the higher proportions of patients allocated to chiropractic who received further treatment in the later stages of follow up, however, do not apply to the results at six weeks and only apply to a limited extent at six months, when the proportions followed up were high and extra treatment had either not occurred at all or was not yet extensive. Benefits atributable to chiropractic were already evident (especially on pain, table II) at these shorter intervals.

 

We believe there is now more support for the need for “fastidious” trials focusing on specific components of management and on their feasibility. Meanwhile, the results of our trial show that chiropractic has a valuable part to play in the management of low back pain.

 

We thank Dr Iain Chalmers for commenting on an earlier draft of the paper. We thank the nurse coordinators, medical staff, physiotherapists, and chiropractors in the 11 centres for their work, and Dr Alan Breen of the British Chiropractic Association for his help. The centres were in Harrow Taunton, Plymouth, Bournemouth and Poole, Oswestry, Chertsey, Liverpool, Chelmsford, Birmingham, Exeter, and Leeds. Without the assistance of many staff members in each the trial could not have been completed.

 

Funding: Medical Research Council, the National Back Pain Association, the European Chiropractors Union, and the King Edward’s Hospital Fund for London.

 

Conflict of interest: None.

 

In conclusion,�after three years, the results of the research study comparing chiropractic care and hospital outpatient management for low back pain determined that people treated by chiropractic experienced more benefits as well as long-term satisfaction than those treated by hospitals. Because back pain is one of the most common�causes people visit their healthcare professional every year, its essential to seek the most effective type of health care. Information referenced from the National Center for Biotechnology Information (NCBI). The scope of our information is limited to chiropractic as well as to spinal injuries and conditions. To discuss the subject matter, please feel free to ask Dr. Jimenez or contact us at 915-850-0900 .

 

Curated by Dr. Alex Jimenez

 

References

 

  1. Meade TW, Dyer S, Browne W, Townsend J, Frank AO. Low back pain of mechanical origin: randomised comparison of chiropractic and hospital outpatient treatment.�BMJ.�1990 Jun 2;300(6737):1431�1437.�[PMC free article][PubMed]
  2. Fairbank JC, Couper J, Davies JB, O’Brien JP. The Oswestry low back pain disability questionnaire.�Physiotherapy.�1980 Aug;66(8):271�273.�[PubMed]
  3. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.�Biometrics.�1975 Mar;31(1):103�115.�[PubMed]

 

Green-Call-Now-Button-24H-150x150-2-3.png

 

Additional Topics: Sciatica

 

Sciatica is referred to as a collection of symptoms rather than a single type of injury or condition. The symptoms are characterized as radiating pain, numbness and tingling sensations from the sciatic nerve in the lower back, down the buttocks and thighs and through one or both legs and into the feet. Sciatica is commonly the result of irritation, inflammation or compression of the largest nerve in the human body, generally due to a herniated disc or bone spur.

 

blog picture of cartoon paperboy big news

 

IMPORTANT TOPIC: EXTRA EXTRA: Treating Sciatica Pain

 

 

Genetically Modified (GM) Food Nation: The History

Genetically Modified (GM) Food Nation: The History

The late nineties were an era of strong debate on the issue of genetically modified food and organisms in the UK. Controversy surrounded both the scientific and political aspects of GM, with government advisory bodies being accused of biased behavior and concerns being raised over the ethical issues of the science behind GM. At lunch, a bowl of good vegetable-based soup (home-made or Simply Organic�s naturally!) counts for another 1 or 2 portions and each one of our Pure & Pronto ready meals counts for a whopping 3 portions. Add a piece of fruit or two during the day and a salad or veg in the evening and you�re already at 6 or 7 portions of fruit and veg for the day � well above the 5.

At the same time there was substantial media coverage of scientific advances including cloning and the BSE crisis that fueled public concern into the governance of such issues. It was in this climate of debate, concern and contestation that the UK Government launched GM Nation, a national debate about the future of genetically modified crops and food in the UK.

Objectives: Genetically Modified Foods

geneticallyThe stated aims of the GM Nation debate were twofold: to promote an innovative, effective and deliberative program of debate on GM issues, framed by the public, against the background of the possible commercial production of GM crops in the UK and the options for possibly proceeding with this; and through the debate provide meaningful information to Government about the nature and spectrum of the public views, particularly at grass roots level, on the issue to inform decision-making.

We aim to develop business performance by ensuring the effectiveness and efficiency of people development relevant to our industry.

Eat your fruit and veg � you�re aiming for at least 5 portions a day but it�s not as hard as you might think. A glass of pure fruit juice and a handful of dried fruit added to your cereal at breakfast each count as 1 portion.

The focus of the debate was very much on empowering the public to lead the discussion and enabling wide participation, not just involving the usual suspects. The Agriculture and Environment Biotechnology Commission were clear in their recommendations for a wider public debate that it should not require a simple yes or no decision. Instead it stated it should “establish the nature and full spectrum of the public�s views on GM and the possible commercialization of GM crops, and any conditions it might want to impose on this”.

If you�re a journalist but you don�t like talking to pr people (even though ours are very nice), you can e-mail Chris or Gerry direct:

Is it time we faced up to the reality of GM in modern world?

The Government has given the go-ahead for the first growing trials of GM wheat. Farming Editor Peter Hall looks at the latest developments in this highly emotive topic.

The Question: Why So Much Disagreement?

There is so much disagreement about the benefits and risks of GM because there are so many different views surrounding it. Some focus on the benefits and view it as a natural development of existing plant breeding, while others say that such views do not take into account the genuine concerns of the public and that risks and benefits have not been scrutinized enough.

The debate was criticized for not having enough time or funding to give it the publicity it would need in order to reach a truly representative cross-section of the UK public, including at grass roots level. The lack of results from the scientific and economic studies meant that there was no new information available to feed into the debate. However feedback forms were generally positive about the debate and the chance to express views on such a controversial issue.

Details of Parliamentary and other events, including Labour Party Conference, the All Party Group on Advertising and the Debating Group.

Results:�Genetically Modified Foods

Those who had strong opposing views on GM and surrounding issues tended to agree with the outcomes and some did not pay too much attention to the process issues. However, independent evaluators tended to disregard the outcomes as not valid and focused on the process. The general view was therefore not a positive one. Taking these together, the Food Standards Agency outlined a precautionary, evidence-based approach, taking a case-by-case methodology for the future development of GM crops in the UK which was a component of all these different reports. They said that whilst there was no scientific case for a blanket approval of all the uses of GM, there was also no scientific case for a blanket ban on the use of genetic modification.

Written by:�History Of GM Nation Website

Chiropractic Care For The Boomers

Functional Fitness & Chiropractic Care for Back Pain

Functional Fitness & Chiropractic Care for Back Pain

In association with professional experience in fitness and chiropractic care,�symptoms of back pain have been determined to improve in people who participate in physical activity and exercise, as directed by a physiotherapist, or physical therapist, or any other healthcare professional, such as a chiropractor. Various complementary and alternative treatment options for back pain also involve the use of functional fitness therapy, however, additional evidence-based research studies on the effectiveness of physical activity and exercise are still needed.

 

On a personal note, chiropractic care utilizes spinal adjustments and manual manipulations to carefully correct misalignments on the spine, or spinal subluxations. Along with chiropractic treatment, a doctor of chiropractor may also recommend a series of stretches and exercises to help increase flexibility, strength and mobility, improving the overall function of the spine. Physical activity for low back pain has been evaluated in the randomized controlled trial below.

Abstract

 

Objective

 

To evaluate effectiveness of an exercise programme in a community setting for patients with low back pain to encourage a return to normal activities.

 

Design

 

Randomised controlled trial of progressive exercise programme compared with usual primary care management. Patients� preferences for type of management were elicited independently of randomisation.

 

Participants

 

187 patients aged 18-60 years with mechanical low back pain of 4 weeks to 6 months� duration.

 

Interventions

 

Exercise classes led by a physiotherapist that included strengthening exercises for all main muscle groups, stretching exercises, relaxation session, and brief education on back care. A cognitive-behavioural approach was used.

 

Main Outcome Measures

 

Assessments of debilitating effects of back pain before and after intervention and at 6 months and 1 year later. Measures included Roland disability questionnaire, Aberdeen back pain scale, pain diaries, and use of healthcare services.

 

Results

 

At 6 weeks after randomisation, the intervention group improved marginally more than the control group on the disability questionnaire and reported less distressing pain. At 6 months and 1 year, the intervention group showed significantly greater improvement in the disability questionnaire score (mean difference in changes 1.35, 95% confidence interval 0.13 to 2.57). At 1 year, the intervention group also showed significantly greater improvement in the Aberdeen back pain scale (4.44, 1.01 to 7.87) and reported only 378 days off work compared with 607 in the control group. The intervention group used fewer healthcare resources. Outcome was not influenced by patients� preferences.

 

Conclusions

 

The exercise class was more clinically effective than traditional general practitioner management, regardless of patient preference, and was cost effective.

 

Key Messages

 

  • Patients with back pain need to return to normal activities as soon as possible but are often afraid that movement or activity may be harmful
  • An exercise programme led by a physiotherapist in the community and based on cognitive-behavioural principles helped patients to cope better with their pain and function better even one year later
  • Patients� preferences for type of management did not affect outcome
  • Patients in the intervention group tended to use fewer healthcare resources and took fewer days off work
  • This type of exercise programme should be more widely available

 

Introduction

 

Low back pain is common and, although it may settle quickly, recurrence rates are about 50% in the following 12 months. Recent management guidelines recommend that an early return to physical activities should be encouraged, but patients are often afraid of movement after an acute onset of back pain. Trials of specific exercise programmes for acute back pain have not shown them to be effective, but a specific exercise programme may have to be tailored to suit the individual patient and so is less likely to be effective for a heterogeneous group of patients.

 

However, there is some evidence that a general exercise programme, which aims to increase individuals� confidence in the use of their spine and overcome the fear of physical activity, can be effective for patients with chronic back pain (of more than six months� duration). A recent randomised trial of a supervised exercise programme in a hospital setting reported significantly better outcomes at six months and two years for the exercise group compared with the control group. Whether this approach would be effective and cost effective for patients with low back pain of less than six months� duration in a primary care setting is unknown.

 

Image 1 Exercise Classes for Back Pain

 

An important methodological problem occurs when it is not possible to blind subjects to the treatment they receive, since outcome is probably directly influenced by their preconceived ideas regarding the effectiveness of intervention. Thus, in trials where a double blind procedure is not feasible, participants who are not randomised to their treatment of choice may be disappointed and suffer from resentful demoralisation, whereas those randomised to their preferred treatment may have a better outcome irrespective of the physiological efficacy of the intervention. However, this problem may be partly ameliorated if patients� treatment preferences are elicited before randomisation, so that they can be used to inform the analysis of costs and outcomes.

 

In this paper, we report a fully randomised trial for the treatment of subacute low back pain in which the analysis was informed by patient preference.

 

Subjects and Methods

 

Recruitment of Subjects

 

Eighty seven general practitioners agreed to participate in the study, and the principal investigator (JKM) visited each practice to discuss participation. Selection of general practitioners was based in the York area and restricted by the need to provide easy access for patients to the classes. Only one invited practice declined to participate. Single handed practices were not invited. The general practitioners referred patients directly to the research team or sent a monthly list of patients who had consulted with back pain. Inclusion criteria were patients with mechanical low back pain of at least four weeks� duration but less than six months, aged between 18 and 60, declared medically fit by their general practitioner to undertake the exercise, and who had consulted one of the general practitioners participating in the study. Patients with any potentially serious pathology were excluded, as were any who would have been unable to attend or participate in the classes. The exclusion criteria were the same as described by Frost et al except that concurrent physiotherapy rather than previous physiotherapy was an exclusion criterion in this trial.

 

Evaluation

 

Patients who seemed eligible were contacted by telephone and if they were interested in participating in the study were invited to an initial interview, at which the study and its implications for participants were explained. Patients who met all the eligibility criteria and consented to participate attended a first assessment a week later.

 

Image 2 Physical Examination for Back Pain

 

This included a physical examination (to exclude possible serious spinal pathology) and collection of baseline data by means of validated measures of health status. The main outcome measures were the Roland back pain disability questionnaire, which measures functional limitations due to back pain, and the Aberdeen back pain scale, which is more a measure of clinical status. The Roland disability questionnaire consists of a 24 point scale: a patient scoring three points on the scale means that he or she reports, for example, �Because of my back I am not doing any of the jobs that I usually do around the house, I use a handrail to get upstairs, and I lie down to rest more often.� We also administered the EuroQoL health index (EQ-5D) and the fear and avoidance beliefs questionnaire (FABQ).

 

The second assessment was carried out at the patients� general practice six weeks after randomisation to treatment. The brief physical examination was repeated, and the patients were asked to complete the same outcome questionnaires.

 

In addition, patients were asked to complete pain diaries in the week before their first assessment and in the week before their second assessment. The diaries were used to assess subjective pain reports and asked �How strong is the pain?� and �How distressing is the pain?�

 

We also evaluated patients at six and 12 months� follow up by sending them outcome questionnaires to complete and return.

 

Randomisation and Treatments

 

A pre-prepared randomisation list was generated from a random numbers table and participants were stratified by practice in blocks of six. The trial coordinator ensured concealment of allocation from the clinical researchers by providing the research physiotherapist with a sealed envelope for a named patient before baseline assessment. A note inside the envelope invited the participant either to attend exercise classes or to continue with the current advice or treatment offered by his or her general practitioner. (One of the referring general practitioners used manipulation as usual treatment on most of his patients so that up to 37 patients in each arm of the study could also have received manipulation.) Each patient had an equal chance of being allocated to the intervention or the control group. Before patients were given their envelope they were asked whether they had any preference for the treatment assignment. The participants opened the envelope after leaving the surgery.

 

Intervention group�The exercise programme consisted of eight sessions, each lasting an hour, spread out over four weeks, with up to 10 participants in each class. The programme was similar to the Oxford fitness programme and included stretching exercises, low impact aerobic exercises, and strengthening exercises aimed at all the main muscle groups. The overall aim was to encourage normal movement of the spine. No special equipment was needed. Participants were discouraged from viewing themselves as invalids and from following the precept of �Let pain be your guide.� They were encouraged to improve their individual record and were selectively rewarded with attention and praise. Although partly based on a traditional physiotherapy approach, the programme used cognitive-behavioural principles. One simple educational message encouraging self reliance was delivered at each class. Participants were told that they should regard the classes as a stepping stone to increasing their own levels of activity.

 

Controls�Patients allocated to the control group continued under the care of their doctor and in some cases were referred to physiotherapy as usual. No attempt was made to regulate the treatment they received, but it was recorded.

 

Economic Analysis

 

We recorded patients� use of healthcare services using a combination of retrospective questionnaires and prospective diary cards, which they returned at 6 and 12 months� follow up. From this information we estimated the cost of each patient�s treatment. We compared the mean costs of treatment for the two groups by using Student�s t tests and standard confidence intervals. However, as cost data were highly positively skewed, these results were checked with a non-parametric �bootstrap.� The economic evaluation addressed both costs to the NHS and the costs to society. Participants were not charged for the classes, in line with any treatment currently available on the NHS.

 

Statistical Analysis

 

Our original intention was to recruit 300 patients, which, given a standard deviation of 4, would have provided 90% power at the 5% significance level to detect a 1.5 point difference between the two groups in the mean change on the Roland disability questionnaire. However, recruitment of patients to the study proved much slower than expected, and, because of the limitations of study resources, recruiting was stopped after 187 patients had been included into the study. This smaller sample reduced the power to detect such a difference to 72%, but there was still 90% power to detect a 2 point difference in outcome.

 

Our analysis was based on intention to treat. We estimated the effects of treatment on the outcome measures by means of analysis of covariance, with the change in scores as the dependent variable and adjustment being made for baseline score and patient preference. We used Student�s t tests to analyse the data from the pain diaries as the baseline scores were quite similar.

 

Dr. Alex Jimenez’s Insight

In consideration with the research study regarding a randomized controlled trial coordinated to determine the effectiveness of functional fitness towards the improvement of low back pain, we supplement our philosophies of overall health and wellness to our patients and we make sure to take their recovery and rehabilitation to the next level. Our fitness and chiropractic care treatment goes beyond many other medically advanced methods. The proprietary treatment methods offered at our clinic promote true well-being and fitness practices with a primary goal on the calibration of the human body. The outcome measures of the randomized controlled trial on exercise for low back pain involved two groups of participants, an intervention group and a control group. The results are recorded below.

 

Results

 

Study Population

 

Of the 187 patients included in the trial, 89 were randomised to the intervention and 98 to the control group. The figure shows their progress through the trial. In both groups those with the most severe back pain at randomisation were less likely to return follow up questionnaires: the mean Roland disability questionnaire score for responders at one year follow up was 5.80 (SD 3.48) compared with a mean score of 9.06 (4.58) for non responders respectively (P=0.002).

 

Baseline Characteristics

 

The clinical and demographic characteristics of the patients in the two groups were fairly well balanced at randomisation (Table 1), although those allocated to the intervention group tended to report more disability on the Roland disability questionnaire than did the control group. Most patients (118, 63%), when asked, would have preferred to be allocated to the exercise programme. Attendance of the classes was considered quite good, with 73% of the intervention group attending between six and eight of the classes. Four people failed to attend any classes and were included in the intention to treat analysis. No patients allocated to the control group took part in the exercise programme.

 

Table 1 Baseline Characteristics of Patients with Mechanical Low Back Pain Included in Study

Table 1: Baseline characteristics of patients with mechanical low back pain included in study. Values are means (standard deviations) unless stated otherwise.

 

Clinical Outcomes

 

Table ?2 shows the mean changes in outcome measures over time, from randomisation to final follow up at one year. After adjustment for baseline scores, the intervention group showed greater decreases in all measures of back pain and disability compared with the controls. At six weeks after randomisation, patients in the intervention group reported less distressing pain than the control group (P=0.03) and a marginally significant difference on the Roland disability questionnaire scores. Other variables were not significantly different, but the differences in change were all in favour of the intervention group. At six months the difference of the mean change scores of the Roland disability questionnaire was significant, and at one year the differences in changes of both the Roland disability questionnaire and the Aberdeen back pain scale were significant (Table ?2). Most of the intervention group improved by at least three points on the Roland disability questionnaire: 53% (95% confidence interval 42% to 64%) had done so at six weeks, 60% (49% to 71%) at six months, and 64% (54% to 74%) at one year. A smaller proportion of the control group achieved this clinically important improvement: 31% (22% to 40%) at six weeks, 40% (29% to 50%) at six months, and 35% (25% to 45%) at one year.

 

Table 2 Changes in Back Pain Scores from Baseline Values in Intervention and Control Groups

Table 2: Changes in back pain scores from baseline values in intervention and control groups at 6 weeks, 6 months, and 1 year follow up.

 

Patients� Preference

 

We examined the effect of patients� baseline preference for treatment on outcome after adjusting for baseline scores and main effects. Preference did not significantly affect response to treatment. The intervention had similar effects on both costs and outcomes regardless of baseline preference. For example, the change in the Roland disability questionnaire score at 12 months in the control group was ?1.93 for patients who preferred intervention and ?1.18 for those who were indifferent (95% confidence interval of difference ?1.05 to 2.55), and in the intervention group the change in score was ?3.10 for those who preferred intervention and ?3.15 for those who were indifferent ((95% confidence interval of difference ?1.47 to 3.08). As the interaction term (preference by random allocation) was non-significant, the results shown in Table ?2 exclude the preference term.

 

Economic Evaluation

 

Patients in the intervention group tended to use fewer healthcare and other resources compared with those in the control group (Table ?3). However, the mean difference, totalling �148 per patient, was not significant: the 95% confidence interval suggests there could have been a saving of as much as �442 per patient in the intervention group or an additional cost of up to �146. Patients in the control group took a total of 607 days off work during the 12 months after randomisation compared with 378 days taken off by the intervention group.

 

Table 3 Use of Services and their Costs Associated with Back Pain in the Two Study Groups

Table 3: Use of services and their costs associated with back pain in the two study groups at 12 months follow up.

 

Discussion

 

Our results support the hypothesis that a simple exercise class can lead to long term improvements for back pain sufferers. Studies have shown that a similar programme for patients with chronic back pain can be effective in the hospital setting. In this study we show the clinical effectiveness for patients with subacute or recurrent low back pain who were referred by their general practitioner to a community programme.

 

Current management guidelines for low back pain recommend a return to physical activity and taking exercise. In particular, they recommend that patients who are not improving at six weeks after onset of back pain, which may be a higher proportion than previously realised, should be referred to a reactivation programme. The programme we evaluated fits that requirement well. It shows participants how they can safely start moving again and increase their levels of physical activity. It is simple and less costly than individual treatment.

 

It seemed to have beneficial effects even one year later, as measured by functional disability (Roland disability questionnaire) and clinical status (Aberdeen back pain scale). The mean changes in scores on these instruments were small, with many patients reporting mild symptoms on the day of entry to the trial. However, a substantially larger proportion of participants in the exercise classes gained increases of over three points on the Roland disability questionnaire at six weeks, six months, and one year, which might be clinically important. At six weeks, participants in the exercise classes reported significantly less distressing pain compared with the control group, although the intensity of pain was not significantly different. This is consistent with findings from a study of chronic back pain patients in Oxford, in which changes in distressing pain were much greater than were the changes in intensity of pain.

 

People with back pain who use coping strategies that do not avoid movement and pain have less disability. In our study the participants in the exercise classes were able to function better according to Roland disability questionnaire scores than the control group at six months and one year after randomisation to treatment, and at one year they also showed a significantly greater improvement in clinical status as measured by the Aberdeen back pain scale. This increase in differences in effect between the intervention and control groups over time is consistent with the results from long term follow up in comparable back pain trials.

 

Study Design

 

The design of this study was a conventional randomised controlled trial in that all eligible patients were randomised. However, the participants were asked to state their preferred treatment before they knew of their allocation. A study of antenatal services showed that preferences can be an important determinant of outcome, but we did not find any strong effect of preference on the outcome, although a much larger sample size would be needed to confidently exclude any modest interaction between preference and outcome. This information may be useful to clinicians in that it suggests that exercise classes are effective even in patients who are not highly motivated. Our trial design, of asking patients for their preferences at the outset, has substantial advantages over the usual patient preference design, in which costs and outcomes cannot be reliably controlled for confounding by preference.

 

Conclusions

 

Our exercise programme did not seem to influence the intensity of pain but did affect the participants� ability to cope with the pain in the short term and even more so in the longer term. It used a cognitive-behavioural model, shifting the emphasis away from a disease model to a model of normal human behaviour, and with minimal extra training a physiotherapist can run it. Patients� preferences did not seem to influence the outcome.

 

Figure 1 Flow Chart Describing Patient Progress Through the Trial

Figure 1: Flow chart describing patients’ progress through the trial.

 

Footnotes

 

Funding: This research was funded by the Arthritis Research Campaign, the Northern and Yorkshire Regional Health Authority, and the National Back Pain Association.

 

Competing interests: None declared.

 

In conclusion,�the participation of patients in functional fitness and/or exercise as recommended by a physiotherapist, or physical therapist, or any other healthcare professional, such as a chiropractor, is essential towards the improvement of their symptoms of low back pain. The exercise programme helped patients better cope with their symptoms of back pain where the intervention group showed that they used fewer healthcare resources and took fewer day off work, according to the outcome measures of the research study. Information referenced from the National Center for Biotechnology Information (NCBI). The scope of our information is limited to chiropractic as well as to spinal injuries and conditions. To discuss the subject matter, please feel free to ask Dr. Jimenez or contact us at 915-850-0900 .

 

Curated by Dr. Alex Jimenez

 

Green-Call-Now-Button-24H-150x150-2-3.png

 

Additional Topics: Sciatica

 

Sciatica is referred to as a collection of symptoms rather than a single type of injury or condition. The symptoms are characterized as radiating pain, numbness and tingling sensations from the sciatic nerve in the lower back, down the buttocks and thighs and through one or both legs and into the feet. Sciatica is commonly the result of irritation, inflammation or compression of the largest nerve in the human body, generally due to a herniated disc or bone spur.

 

blog picture of cartoon paperboy big news

 

IMPORTANT TOPIC: EXTRA EXTRA: Treating Sciatica Pain

 

 

Blank
References
1.�Croft P, editor.�Low back pain.�Oxford: Radcliffe Medical Press; 1997.
2.�Clinical Standards Advisory Group.�Back pain.�London: HMSO; 1994.
3.�Waddell G, Feder G, McIntosh A, Lewis M, Hutchinson A.�Low back pain evidence review.�London: Royal College of General Practitioners; 1996.
4.�Malmivaara A, Hakkinen U, Aro T, Heinrichs M, Koskenniemi L, Kuosma E, et al. The treatment of acute low back pain�bed rest, exercises or ordinary activity?�N Engl J Med.�1995;332:351�355.[PubMed]
5.�Faas A, Chavannes A, van Eijk JTM, Gubbels J. A randomized, placebo-controlled trial of exercise therapy in patients with acute low back pain.�Spine.�1993;18:1388�1395.�[PubMed]
6.�Frost H, Klaber Moffett J, Moser J, Fairbank J. Evaluation of a fitness programme for patients with chronic low back pain.�BMJ.�1995;310:151�154.�[PMC free article][PubMed]
7.�Frost H, Lamb S, Klaber Moffett J, Fairbank J, Moser J. A fitness programme for patients with chronic low back pain: 2 year follow-up of a randomised controlled trial.�Pain.�1998;75:273�279.�[PubMed]
8.�McPherson K, Britton A, Wennberg J. Are randomised controlled trials controlled? Patient preferences and unblind trials.�J R Soc Med.�1997;90:652�656.�[PMC free article][PubMed]
9.�Bradley C. Designing medical and educational studies.�Diabetes Care.�1993;16:509�518.�[PubMed]
10.�Clement S, Sikorski J, Wilson J, Candy B. Merits of alternative strategies for incorporating patient preferences into clinical trials must be considered carefully [letter]�BMJ.�1998;317:78.�[PubMed]
11.�Torgerson D, Klaber Moffett J, Russell I. Patient preferences in randomised trials: threat or opportunity?�J Health Serv Res Policy.�1996;1(4):194�197.�[PubMed]
12.�Roland M, Morris R. A study of the natural causes of back pain. Part 1: Development of a reliable and sensitive measure of disability in low-back pain.�Spine.�1983;8:141�144.�[PubMed]
13.�Ruta D, Garratt A, Wardlaw D, Russell I. Developing a valid and reliable measure of health outcome for patients with low back pain.�Spine.�1994;19:1887�1896.�[PubMed]
14.�Brooks R.with EuroQoL Group.�EuroQoL: the current state of play�Health Policy�19963753�72.[PubMed]
15.�Waddell G, Newton M, Henderson I, Somerville D, Main C. A fear-avoidance beliefs questionnaire (FABQ) and the role of fear-avoidance beliefs in chronic low back pain and disability.�Pain.�1993;52:157�168.�[PubMed]
16.�Jensen M, McFarland C. Increasing the reliability and validity of pain intensity measurement in chronic pain patients.�Pain.�1993;55:195�203.�[PubMed]
17.�Efron B, Tibshirani R.�An introduction to bootstrap.�New York: Chapman and Hall; 1993.
18.�Williams D, Keefe F. Pain beliefs and use of cognitive-behavioral coping strategies.�Pain.�1991;46:185�190.�[PubMed]
19.�Estlander A, Harkapaa K. Relationships between coping strategies, disability and pain levels in patients with chronic low back pain.�Scand J Behav Ther.�1989;18:56�69.
20.�Holmes J, Stevenson C. Differential effects of avoidant and attentional coping strategies on adaption to chronic and recent-onset pain.�Health Psychology.�1990;9:577�584.�[PubMed]
21.�Rosenstiel A, Keefe F. The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustments.�Pain.�1983;17:33�44.�[PubMed]
22.�Slade P, Troup J, Lethem J, Bentley G. The fear avoidance model of exaggerated pain perception II Preliminary studies of coping strategies for pain.�Behav Res Ther.�1983;21:409�416.�[PubMed]
23.�Meade T, Dyer S, Browne W, Frank A. Randomised comparison of chiropractic and hospital outpatient management for low back pain: results from extended follow up.�BMJ.�1995;311:349�351.[PMC free article][PubMed]
24.�Cherkin D, Deyo R, Battie M, Street J, Barlow W. A comparison of physical therapy, chiropractic manipulation, and provision of an educational booklet for the treatment of patients with low back pain.�N Engl J Med.�1998;339:1021�1029.�[PubMed]
Close Accordion
Non-Invasive Treatment Modalities for Back Pain

Non-Invasive Treatment Modalities for Back Pain

Attributed from a personal perspective, as a practicing chiropractor with experience on a variety of spinal injuries and conditions, back pain is one of the most common health issues reported among the general population, affecting about 8 out of 10 individuals at some point throughout their lives. While many different types of treatments are currently available to help improve the symptoms of back pain, health care based on clinical and experimental evidence has caused an impact on the type of treatment individuals will receive for their back pain. Many patients in health care are turning to non-invasive treatment modalities for their back pain as a result of growing evidence associated with its safety and effectiveness.

 

On a further note, non-invasive treatment modalities are defined as conservative procedures which do not require incision into the body, where no break in the skin is created and there is no contact with the mucosa or internal body cavity beyond a natural or artificial body orifice, or the removal of tissue. The clinical and experimental methods and results of a variety of non-invasive treatment modalities on back pain have been described and discussed in detail below.

 

Abstract

 

At present, there is an increasing international trend towards evidence-based health care. The field of low back pain (LBP) research in primary care is an excellent example of evidence-based health care because there is a huge body of evidence from randomized trials. These trials have been summarized in a large number of systematic reviews. This paper summarizes the best available evidence from systematic reviews conducted within the framework of the Cochrane Back Review Group on non-invasive treatments for non-specific LBP. Data were gathered from the latest Cochrane Database of Systematic Reviews 2005, Issue 2. The Cochrane reviews were updated with additional trials, if available. Traditional NSAIDs, muscle relaxants, and advice to stay active are effective for short-term pain relief in acute LBP. Advice to stay active is also effective for long-term improvement of function in acute LBP. In chronic LBP, various interventions are effective for short-term pain relief, i.e. antidepressants, COX2 inhibitors, back schools, progressive relaxation, cognitive�respondent treatment, exercise therapy, and intensive multidisciplinary treatment. Several treatments are also effective for short-term improvement of function in chronic LBP, namely COX2 inhibitors, back schools, progressive relaxation, exercise therapy, and multidisciplinary treatment. There is no evidence that any of these interventions provides long-term effects on pain and function. Also, many trials showed methodological weaknesses, effects are compared to placebo, no treatment or waiting list controls, and effect sizes are small. Future trials should meet current quality standards and have adequate sample size.

 

Keywords: Non-specific low back pain, Non-invasive treatment, Primary care, Effectiveness, Evidence review

 

Introduction

 

Low back pain is most commonly treated in primary health care settings. Clinical management of acute as well as chronic low back pain (LBP) varies substantially among health care providers. Also, many different primary health care professionals are involved in the management of LBP, such as general practitioners, physical therapists, chiropractors, osteopaths, manual therapists, and others. There is a need to increase consistency in the management of LBP across professions.

 

At present, there is an increasing international trend towards evidence-based health care. Within the framework of evidence-based health care, clinicians should conscientiously, explicitly, and judiciously use the best current evidence in making decisions about the care of individual patients. The field of LBP research in primary care is an excellent example of evidence-based health care because there is a huge body of evidence. At present, more than 500 randomized controlled trials (RCTs) have been published, evaluating all types of conservative and alternative treatments for LBP that are commonly used in primary care. These trials have been summarized in a large number of systematic reviews. The Cochrane Back Review Group (CBRG) offers a framework for conducting and publishing systematic reviews in the fields of back and neck pain. However, method guidelines have also been developed and published by the CBRG to improve the quality of reviews in this field and to facilitate comparison across reviews and enhance consistency among reviewers. This paper summarizes the best available evidence from systematic reviews conducted within the framework of the CBRG on non-invasive treatments for non-specific LBP.

 

Objectives

 

To determine the effectiveness of non-invasive (pharmaceutical and non-pharmaceutical) interventions compared to placebo (or sham treatment, no intervention and waiting list control) or other interventions for acute, subacute, and chronic non-specific LBP. Trials comparing various types of the same interventions (e.g. various types of NSAIDs or various types of exercises) were excluded. The evidence on complementary and alternative medicine interventions (acupuncture, botanical medicines, massage, and neuroreflexotherapy) has been published elsewhere. Evidence on surgical and other invasive interventions for LBP will be presented in another paper in the same issue of the European Spine Journal.

 

Methods

 

The results of systematic reviews conducted within the framework of the CBRG were used. Most of these reviews were published, but preliminary results from one Cochrane review on patient education (A. Engers et al., submitted for publication) that has been submitted for publication were also used. Because no Cochrane review was available, we used two recently published systematic reviews for the evidence summary on antidepressants. The Cochrane review on work conditioning, work hardening, and functional restoration was not taken into account because all trials included in this review were also included in the reviews on exercise therapy and multidisciplinary treatment. The Cochrane reviews were updated with additional trials, if available, using Clinical Evidence as source (www.clinicalevidence.com). This manuscript consists of two parts: one on evidence of pharmaceutical interventions and the other on evidence of non-pharmaceutical interventions for non-specific LBP.

 

Search Strategy and Study Selection

 

The following search strategy was used in the Cochrane reviews:

 

  1. A computer aided search of the Medline and Embase databases since their beginning.
  2. A search of the Cochrane Central Register of Controlled Trials (Central).
  3. Screening references given in relevant systematic reviews and identified trials.
  4. Personal communication with content experts in the field.

 

Two reviewers independently applied the inclusion criteria to select the potentially relevant trials from the titles, abstracts, and keywords of the references retrieved by the literature search. Articles for which disagreement existed, and articles for which title, abstract, and keywords provided insufficient information for a decision on selection were obtained to assess whether they met the inclusion criteria. A consensus method was used to resolve disagreements between the two reviewers regarding the inclusion of studies. A third reviewer was consulted if disagreements were not resolved in the consensus meeting.

 

Inclusion Criteria

 

Study design. RCTs were included in all reviews.

 

Participants. Participants of trials that were included in the systematic reviews usually had acute (less than 6 weeks), subacute (6�12 weeks), and/or chronic (12 weeks or more) LBP. All reviews included patients with non-specific LBP.

 

Interventions. All reviews included one specific intervention. Typically any comparison group was allowed, but comparisons with no treatment/placebo/waiting list controls and other interventions were separately presented.

 

Outcomes. The outcome measures included in the systematic reviews were outcomes of symptoms (e.g. pain), overall improvement or satisfaction with treatment, function (e.g. back-specific functional status), well-being (e.g. quality of life), disability (e.g. activities of daily living, work absenteeism), and side effects. Results were separately presented for short-term and long-term follow-up.

 

Methodological Quality Assessment

 

In most reviews, the methodological quality of trials included in the reviews was assessed using the criteria recommended by the CBRG. The studies were not blinded for authors, institutions, or the journals in which the studies were published. The criteria were: (1) adequate allocation concealment, (2) adequate method of randomization, (3) similarity of baseline characteristics, (4) blinding of patients, (5) blinding of care provider, (6) equal co-interventions, (7) adequate compliance, (8) identical timing of outcome assessment, (9) blinded outcome assessment, (10) withdrawals and drop outs adequate, and (11) intention-to-treat analysis. All items were scored as positive, negative, or unclear. High quality was typically defined as fulfilling 6 or more of the 11 quality criteria. We refer readers to the original Cochrane reviews for details of the quality of trials.

 

Data Extraction

 

The data that were extracted and presented in tables included characteristics of participants, interventions, outcomes, and results. We refer readers to the original Cochrane reviews for summaries of trial data.

 

Data Analysis

 

Some reviews conducted a meta-analysis using statistical methods to analyse and summarize the data. If relevant valid data were lacking (data were too sparse or of inadequate quality) or if data were statistically too heterogeneous (and the heterogeneity could not be explained), statistical pooling was avoided. In these cases, reviewers performed a qualitative analysis. In the qualitative analyses, various levels of evidence were used that took into account the participants, interventions, outcomes, and methodological quality of the original studies. If only a subset of available trials provided sufficient data for inclusion in a meta-analysis (e.g. only some trials reported standard deviations), both a quantitative and qualitative analysis was used.

 

Dr. Alex Jimenez’s Insight

The purpose of the following research study was to determine which of the various non-invasive treatment modalities used could be safe and most effective towards the prevention, diagnosis and treatment of acute, subacute and chronic non-specific low back pain, as well as general back pain. All of the systematic reviews included participants with some type of non-specific low back pain, or LBP, where each received health care for one specific intervention. The outcome measures included in the systematic reviews were based on symptoms, overall improvement or satisfaction with treatment, function, well-being, disability and side effects. The data of the results was extracted and presented in Tables 1 and 2. The researchers of the study performed a qualitative analysis of all the presented clinical and experimental data before demonstrating it in this article. As a healthcare professional, or patient with back pain, the information in this research study may help determine which non-invasive treatment modality should be considered to achieve the desired recovery outcome measures.

 

Results

 

Pharmaceutical Interventions

 

Antidepressants

 

There are three reasons for using antidepressants in the treatment of LBP. The first reason is that chronic LBP patients often also cope with depression, and treatment with antidepressants may elevate mood and increase pain tolerance. Second, many antidepressant drugs are sedating, and it has been suggested that part of their value for managing chronic pain syndromes simply could be improving sleep. The third reason for the use of antidepressants in chronic LBP patients is their supposed analgesic action, which occurs at lower doses than the antidepressant effect.

 

Effectiveness of antidepressants for acute LBP No trials were identified.

 

Effectiveness of antidepressants for chronic LBP Antidepressants versus placebo. We found two systematic reviews including a total of nine trials. One review found that antidepressants significantly increased pain relief compared with placebo but found no significant difference in functioning [pain: standardized mean difference (SMD) 0.41, 95% CI 0.22�0.61; function: SMD 0.24, 95% CI -0.21 to +0.69]. The other review did not statistically pool data but had similar results.

 

Adverse effects Adverse effects of antidepressants include dry mouth, drowsiness, constipation, urinary retention, orthostatic hypotension, and mania. One RCT found that the prevalence of dry mouth, insomnia, sedation, and orthostatic symptoms was 60�80% with tricyclic antidepressants. However, rates were only slightly lower in the placebo group and none of the differences were significant. In many trials, the reporting of side effects was insufficient.

 

Muscle Relaxants

 

The term �muscle relaxants� is very broad and includes a wide range of drugs with different indications and mechanisms of action. Muscle relaxants can be divided into two main categories: antispasmodic and antispasticity medications.

 

Antispasmodics are used to decrease muscle spasm associated with painful conditions such as LBP. Antispasmodics can be subclassified into benzodiazepines and non-benzodiazepines. Benzodiazepines (e.g. diazepam, tetrazepam) are used as anxiolytics, sedatives, hypnotics, anticonvulsants, and/or skeletal muscle relaxants. Non-benzodiazepines include a variety of drugs that can act at the brain stem or spinal cord level. The mechanisms of action with the central nervous system are still not completely understood.

 

Antispasticity medications are used to reduce spasticity that interferes with therapy or function, such as in cerebral palsy, multiple sclerosis, and spinal cord injuries. The mechanism of action of the antispasticity drugs with the peripheral nervous system (e.g. dantrolene sodium) is the blockade of the sarcoplasmic reticulum calcium channel. This reduces calcium concentration and diminishes actin�myosin interaction.

 

Effectiveness of muscle relaxants for acute LBP Benzodiazepines versus placebo. One study showed that there is limited evidence (one trial; 50 people) that an intramuscular injection of diazepam followed by oral diazepam for 5 days is more effective than placebo for patients with acute LBP on short-term pain relief and better overall improvement, but is associated with substantially more central nervous system side effects.

 

Non-benzodiazepines versus placebo. Eight studies were identified. One high quality study on acute LBP showed that there is moderate evidence (one trial; 80 people) that a single intravenous injection of 60 mg orphenadrine is more effective than placebo in immediate relief of pain and muscle spasm for patients with acute LBP.

 

Three high quality and one low quality trial showed that there is strong evidence (four trials; 294 people) that oral non-benzodiazepines are more effective than placebo for patients with acute LBP on short-term pain relief, global efficacy, and improvement of physical outcomes. The pooled RR and 95% CIs for pain intensity was 0.80 (0.71�0.89) after 2�4 days (four trials; 294 people) and 0.58 (0.45�0.76) after 5�7 days follow-up (three trials; 244 people). The pooled RR and 95% CIs for global efficacy was 0.49 (0.25�0.95) after 2�4 days (four trials; 222 people) and 0.68 (0.41�1.13) after 5�7 days follow-up (four trials; 323 people).

 

Antispasticity drugs versus placebo. Two high quality trials showed that there is strong evidence (two trials; 220 people) that antispasticity muscle relaxants are more effective than placebo for patients with acute LBP on short-term pain relief and reduction of muscle spasm after 4 days. One high quality trial also showed moderate evidence on short-term pain relief, reduction of muscle spasm, and overall improvement after 10 days.

 

Effectiveness of muscle relaxants for chronic LBP Benzodiazepines versus placebo. Three studies were identified. Two high quality trials on chronic LBP showed that there is strong evidence (two trials; 222 people) that tetrazepam 50 mg t.i.d. is more effective than placebo for patients with chronic LBP on short-term pain relief and overall improvement. The pooled RRs and 95% CIs for pain intensity were 0.82 (0.72�0.94) after 5�7 days follow-up and 0.71 (0.54�0.93) after 10�14 days. The pooled RR and 95% CI for overall improvement was 0.63 (0.42�0.97) after 10�14 days follow-up. One high quality trial showed that there is moderate evidence (one trial; 50 people) that tetrazepam is more effective than placebo on short-term decrease of muscle spasm.

 

Non-benzodiazepines versus placebo. Three studies were identified. One high quality trial showed that there is moderate evidence (one trial; 107 people) that flupirtin is more effective than placebo for patients with chronic LBP on short-term pain relief and overall improvement after 7 days, but not on reduction of muscle spasm. One high quality trial showed that there is moderate evidence (one trial; 112 people) that tolperisone is more effective than placebo for patients with chronic LBP on short-term overall improvement after 21 days, but not on pain relief and reduction of muscle spasm.

 

Adverse effects Strong evidence from all eight trials on acute LBP (724 people) showed that muscle relaxants are associated with more total adverse effects and central nervous system adverse effects than placebo, but not with more gastrointestinal adverse effects; RRs and 95% CIs were 1.50 (1.14�1.98), 2.04 (1.23�3.37), and 0.95 (0.29�3.19), respectively. The most commonly and consistently reported adverse events involving the central nervous system were drowsiness and dizziness. For the gastrointestinal tract this was nausea. The incidence of other adverse events associated with muscle relaxants was negligible.

 

NSAIDs

 

The rationale for the treatment of LBP with NSAIDs is based both on their analgesic potential and their anti-inflammatory action.

 

Effectiveness of NSAIDs for acute LBP NSAIDs versus placebo. Nine studies were identified. Two studies reported on LBP without radiation, two on sciatica, and the other five on a mixed population. There was conflicting evidence that NSAIDs provide better pain relief than placebo in acute LBP. Six of the nine studies which compared NSAIDs with placebo for acute LBP reported dichotomous data on global improvement. The pooled RR for global improvement after 1 week using the fixed effects model was 1.24 (95% CI 1.10�1.41), indicating a statistically significant effect in favour of NSAIDs compared to placebo. The pooled RR (three trials) for analgesic use using the fixed effects model was 1.29 (95% CI 1.05�1.57), indicating significantly less use of analgesics in the NSAIDs group.

 

NSAIDs versus paracetamol/acetaminophen. There were no differences between NSAIDs and paracetamol reported in two studies, but one study reported better outcomes for two of the four types of NSAIDs. There is conflicting evidence that NSAIDs are more effective than paracetamol for acute LBP.

 

NSAIDs versus other drugs. Six studies reported on acute LBP, of which five did not find any differences between NSAIDs and narcotic analgesics or muscle relaxants. Group sizes in these studies ranged from 19 to 44 and, therefore, these studies simply may have lacked power to detect a statistically significant difference. There is moderate evidence that NSAIDs are not more effective than other drugs for acute LBP.

 

Effectiveness of NSAIDs for chronic LBP NSAIDs versus placebo. One small cross-over study (n=37) found that naproxen sodium 275 mg capsules (two capsules b.i.d.) decreased pain more than placebo at 14 days.

 

COX2 inhibitors versus placebo. Four additional trials were identified. There is strong evidence that COX2 inhibitors (etoricoxib, rofecoxib and valdecoxib) decreased pain and improved function compared with placebo at 4 and 12 weeks, but effects were small.

 

Adverse effects NSAIDs may cause gastrointestinal complications. Seven of the nine studies which compared NSAIDs with placebo for acute LBP reported data on side effects. The pooled RR for side effects using the fixed effects model was 0.83 (95% CI 0.64�1.08), indicating no statistically significant difference. One systematic review of the harms of NSAIDs found that ibuprofen and diclofenac had the lowest gastrointestinal complication rate, mainly because of the low doses used in practice (pooled OR for adverse effects vs. placebo 1.30, 95% CI 0.91�1.80). COX2 inhibitors have been shown to have less gastrointestinal side effects in osteoarthritis and rheumatoid arthritis studies. However, increased cardiovascular risk (myocardial infarction and stroke) has been reported with long-term use.

 

Non-Pharmaceutical Interventions

 

Advice to Stay Active

 

Effectiveness of advice to stay active for acute LBP Stay active versus bed rest. The Cochrane review found four studies that compared advice to stay active as single treatment with bed rest. One high quality study showed that advice to stay active significantly improved functional status and reduced sick leave after 3 weeks compared with advice to rest in bed for 2 days. It also found a significant reduction of pain intensity in favour of the stay active group at intermediate follow-up (more than 3 weeks). The low quality studies showed conflicting results. The additional trial (278 people) found no significant differences in pain intensity and functional disability between advice to stay active and bed rest after 1 month. However, it found that advice to stay active significantly reduced sick leave compared with bed rest up to day 5 (52% with advice to stay active vs. 86% with bed rest; P<0.0001).

 

Stay active versus exercise. One trial found short-term improvement in functional status and reduction in sick leave in favour of advice to stay active. A significant reduction in sick leave in favour of the stay active group was also reported at long-term follow-up.

 

Effectiveness of advice to stay active for chronic LBP No trials identified.

 

Adverse effects No trials reported side effects.

 

Back Schools

 

The original �Swedish back school� was introduced by Zachrisson Forsell in 1969. It was intended to reduce the pain and prevent recurrences. The Swedish back school consisted of information on the anatomy of the back, biomechanics, optimal posture, ergonomics, and back exercises. Four small group sessions were scheduled during a 2-week period, with each session lasting 45 min. The content and length of back schools has changed and appears to vary widely today.

 

Effectiveness of back schools for acute LBP Back schools versus waiting list controls or �placebo� interventions. Only one trial compared back school with placebo (shortwaves at the lowest intensity) and showed better short-term recovery and return to work for the back school group. No other short- or long-term differences were found.

 

Back schools versus other interventions. Four studies (1,418 patients) showed conflicting evidence on the effectiveness of back schools compared to other treatments for acute and subacute LBP on pain, functional status, recovery, recurrences, and return to work (short-, intermediate-, and long-term follow-up).

 

Effectiveness of back schools for chronic LBP Back schools versus waiting list controls or �placebo� interventions. There is conflicting evidence (eight trials; 826 patients) on the effectiveness of back schools compared to waiting list controls or placebo interventions on pain, functional status, and return to work (short-, intermediate-, and long-term follow-up) for patients with chronic LBP.

 

Back schools versus other treatments. Six studies were identified comparing back schools with exercises, spinal or joint manipulation, myofascial therapy, and some kind of instructions or advice. There is moderate evidence (five trials; 1,095 patients) that a back school is more effective than other treatments for patients with chronic LBP for pain and functional status (short- and intermediate-term follow-up). There is moderate evidence (three trials; 822 patients) that there is no difference in long-term pain and functional status.

 

Adverse effects None of the trials reported any adverse effects.

 

Bed Rest

 

One rationale for bed rest is that many patients experience relief of symptoms in a horizontal position.

 

Effectiveness of bed rest for acute LBP Twelve trials were included in the Cochrane review. Some trials were on a mixed population of patients with acute and chronic LBP or on a population of patients with sciatica.

 

Bed rest versus advice to stay active. Three trials (481 patients) were included in this comparison. The results of two high quality trials showed small but consistent and significant differences in favour of staying active, at 3- to 4-week follow-up [pain: SMD 0.22 (95% CI 0.02�0.41); function: SMD 0.31 (95% CI 0.06�0.55)], and at 12-week follow-up [pain: SMD 0.25 (95% CI 0.05�0.45); function: SMD 0.25 (95% CI 0.02�0.48)]. Both studies also reported significant differences in sick leave in favour of staying active. There is strong evidence that advice to rest in bed is less effective than advice to stay active for reducing pain and improving functional status and speeding-up return to work.

 

Bed rest versus other interventions. Three trials were included. Two trials compared advice to rest in bed with exercises and found strong evidence that there was no difference in pain, functional status, or sick leave at short- and long-term follow-up. One study found no difference in improvement on a combined pain, disability, and physical examination score between bed rest and manipulation, drug therapy, physiotherapy, back school, or placebo.

 

Short bed rest versus longer bed rest. One trial in patients with sciatica reported no significant difference in pain intensity between 3 and 7 days of bed rest, measured 2 days after the end of treatment.

 

Effectiveness of bed rest for chronic LBP There were no trials identified.

 

Adverse effects No trials reported adverse effects.

 

Behavioural Treatment

 

The treatment of chronic LBP not only focuses on removing the underlying organic pathology, but also tries to reduce disability through the modification of environmental contingencies and cognitive processes. In general, three behavioural treatment approaches can be distinguished: operant, cognitive, and respondent. Each of these approaches focus on the modification of one of the three response systems that characterize emotional experiences: behaviour, cognition, and physiological reactivity.

 

Operant treatments include positive reinforcement of healthy behaviours and consequent withdrawal of attention towards pain behaviours, time-contingent instead of pain-contingent pain management, and spousal involvement. The operant treatment principles can be applied by all health care disciplines involved with the patient.

 

Cognitive treatment aims to identify and modify patients� cognitions regarding their pain and disability. Cognition (the meaning of pain, expectations regarding control over pain) can be modified directly by cognitive restructuring techniques (such as imagery and attention diversion), or indirectly by the modification of maladaptive thoughts, feelings, and beliefs.

 

Respondent treatment aims to modify the physiological response system directly, e.g. by reduction of muscular tension. Respondent treatment includes providing the patient with a model of the relationship between tension and pain, and teaching the patient to replace muscular tension by a tension-incompatible reaction, such as the relaxation response. Electromyographic (EMG) biofeedback, progressive relaxation, and applied relaxation are frequently used.

 

Behavioural techniques are often applied together as part of a comprehensive treatment approach. This so-called cognitive�behavioural treatment is based on a multidimensional model of pain that includes physical, affective, cognitive, and behavioural components. A large variety of behavioural treatment modalities are used for chronic LBP because there is no general consensus about the definition of operant and cognitive methods. Furthermore, behavioural treatment often consists of a combination of these modalities or is applied in combination with other therapies (such as medication or exercises).

 

Effectiveness of behavioural therapy for acute LBP One RCT (107 people) identified by the review found that cognitive�behavioural therapy reduced pain and perceived disability after 9�12 months compared with traditional care (analgesics plus back exercises until pain had subsided).

 

Effectiveness of behavioural therapy for chronic LBP Behavioural treatment versus waiting list controls. There is moderate evidence from two small trials (total of 39 people) that progressive relaxation has a large positive effect on pain (1.16; 95% CI 0.47�1.85) and behavioural outcomes (1.31; 95% CI 0.61�2.01) in the short-term. There is limited evidence that progressive relaxation has a positive effect on short-term back-specific and generic functional status.

 

There is moderate evidence from three small trials (total of 88 people) that there is no significant difference between EMG biofeedback and waiting list control on behavioural outcomes in the short-term. There is conflicting evidence (two trials; 60 people) on the effectiveness of EMG versus waiting list control on general functional status.

 

There is conflicting evidence from three small trials (total of 153 people) regarding the effect of operant therapy on short-term pain intensity, and moderate evidence that there is no difference [0.35 (95% CI -0.25 to 0.94)] between operant therapy and waiting list control for short-term behavioural outcomes. Five studies compared combined respondent and cognitive therapy with waiting list controls. There is strong evidence from four small trials (total of 134 people) that combined respondent and cognitive therapy has a medium sized, short-term positive effect on pain intensity. There is strong evidence that there are no differences [0.44 (95% CI -0.13 to 1.01)] on short-term behavioural outcomes.

 

Behavioural treatment versus other interventions. There is limited evidence (one trial; 39 people) that there are no significant differences between behavioural treatment and exercise on pain intensity, generic functional status and behavioural outcomes, either post-treatment, or at 6- or 12-month follow-up.

 

Adverse effects None reported in the trials.

 

Exercise Therapy

 

Exercise therapy is a management strategy that is widely used in LBP; it encompasses a heterogeneous group of interventions ranging from general physical fitness or aerobic exercise, to muscle strengthening, to various types of flexibility and stretching exercises.

 

Effectiveness of exercise therapy for acute LBP Exercise versus no treatment. The pooled analysis failed to show a difference in short-term pain relief between exercise therapy and no treatment, with an effect of -0.59 points/100 (95% CI -12.69 to 11.51).

 

Exercise versus other interventions. Of 11 trials involving 1,192 adults with acute LBP, 10 had non-exercise comparisons. These trials provide conflicting evidence. The pooled analysis showed that there was no difference at the earliest follow-up in pain relief when compared to other conservative treatments: 0.31 points (95% CI -0.10 to 0.72). Similarly, there was no significant positive effect of exercise on functional outcomes. Outcomes show similar trends at short-, intermediate-, and long-term follow-up.

 

Effectiveness of exercise therapy for subacute LBP Exercise versus other interventions. Six studies involving 881 subjects had non-exercise comparisons. Two trials found moderate evidence of reduced work absenteeism with a graded activity intervention compared to usual care. The evidence is conflicting regarding the effectiveness of other exercise therapy types in subacute LBP compared to other treatments.

 

Effectiveness of exercise therapy for chronic LBP Exercise versus other interventions. Thirty-three exercise groups in 25 trials on chronic LBP had non-exercise comparisons. These trials provide strong evidence that exercise therapy is at least as effective as other conservative interventions for chronic LBP. Two exercise groups in high quality studies and nine groups in low quality studies found exercise more effective than comparison treatments. These studies, mostly conducted in health care settings, commonly used exercise programs that were individually designed and delivered (as opposed to independent home exercises). The exercise programs commonly included strengthening or trunk stabilizing exercises. Conservative care in addition to exercise therapy was often included in these effective interventions, including behavioural and manual therapy, advice to stay active, and education. One low quality trial found a group-delivered aerobics and strengthening exercise program resulted in less improvement in pain and function outcomes than behavioural therapy. Of the remaining trials, 14 (2 high quality and 12 low quality) found no statistically significant or clinically important differences between exercise therapy and other conservative treatments; 4 of these trials were inadequately powered to detect clinically important differences on at least one outcome. Trials were rated low quality most commonly because of inadequate assessor blinding.

 

Meta-analysis of pain outcomes at the earliest follow-up included 23 exercise groups with an independent comparison and adequate data. Synthesis resulted in a pooled weighted mean improvement of 10.2 points (95% CI 1.31�19.09) for exercise therapy compared to no treatment, and 5.93 points (95% CI 2.21�9.65) compared to other conservative treatment [vs. all comparisons 7.29 points (95% CI 3.67�0.91)]. Smaller improvements were seen in functional outcomes with an observed mean positive effect of 3.15 points (95% CI -0.29 to 6.60) compared to no treatment, and 2.37 points (95% CI 0.74�4.0) versus other conservative treatment at the earliest follow-up [vs. all comparisons 2.53 points (95% CI 1.08�3.97)].

 

Adverse effects Most trials did not report any side effects. Two studies reported cardiovascular events that were considered not to be caused by the exercise therapy.

 

Lumbar Supports

 

Lumbar supports are provided as treatment to people suffering from LBP with the aim of making the impairment and disability vanish or decrease. Different desired functions have been suggested for lumbar supports: (1) to correct deformity, (2) to limit spinal motion, (3) to stabilize part of the spine, (4) to reduce mechanical uploading, and (5) miscellaneous effects: massage, heat, placebo. However, at the present time the putative mechanisms of action of a lumbar support remain a matter of debate.

 

Effectiveness of lumbar supports for acute LBP No trials were identified.

 

Effectiveness of lumbar supports for chronic LBP No RCT compared lumbar supports with placebo, no treatment, or other treatments for chronic LBP.

 

Effectiveness of lumbar supports for a mixed population of acute, subacute, and chronic LBP Four studies included a mix of patients with acute, subacute, and chronic LBP. One study did not give any information about the duration of the LBP complaints of the patients. There is moderate evidence that a lumbar support is not more effective in reducing pain than other types of treatment. Evidence on overall improvement and return to work was conflicting.

 

Adverse effects Potential adverse effects associated with prolonged lumbar support use include decreased strength of the trunk musculature, a false sense of security, heat, skin irritation, skin lesions, gastrointestinal disorders and muscle wasting, higher blood pressure and higher heart rates, and general discomfort.

 

Multidisciplinary Treatment Programmes

 

Multidisciplinary treatments for back pain evolved from pain clinics. Initially, multidisciplinary treatments focused on a traditional biomedical model and in the reduction of pain. Current multidisciplinary approaches to chronic pain are based on a multifactorial biopsychosicial model of interrelating physical, psychological, and social/occupational factors. The content of multidisciplinary programs varies widely and, at present, it is unclear what the optimal content is and who should be involved.

 

Effectiveness of multidisciplinary treatment for subacute LBP No trials identified.

 

Effectiveness of multidisciplinary treatment for subacute LBP Multidisciplinary treatment versus usual care. Two RCTs on subacute LBP were included. The study population in both studies consisted of workers on sick leave. In one study the patients in the intervention group returned to work sooner (10 weeks) compared with the control group (15 weeks) (P=0.03). The intervention group also had fewer sick leave during follow-up than the control group (mean difference=-7.5 days, 95% CI -15.06 to 0.06). There was no statistically significant difference in pain intensity between the intervention and control group, but subjective disability had decreased significantly more in the intervention group than in the control group (mean difference=-1.2, 95% CI -1.984 to -0.416). In the other study, the median duration of absence from regular work was 60 days for the group with a combination of occupational and clinical intervention, 67 days with the occupational intervention group, 131 days with the clinical intervention group, and 120.5 days with the usual care group (P=0.04). Return to work was 2.4 times faster in the group with both an occupational and clinical intervention (95% CI 1.19�4.89) than the usual care group, and 1.91 times faster in the two groups with occupational intervention than the two groups without occupational interventions (95% CI 1.18�3.1). There is moderate evidence that multidisciplinary treatment with a workplace visit and comprehensive occupational health care intervention is effective with regard to return to work, sick leave, and subjective disability for patients with subacute LBP.

 

Effectiveness of multidisciplinary treatment for chronic LBP Multidisciplinary treatment versus other interventions. Ten RCTs with a total of 1,964 subjects were included in the Cochrane review. Three additional papers reported on long-term outcomes of two of these trials. All ten trials excluded patients with significant radiculopathy or other indication for surgery. There is strong evidence that intensive multidisciplinary treatment with a functional restoration approach improves function when compared with inpatient or outpatient non-multidisciplinary treatments. There is moderate evidence that intensive multidisciplinary treatment with a functional restoration approach reduces pain when compared with outpatient non-multidisciplinary rehabilitation or usual care. There is contradictory evidence regarding vocational outcomes. Five trials evaluating less intensive multidisciplinary treatment programmes could not demonstrate beneficial effects on pain, function, or vocational outcomes when compared with non-multidisciplinary outpatient treatment or usual care. One additional RCT was found that showed no difference between multidisciplinary treatment and usual care on function and health related quality of life after 2 and 6 months.

 

The reviewed studies provide evidence that intensive (>100 h of therapy) MBPSR with a functional restoration approach produces greater improvements in pain and function for patients with disabling chronic LBP than non-multidisciplinary rehabilitation or usual care. Less intensive treatments did not seem effective.

 

Adverse effects No adverse effects were reported.

 

Spinal Manipulation

 

Spinal manipulation is defined as a form of manual therapy which involves movement of a joint past its usual end range of motion, but not past its anatomic range of motion. Spinal manipulation is usually considered as that of long lever, low velocity, non-specific type manipulation as opposed to short lever, high velocity, specific adjustment. Potential hypotheses for the working mechanism of spinal manipulation are: (1) release for the entrapped synovial folds, (2) relaxation of hypertonic muscle, (3) disruption of articular or periarticular adhesion, (4) unbuckling of motion segments that have undergone disproportionate displacement, (5) reduction of disc bulge, (6) repositioning of miniscule structures within the articular surface, (7) mechanical stimulation of nociceptive joint fibres, (8) change in neurophysiological function, and (9) reduction of muscle spasm.

 

Effectiveness of spinal manipulation for acute LBP Spinal manipulation versus sham. Two trials were identified. Patients receiving treatment that included spinal manipulation had statistically significant and clinically important short-term improvements in pain (10-mm difference; 95% CI 2�17 mm) compared with sham therapy. However, the improvement in function was considered clinically relevant but not statistically significant (2.8-mm difference on the Roland Morris scale; 95% CI -0.1 to 5.6).

 

Spinal manipulation versus other therapies. Twelve trials were identified. Spinal manipulation resulted in statistically significant more short-term pain relief compared with other therapies judged to be ineffective or possibly even harmful (4-mm difference; 95% CI 1�8 mm). However, the clinical significance of this finding is questionable. The point estimate of improvement in short-term function for treatment with spinal manipulation compared with the ineffective therapies was considered clinically significant but was not statistically significant (2.1-point difference on the Roland Morris scale; 95% CI -0.2 to 4.4). There were no differences in effectiveness between patients treated with spinal manipulation and those treated with any of the conventionally advocated therapies.

 

Effectiveness of spinal manipulation for chronic LBP Spinal manipulation versus sham. Three trials were identified. Spinal manipulation was statistically significantly more effective compared with sham manipulation on short-term pain relief (10 mm; 95% CI 3�17 mm) and long-term pain relief (19 mm; 95% CI 3�35 mm). Spinal manipulation was also statistically significantly more effective on short-term improvement of function (3.3 points on the Roland and Morris Disability Questionnaire (RMDQ); 95% CI 0.6�6.0).

 

Spinal manipulation versus other therapies. Eight trials were identified. Spinal manipulation was statistically significantly more effective compared with the group of therapies judged to be ineffective or perhaps harmful on short-term pain relief (4 mm; 95% CI 0�8), and short-term improvement in function (2.6 points on the RMDQ; 95% CI 0.5�4.8). There were no differences in short- and long-term effectiveness compared with other conventionally advocated therapies such as general practice care, physical or exercise therapy, and back school.

 

Adverse effects In the RCTs identified by the review that used a trained therapist to select people and perform spinal manipulation, the risk of serious complications was low. An estimate of the risk of spinal manipulation causing a clinically worsened disk herniation or cauda equina syndrome in a patient presenting with lumbar disk herniation is calculated from published data to be less than 1 in 3.7 million.

 

Traction

 

Lumbar traction uses a harness (with velcro strapping) that is put around the lower rib cage and around the iliacal crest. Duration and level of force exerted through this harness can be varied in a continuous or intermittent mode. Only in motorized and bed rest traction can the force be standardized. With other techniques total body weight and the strength of the patient or therapist determine the forces exerted. In the application of traction force, consideration must be given to counterforces such as lumbar muscle tension, lumbar skin stretch and abdominal pressure, which depend on the patient�s physical constitution. If the patient is lying on the traction table, the friction of the body on the table provides the main counterforce during traction. The exact mechanism through which traction might be effective is unclear. It has been suggested that spinal elongation, through decreasing lordosis and increasing intervertebral space, inhibits nociceptive impulses, improves mobility, decreases mechanical stress, reduces muscle spasm or spinal nerve root compression (due to osteophytes), releases luxation of a disc or capsule from the zygo-apophysial joint, and releases adhesions around the zygo-apophysial joint and the annulus fibrosus. So far, the proposed mechanisms have not been supported by sufficient empirical information.

 

Thirteen of the studies identified in the Cochrane review included a homogeneous population of LBP patients with radiating symptoms. The remaining studies included a mix of patients with and without radiation. There were no studies exclusively involving patients who had no radiating symptoms.

 

Five studies included solely or primarily patients with chronic LBP of more than 12 weeks; in one study patients were all in the subacute range (4�12 weeks). In 11 studies the duration of LBP was a mixture of acute, subacute, and chronic. In four studies duration was not specified.

 

Effectiveness of traction for acute LBP No RCTs included primarily people with acute LBP. One study was identified that included patients with subacute LBP, but this population consisted of a mix of patients with and without radiation.

 

Effectiveness of traction for chronic LBP One trial found that continuous traction is not more effective on pain, function, overall improvement, or work absenteeism than placebo. One RCT (42 people) found no difference in effectiveness between standard physical therapy including continuous traction and the same program without traction. One RCT (152 people) found no significant difference between lumbar traction plus massage and interferential treatment in pain relief, or improvement of disability 3 weeks and 4 months after the end of treatment. This RCT did not exclude people with sciatica, but no further details of the proportion of people with sciatica were reported. One RCT (44 people) found that autotraction is more effective than mechanical traction on global improvement, but not on pain and function, in chronic LBP patients with or without radiating symptoms. However, this trial had several methodological problems that may be associated with biased results.

 

Adverse effects Little is known about the adverse effects of traction. Only a few case reports are available, which suggest that there is some danger for nerve impingement in heavy traction, i.e. lumbar traction forces exceeding 50% of the total body weight. Other risks described for lumbar traction are respiratory constraints due to the traction harness or increased blood pressure during inverted positional traction. Other potential adverse effects of traction include debilitation, loss of muscle tone, bone demineralization, and thrombophlebitis.

 

Transcutaneous Electrical Nerve Stimulation

 

Transcutaneous electrical nerve stimulation (TENS) is a therapeutic non-invasive modality mainly used for pain relief by electrically stimulating peripheral nerves via skin surface electrodes. Several types of TENS applications, differing in intensity and electrical characteristics, are used in clinical practice: (1) high frequency, (2) low frequency, (3) burst frequency, and (4) hyperstimulation.

 

Effectiveness of TENS for acute LBP: No trials were identified.

 

Effectiveness of TENS for chronic LBP The Cochrane review included two RCTs of TENS for chronic LBP. The results of one small trial (N=30) showed a significant decrease in subjective pain intensity with active TENS treatment compared to placebo over the course of the 60-min treatment session. The pain reduction seen at the end of stimulation was maintained for the entire 60-min post-treatment time interval assessed (data not shown). Longer term follow-up was not conducted in this study. The second trial (N=145) demonstrated no significant difference between active TENS and placebo for any of the outcomes measured, including pain, functional status, range of motion, and use of medical services.

 

Adverse effects In a third of the participants in one trial, minor skin irritation occurred at the site of electrode placement. These adverse effects were observed equally in the active TENS and placebo groups. One participant randomized to placebo TENS developed severe dermatitis 4 days after beginning therapy and was required to withdraw (Tables 1, ?2).

 

Table 1 Effectiveness of Conservative Interventions for Acute Non Specific Low Back Pain

Table 1: Effectiveness of conservative interventions for acute non-specific low back pain.

 

Table 2 Effectiveness of Conservative Interventions for Chronic Non Specific Low Back Pain

Table 2: Effectiveness of conservative interventions for chronic non-specific low back pain.

 

Discussion

 

The best available evidence for conservative treatments for non-specific LBP summarized in this paper shows that some interventions are effective. Traditional NSAIDs, muscle relaxants, and advice to stay active are effective for short-term pain relief in acute LBP. Advice to stay active is also effective for long-term improvement of function in acute LBP. In chronic LBP, various interventions are effective for short-term pain relief, i.e. antidepressants, COX2 inhibitors, back schools, progressive relaxation, cognitive�respondent treatment, exercise therapy, and intensive multidisciplinary treatment. Several treatments are also effective for short-term improvement of function in chronic LBP, namely COX2 inhibitors, back schools, progressive relaxation, exercise therapy, and multidisciplinary treatment. There is no evidence that any of these interventions provides long-term effects on pain and function. Also, many trials showed methodological weaknesses, effects are compared to placebo, no treatment or waiting list controls, and effect sizes are small. Future trials should meet current quality standards and have adequate sample size. However, in summary, there is evidence that some interventions are effective while evidence for many other interventions is lacking or there is evidence that they are not effective.

 

During the last decade, various clinical guidelines on the management of acute LBP in primary care have been published that have used this evidence. At present, guidelines exist in at least 12 different countries: Australia, Denmark, Finland, Germany, Israel, the Netherlands, New Zealand, Norway, Sweden, Switzerland, the United Kingdom, and the United States. Since the available evidence is international, one would expect that each country�s guidelines would give more or less similar recommendations regarding diagnosis and treatment. Comparison of clinical guidelines for the management of LBP in primary care from 11 different countries showed that the content of the guidelines regarding therapeutic interventions is quite similar. However, there were also some discrepancies in recommendations across guidelines. Differences in recommendations between guidelines may be due to incompleteness of the evidence, different levels of evidence, magnitude of effects, side effects and costs, differences in health care systems (organization/financial), or differences in membership of guidelines committees. More recent guidelines may have included more recently published trials and, therefore, may end up with slightly different recommendations. Also, guidelines may have been based on systematic reviews that included trials in different languages; the majority of existing reviews have considered only studies published in a few languages, and several, only those published in English. Recommendations in guidelines are not only based on scientific evidence, but also on consensus. Guideline committees may consider various arguments differently, such as the magnitude of the effects, potential side effects, cost-effectiveness, and current routine practice and available resources in their country. Especially as we know that effects in the field of LBP, if any, are usually small and short-term effects only, interpretation of effects may vary among guideline committees. Also, guideline committees may differently weigh other aspects such as side effects and costs. The constitution of the guideline committees and the professional bodies they represent may introduce bias�either for or against a particular treatment. This does not necessarily mean that one guideline is better than the other or that one is right and the other is wrong. It merely shows that when translating the evidence into clinically relevant recommendations more aspects play a role, and that these aspects may vary locally or nationally.

 

Recently European guidelines for the management of LBP were developed to increase consistency in the management of non-specific LBP across countries in Europe. The European Commission has approved and funded this project called �COST B13�. The main objectives of this COST action were developing European guidelines for the prevention, diagnosis and treatment of non-specific LBP, ensuring an evidence-based approach through the use of systematic reviews and existing clinical guidelines, enabling a multidisciplinary approach, and stimulating collaboration between primary health care providers and promoting consistency across providers and countries in Europe. Representatives from 13 countries participated in this project that was conducted between 1999 and 2004. The experts represented all relevant health professions in the field of LBP: anatomy, anaesthesiology, chiropractic, epidemiology, ergonomy, general practice, occupational care, orthopaedic surgery, pathology, physiology, physiotherapy, psychology, public health care, rehabilitation, and rheumatology. Within this COST B13 project four European guidelines were developed on: (1) acute LBP, (2) chronic LBP, (3) prevention of LBP, and (4) pelvic girdle pain. The guidelines will soon be published as a supplement to the European Spine Journal.

 

Contributor Information

 

Maurits W. van Tulder, Bart Koes, Antti Malmivaara: Ncbi.nlm.nih.gov

 

In conclusion,�the clinical and experimental evidence above for non-invasive treatment modalities on back pain demonstrated that several of the treatments are safe and effective. While the results of a variety of the methods used to improve back pain symptoms were proven to be efficient, many other treatment modalities requires additional evidence and others were reported to not be effective towards improving symptoms of back pain.�The main objective of the research study was to determine the safest and most effective guideline for the prevention, diagnosis and treatment of non-specific back pain.�Information referenced from the National Center for Biotechnology Information (NCBI). The scope of our information is limited to chiropractic as well as to spinal injuries and conditions. To discuss the subject matter, please feel free to ask Dr. Jimenez or contact us at 915-850-0900 .

 

Curated by Dr. Alex Jimenez

 

Green-Call-Now-Button-24H-150x150-2-3.png

 

Additional Topics: Sciatica

 

Sciatica is referred to as a collection of symptoms rather than a single type of injury or condition. The symptoms are characterized as radiating pain, numbness and tingling sensations from the sciatic nerve in the lower back, down the buttocks and thighs and through one or both legs and into the feet. Sciatica is commonly the result of irritation, inflammation or compression of the largest nerve in the human body, generally due to a herniated disc or bone spur.

 

blog picture of cartoon paperboy big news

 

IMPORTANT TOPIC: EXTRA EXTRA: Treating Sciatica Pain

 

 

Blank
References
1.�Alaranta H, Rytokoski U, Rissanen A, Talo S, Ronnemaa T, Puukka P, Karppi SL, Videman T, Kallio V, Slatis P. Intensive physical and psychosocial training program for patients with chronic low back pain.�A controlled trial. Spine.�1994;19:1340�1349.�[PubMed]
2.�Alcoff J, Jones E, Rust P, Newman R. Controlled trial of imipramine for chronic low back pain.�J Fam Pract.�1982;14:841�846.�[PubMed]
3.�Alexandre NM, Moraes MA, Correa Filho HR, Jorge SA. Evaluation of a program to reduce back pain in nursing personnel.�Rev Salud Publica.�2001;35:356�361.�[PubMed]
4.�Amlie E, Weber H, Holme I. Treatment of acute low back pain with piroxicam: results of a double-blind placebo-controlled trial.�Spine.�1987;12:473�476. doi: 10.1097/00007632-198706000-00010.�[PubMed][Cross Ref]
5.�Arbus L, Fajadet B, Aubert D, Morre M, Goldfinger E. Activity of tetrazepam in low back pain.�Clin Trials J.�1990;27:258�267.
6.�Assendelft WJ, Morton SC, Yu EI, Suttorp MJ, Shekelle P. Spinal manipulative therapy for low back pain. A meta-analysis of effectiveness relative to other therapies.�Ann Intern Med.�2003;138:871�881.[PubMed]
7.�Atkinson JH, Slater MA, Williams RA. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain.�Pain.�1998;76:287�296. doi: 10.1016/S0304-3959(98)00064-5.�[PubMed][Cross Ref]
8.�Atkinson JH, Slater MA, Wahlgren DR. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity.�Pain.�1999;83:137�145. doi: 10.1016/S0304-3959(99)00082-2.�[PubMed][Cross Ref]
9.�Babej-Dolle R, Freytag S, Eckmeyer J, Zerle G, Schinzel S, Schmeider G, Stankov G. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer-blind multicenter study.�Int J Clin Pharmacol Ther.�1994;32:204�209.�[PubMed]
10.�Baptista R, Brizzi J, Dutra F, Josef H, Keisermann M, de Lucca R (1988) Terapeutica da lombalgia com a tizanidina (DS 103-282), un novo agente mioespasmolitico. Estudo multicentrico, duplo-cego e comparativo. Folha Medica
11.�Barrata R. A double-blind study of cyclobenzaprine and placebo in the treatment of acute muskuloskeletal conditions of the low back.�Curr Ther Res.�1982;32:646�652.
12.�Basler H, Jakle C, Kroner-Herwig B. Incorporation of cognitive�behavioral treatment into the medical care of chronic low back patients: a controlled randomized study in German pain treatment centers.�Patient Educ Couns.�1997;31:113�124. doi: 10.1016/S0738-3991(97)00996-8.�[PubMed][Cross Ref]
13.�Basmajian J. Cyclobenzaprine hydrochloride effect on skeletal muscle spasm in the lumbar region and neck: two double-blind controlled clinical and laboratory studies.�Arch Phys Med Rehabil.�1978;59:58�63.[PubMed]
14.�Basmajian JV. Acute back pain and spasm: a controlled multicenter trial of combined analgesic and antispasm agents.�Spine.�1989;14:438�439. doi: 10.1097/00007632-198904000-00019.�[PubMed][Cross Ref]
15.�Bendix AF, Bendix T, Ostenfeld S, Bush E, Andersen A. Active treatment programs for patients with chronic low back pain: a prospective randomized, observer-blinded study.�Eur Spine J.�1995;4:148�152. doi: 10.1007/BF00298239.�[PubMed][Cross Ref]
16.�Bendix AF, Bendix T, Vaegter KV, Lund C, Frolund L, Holm L. Multidisciplinary intensive treatment for chronic low back pain: a randomized, prospective study.�Cleve Clin J Med.�1996;63:62�69.�[PubMed]
17.�Bendix AE, Bendix T, Lund C, Kirkbak S, Ostenfeld S. Comparison of three intensive programs for chronic low back pain patients: a prospective, randomized, observer-blinded study with one-year follow-up.�Scand J Rehabil Med.�1997;29:81�89.�[PubMed]
18.�Bendix AE, Bendix T, Haestrup C, Busch E. A prospective, randomized 5-year follow-up study of functional restoration in chronic low back pain patients.�Eur Spine J.�1998a;7:111�119. doi: 10.1007/s005860050040.�[PubMed][Cross Ref]
19.�Bendix AE, Bendix T, Labriola M, Boekgaard P. Functional restoration for chronic low back pain. Two-year follow-up of two randomized clinical trials.�Spine.�1998b;23:717�725. doi: 10.1097/00007632-199803150-00013.�[PubMed][Cross Ref]
20.�Bendix T, Bendix A, Labriola M, Haestrup C, Ebbehoj N. Functional restoration versus outpatient physical training in chronic low back pain: a randomized comparative study.�Spine.�2000;25:2494�2500. doi: 10.1097/00007632-200010010-00012.�[PubMed][Cross Ref]
21.�Bergquist-Ullman M, Larsson U. Acute low-back pain in industry.�Acta Orthop Scand.�1977;170(Suppl.):1�117.�[PubMed]
22.�Berry H, Hutchinson D. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain.�J Int Med Res.�1988;16:75�82.�[PubMed]
23.�Berry H, Bloom B, Hamilton EBD, Swinson DR. Naproxen sodium, diflunisal, and placebo in the treatment of chronic back pain.�Ann Rheum Dis.�1982;41:129�132. doi: 10.1136/ard.41.2.129.[PMC free article][PubMed][Cross Ref]
24.�Beurskens AJ, Vet HC, K�ke AJ, Lindeman E, Regtop W, Heijden GJ, Knipschild PG. Efficacy of traction for non-specific low back pain: a randomised clinical trial.�Lancet.�1995;346:1596�1600. doi: 10.1016/S0140-6736(95)91930-9.�[PubMed][Cross Ref]
25.�Beurskens AJ, Vet HC, K�ke AJ, Regtop W, Heijden GJ, Lindeman E, Knipschild PG. Efficacy of traction for nonspecific low back pain. 12-week and 6-month results of a randomized clinical trial.�Spine.�1997;22:2756�2762. doi: 10.1097/00007632-199712010-00011.�[PubMed][Cross Ref]
26.�Bianchi M.�Evaluation of cyclobenzaprine for skeletal muscle spasm of local origin. Clinical evaluation of flexeril (cyclobenzaprine HCL/MSD)�Minneapolis: Postgraduate Medicine Communications; 1978. pp. 25�29.
27.�Bigos S, Bowyer O, Braen G (1994) Acute low back problems in adults. Clinical Practice Guideline No. 14. AHCPR Publication No. 95-0642. Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, Rockville
28.�Bihaug O. Autotraksjon for ischialgpasienter. En kontrollert sammenlikning mellom effekten av Auto-traksjon-B og isometriske ovelser ad modum Hume endall og Jenkins.�Fysioterapeuten.�1978;45:377�379.
29.�Birbara CA, Puopolo AD, Munoz DR. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability: a randomised, placebo-controlled, 3-month trial.�J Pain.�2003;4:307�315. doi: 10.1016/S1526-5900(03)00633-3.�[PubMed][Cross Ref]
30.�Blomberg S, Hallin G, Grann K, Berg E, Sennerby U. Manual therapy with steroid injections�a new approach to treatment of low back pain. A controlled multicenter trial with an evaluation by orthopedic surgeons.�Spine.�1994;19:569�577. doi: 10.1097/00007632-199403000-00013.�[PubMed][Cross Ref]
31.�Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, Study Group VIGOR. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.�N Engl J Med.�2000;343:1520�1528. doi: 10.1056/NEJM200011233432103.�[PubMed][Cross Ref]
32.�Borman P, Keskin D, Bodur H. The efficacy of lumbar traction in the management of patients with low back pain.�Rheumatol Int.�2003;23:82�86.�[PubMed]
33.�Bouter LM, Pennick V, Bombardier C, Editorial Board of the Back Review Group Cochrane Back Review Group.�Spine.�2003;28:1215�1218. doi: 10.1097/00007632-200306150-00002.�[PubMed][Cross Ref]
34.�Braun H, Huberty R. Therapy of lumbar sciatica. A comparative clinical study of a corticoid-free monosubstance and a corticoid containing combination drug.�Med Welt.�1982;33:490�491.�[PubMed]
35.�Bronfort G, Goldsmith CH, Nelson CF, Boline PD, Anderson AV. Trunk exercise combined with spinal manipulative or NSAID therapy for chronic low back pain: a randomized, observer-blinded clinical trial.�J Manipulative Physiol Ther.�1996;19:570�582.�[PubMed]
36.�Brown FL, Bodison S, Dixon J, Davis W, Nowoslawski J. Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back pain.�Clin Ther.�1986;9(Suppl. c):52�58.[PubMed]
37.�Bru E, Mykletun R, Berge W, Svebak S. Effects of different psychological interventions on neck, shoulder and low back pain in female hospital staff.�Psychol Health.�1994;9:371�382. doi: 10.1080/08870449408407495.�[Cross Ref]
38.�Calmels P, Fayolle-Minon I. An update on orthotic devices for the lumbar spine based on a review of the literature.�Rev Rhum.�1996;63:285�291.�[PubMed]
39.�Casale R. Acute low back pain: symptomatic treatment with a muscle relaxant drug.�Clin J Pain.�1988;4:81�88.
40.�Cherkin DC, Deyo RA, Battie M, Street J, Barlow W. A comparison of physical therapy, chiropractic manipulation, and provision of an educational booklet for the treatment of patients with low back pain.�N Engl J Med.�1998;339:1021�1029. doi: 10.1056/NEJM199810083391502.�[PubMed][Cross Ref]
41.�Chok B, Lee R, Latimer J, Seang BT. Endurance training of the trunk extensor muscles in people with subacute low back pain.�Phys Ther.�1999;79:1032�1042.�[PubMed]
42.�Clarke J, van Tulder M, Blomberg S, Bronfort G, van der Heijden G, de Vet HCW (2005) Traction for low back pain: a systematic review within the framework of the Cochrane Collaboration. In: The Cochrane Library, Issue 3. Update Software, Oxford
43.�Coats TL, Borenstein DG, Nangia NK, Brown MT. Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial.�Clin Ther.�2004;26:1249�1260. doi: 10.1016/S0149-2918(04)80081-X.�[PubMed][Cross Ref]
44.�Coomes NE. A comparison between epidural anaesthesia and bed rest in sciatica.�Br Med J.�1961;Jan:20�24.�[PMC free article][PubMed]
45.�Coxhead CE, Inskip H, Meade TW, North WRS, Troup JDG. Multicentre trial of physiotherapy in the management of sciatic symptoms.�Lancet.�1981;1:1065�1068. doi: 10.1016/S0140-6736(81)92238-8.[PubMed][Cross Ref]
46.�Cramer GD, Humphreys CR, Hondras MA, McGregor M, Triano JJ. The Hmax/Mmax ratio as an outcome measure for acute low back pain.�J Manipulative Physiol Ther.�1993;16:7�13.�[PubMed]
47.�Dalichau S, Scheele K. Effects of elastic lumbar belts on the effect of a muscle training program for patients with chronic back pain [German]�Zt Orthop Grenzgeb.�2000;138:8�16. doi: 10.1055/s-2000-10106.�[PubMed][Cross Ref]
48.�Dalichau S, Scheele K, Perrey RM, Elliehausen H-J, Huebner J. Ultraschallgest�tzte Haltungs- und Bewegungsanalyse der Lendenwirbels�ule zum Nachweis der Wirksamkeit einer R�ckenschule.�Zbl Arbeitsmedizin.�1999;49:148�156.
49.�Dapas F. Baclofen for the treatment of acute low-back syndrome.�Spine.�1985;10:345�349. doi: 10.1097/00007632-198505000-00010.�[PubMed][Cross Ref]
50.�Davies JE, Gibson T, Tester L. The value of exercises in the treatment of low back pain.�Rheumatol Rehabil.�1979;18:243�247.�[PubMed]
51.�Deyo RA, Diehl AK, Rosenthal M. How many days of bed rest for acute low back pain? A randomized clinical trial.�N Engl J Med.�1986;315:1064�1070.�[PubMed]
52.�Deyo RA, Walsh NE, Martin DC, Schoenfeld LS, Ramamurthy S. A controlled trial of transcutaneous electrical nerve stimulation (TENS) and exercise for chronic low back pain.�N Engl J Med.�1990;322:1627�1634.�[PubMed]
53.�Dickens C, Jayson M, Sutton C. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain.�Psychosomatics.�2000;41:490�499. doi: 10.1176/appi.psy.41.6.490.�[PubMed][Cross Ref]
54.�Donchin M, Woolf O, Kaplan L, Floman Y. Secondary prevention of low-back pain.�A clinical trial. Spine.�1990;15:1317�1320.�[PubMed]
55.�Doran DML, Newell DJ. Manipulation in treatment of low back pain: a multicentre study.�Br Med J.�1975;2:161�164.�[PMC free article][PubMed]
56.�Evans DP, Burke MS, Lloyd KN, Roberts EE, Roberts GM. Lumbar spinal manipulation on trial. Part 1: clinical assessment.�Rheumatol Rehabil.�1978;17:46�53.�[PubMed]
57.�Evans DP, Burke MS, Newcombe RG. Medicines of choice in low back pain.�Curr Med Res Opin.�1980;6:540�547.�[PubMed]
58.�Faas A, Chavannes AW, Eijk JTM, Gubbels JW. A randomized placebo-controlled trial of exercise therapy in patients with acute low back pain.�Spine.�1993;18:1388�1395.�[PubMed]
59.�Faas A, Eijk JTM, Chavannes AW, Gubbels JW. A randomized trial of exercise therapy in patients with acute low back pain.�Spine.�1995;20:941�947. doi: 10.1097/00007632-199504150-00012.�[PubMed][Cross Ref]
60.�Farrell JP, Twomey LT. Acute low back pain: comparison of two conservative treatment approaches.�Med J Aust.�1982;1:160�164.�[PubMed]
61.�Fordyce WE, Brockway JA, Bergman JA, Spengler D. Acute back pain: a control group comparison of behavioural versus traditional management methods.�J Behav Med.�1986;9:127�140. doi: 10.1007/BF00848473.�[PubMed][Cross Ref]
62.�Frost H, Klaber Moffett JA, Moser JS, Fairbank JCT. Randomised controlled trial for evaluation of fitness programme for patients with chronic low back pain.�Br Med J.�1995;310:151�154.[PMC free article][PubMed]
63.�Frost H, Lamb SE, Klaber Moffett JA, Fairbank JCT, Moser JS. A fitness programme for patients with chronic low back pain: 2-year follow-up of a randomised controlled trial.�Pain.�1998;75:273�279. doi: 10.1016/S0304-3959(98)00005-0.�[PubMed][Cross Ref]
64.�Frost H, Lamb SE, Doll HA, Taffe Carver P, Stewart-Brown S. Randomized controlled trial of physiotherapy compared with advice for low back pain.�Br Med J.�2004;329:708�711. doi: 10.1136/bmj.38216.868808.7C.�[PMC free article][PubMed][Cross Ref]
65.�Galantino ML, Bzdewka TM, Eissler-Russo JL, Holbrook ML, Mogck EP, Geigle P. The impact of modified hatha yoga on chronic low back pain: a pilot study.�Altern Ther Health Med.�2004;10:56�59.[PubMed]
66.�Gemignani G, Olivieri I, Ruju G, Pasero G. Transcutaneous electrical nerve stimulation in ankylosing spondylitis: a double-blind study.�Arthritis Rheum.�1991;34:788�789. doi: 10.1002/art.1780340624.[PubMed][Cross Ref]
67.�Gibson T, Grahame R, Harkness J, Woo P, Blagrave P, Hills R (1985) Controlled comparison of short-wave diathermy treatment with osteopathic treatment in non-specific low back pain. Lancet 1258�1261[PubMed]
68.�Gilbert JR, Taylor DW, Hildebrand A, Evans C. Clinical trial of common treatments for low back pain in family practice.�Br Med J Clin Res Ed.�1985;291:791�794.�[PMC free article][PubMed]
69.�Glomsr�d B, L�nn JH, Soukup MG, B� K, Larsen S. Active back school, prophylactic management for low back pain: three-year follow-up of a randomized controlled trial.�J Rehabil Med.�2001;33:26�30. doi: 10.1080/165019701300006506.�[PubMed][Cross Ref]
70.�Glover JR, Morris JG, Khosla T. Back pain: a randomized clinical trial of rotational manipulation of the trunk.�Br J Ind Med.�1974;31:59�64.�[PMC free article][PubMed]
71.�Godfrey CM, Morgan PP, Schatzker J. A randomized trial of manipulation for low-back pain in a medical setting.�Spine.�1984;9:301�304. doi: 10.1097/00007632-198404000-00015.�[PubMed][Cross Ref]
72.�Gold R. Orphenadrine citrate: sedative or muscle relaxant?�Clin Ther.�1978;1:451�453.
73.�Goldie I. A clinical trial with indomethacin (indomee) in low back pain and sciatica.�Acta Orthop Scand.�1968;39:117�128.�[PubMed]
74.�Goodkin K, Gullion CM, Agras WS. A randomised double blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome.�J Clin Psychopharmacol.�1990;10:269�278. doi: 10.1097/00004714-199008000-00006.�[PubMed][Cross Ref]
75.�Gur A, Karakoc M, Cevik R, Nas K, Sarac AJ, Karakoc M. Efficacy of low power laser therapy and exercise on pain and functions in chronic low back pain.�Lasers Surg Med.�2003;32:233�238. doi: 10.1002/lsm.10134.�[PubMed][Cross Ref]
76.�Guzman J, Esmail R, Karjalainen K. Multidisciplinary rehabilitation for chronic low back pain: systematic review.�Br Med J.�2001;322:1511�1516. doi: 10.1136/bmj.322.7301.1511.�[PMC free article][PubMed][Cross Ref]
77.�Hadler NM, Curtis P, Gillings DB, Stinnett S. A benefit of spinal manipulation as adjunctive therapy for acute low-back pain: a stratified controlled trial.�Spine.�1987;12:703�705. doi: 10.1097/00007632-198709000-00012.�[PubMed][Cross Ref]
78.�Hagen KB, Hilde G, Jamtvedt G (2003) Bed rest for acute low back pain and sciatica (Cochrane Review). In: The Cochrane Library, Issue 1. Update Software, Oxford
79.�Hameroff SR, Weiss JL, Lerman JC. Doxepin�s effects on chronic pain and depression: a controlled study.�J Clin Psychiatry.�1984;45:47�52.�[PubMed]
80.�Hansen FR, Bendix T, Skov P, Jensen CV, Kristensen JH, Krohn L. Intensive, dynamic back-muscle exercises, conventional physiotherapy, or placebo-control treatment of low back pain: a randomized, observer-blind trial.�Spine.�1993;18:98�107. doi: 10.1097/00007632-199301000-00015.�[PubMed][Cross Ref]
81.�H�rk�p�� K, J�rvikoski A, Mellin G, Hurri H. A controlled study on the outcome of inpatient and outpatient treatment of low-back pain. Part I.�Scand J Rehabil Med.�1989;21:81�89.�[PubMed]
82.�H�rk�p�� K, Mellin G, J�rvikoski A, Hurri H. A controlled study on the outcome of inpatient and outpatient treatment of low-back pain. Part III.�Scand J Rehabil Med.�1990;22:181�188.�[PubMed]
83.�Hayden JA, Tulder MW, Malmivaara AV, Koes BW. Meta-analysis: exercise therapy for nonspecific low back pain.�Ann Intern Med.�2005;142:765�775.�[PubMed]
84.�Hemmila HM, Keinanen-Kiukaanniemi SM, Levoska S. Does folk medicine work? A randomized clinical trial on patients with prolonged back pain.�Arch Phys Med Rehabil.�1997;78:571�577. doi: 10.1016/S0003-9993(97)90420-2.�[PubMed][Cross Ref]
85.�Hemmila H, Keinanen-Kiukaanniemi SM, Levoska S, Puska P. Long-term effectiveness of bone-setting, light exercise therapy, and physiotherapy for prolonged back pain: a randomized controlled trial.�J Manipulative Physiol Ther.�2002;25:99�104. doi: 10.1067/mmt.2002.122329.�[PubMed][Cross Ref]
86.�Henry D, Lim LLY, Rodriguez LAG. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis.�Br Med J.�1996;312:1563�1566.�[PMC free article][PubMed]
87.�Herzog W, Conway PJW, Willcox BJ. Effects of different treatment modalities on gait symmetry and clinical measures for sacroiliac joint patients.�J Manipulative Physiol Ther.�1991;14:104�109.�[PubMed]
88.�Heymans MW, Tulder MW, Esmail R, Bombardier C, Koes BW. Back schools for nonspecific low back pain: a systematic review within the framework of the Cochrane Collaboration Back Review Group.�Spine.�2005;30:2153�2163. doi: 10.1097/01.brs.0000182227.33627.15.�[PubMed][Cross Ref]
89.�Hides JA, Jull GA, Richardson CA. Long-term effects of specific stabilizing exercises for first-episode low back pain.�Spine.�2001;26:E243�E248. doi: 10.1097/00007632-200106010-00004.�[PubMed][Cross Ref]
90.�Hilde G, Hagen KB, Jamtvedt G (2003) Advice to stay active as a single treatment for low back pain and sciatica (Cochrane Review). In: The Cochrane Library, Issue 1. Update Software, Oxford�[PubMed]
91.�Hildebrandt VH, Proper KI, van den BR, Douwes M, Heuvel SG, Buuren S. Cesar therapy is temporarily more effective in patients with chronic low back pain than the standard treatment by family practitioner: randomized, controlled and blinded clinical trial with 1 year follow-up [Dutch]�Ned Tijdschr Geneesk.�2000;144:2258�2264.�[PubMed]
92.�Hindle T. Comparison of carisoprodol, butabarbital, and placebo in treatment of the low back syndrome.�Calif Med.�1972;117:7�11.�[PMC free article][PubMed]
93.�Hofstee DJ, Gutenbeek JMM, Hoogland PH, Houwelingen HC, Kloet A, L�tters F, Tans JTJ. Westeinde sciatica trial: randomized controlled study of bed rest and physiotherapy for acute sciatica.�J Neurosurg.�2002;96:45�49.�[PubMed]
94.�Hsieh CJ, Phillips RB, Adams AH, Pope MH. Functional outcomes of low back pain: comparison of four treatment groups in a randomized controlled trial.�J Manipulative Physiol Ther.�1992;15:4�9.[PubMed]
95.�Hurri H. The Swedish back school in chronic low-back pain. Part I. Benefits.�Scand J Rehabil Med.�1989;21:33�40.�[PubMed]
96.�Indahl A, Velund L, Reikeraas O. Good prognosis for low back pain when left untampered. A randomized clinical trial.�Spine.�1995;20:473�477.�[PubMed]
97.�Indahl A, Haldorsen EH, Holm S, Reikeras O, Ursin H. Five-year follow-up study of a controlled clinical trial using light mobilization and an informative approach to low back pain.�Spine.�1998;23:2625�2630. doi: 10.1097/00007632-199812010-00018.�[PubMed][Cross Ref]
98.�Jacobs JH, Grayson MF. Trial of anti-inflammatory agent (indomethacin) in low back pain with and without redicular involvement.�Br Med J.�1968;3:158�160.�[PMC free article][PubMed]
99.�Jenkins DG, Ebbutt AF, Evans CD. Tofranil in the treatment of low back pain.�J Int Med Res.�1976;4:28�40.�[PubMed]
100.�J�ckel WH, Cziske R, Gerdes N, Jacobi E. �berpr�fung der Wirksamkeit station�rer Rehabilitationsma�nahmen bei Patienten mit chronishen Kreuzschmerzen: eine prospective randomisierte, kontrollierte Studie.�Rehabilitation.�1990;29:129�133.�[PubMed]
101.�Kankaanpaa M, Taimela S, Airaksinen O, Hanninen O. The efficacy of active rehabilitation in chronic low back pain. Effect on pain intensity, self-experienced disability, and lumbar fatigability.�Spine.�1999;24:1034�1042. doi: 10.1097/00007632-199905150-00019.�[PubMed][Cross Ref]
102.�Katz N, Ju WD, Krupa DA. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomised, placebo-controlled, parallel-group. Double-blind trials.�Spine.�2003;28:851�859. doi: 10.1097/00007632-200305010-00002.�[PubMed][Cross Ref]
103.�Keijsers JFEM, Groenman NH, Gerards FM, Oudheusden E, Steenbakkers M. A back school in the Netherlands: evaluating the results.�Patient Educ Couns.�1989;14:31�44. doi: 10.1016/0738-3991(89)90005-0.�[PubMed][Cross Ref]
104.�Keijsers JFME, Steenbakkers WHL, Meertens RM, Bouter LM, Kok GJ. The efficacy of the back school: a randomized trial.�Arthritis Care Res.�1990;3:204�209.
105.�Klaber Moffett JA, Chase SM, Portek I, Ennis JR. A controlled prospective study to evaluate the effectiveness of a back school in the relief of chronic low-back pain.�Spine.�1986;11:120�122. doi: 10.1097/00007632-198603000-00003.�[PubMed][Cross Ref]
106.�Klaber Moffett J, Torgerson D, Bell-Syer S, Jackson D, Llewlyn-Phillips H, Farrin A. Randomised controlled trial of exercise for low back pain: clinical outcomes, costs, and preferences.�Br Med J.�1999;319:279�283.�[PMC free article][PubMed]
107.�Klinger N, Wilson R, Kanniainen C., Wagenknecht K, Re O, Gold R. Intravenous orphenadrine for the treatment of lumbar paravertebral muscle strain.�Curr Ther Res.�1988;43:247�254.
108.�Koes BW, Bouter LM, Mameren H, Essers AHM, Verstegen CMJR, Hofhuizen DM, Houben JP, Knipschild PG. Randomised clinical trial of manual therapy and physiotherapy for persistent back and neck complaints: results of one year follow-up.�Br Med J.�1992;304:601�605.�[PMC free article][PubMed]
109.�Koes BW, Tulder MW, Ostelo R, Kim Burton A, Waddell G. Clinical guidelines for the management of low back pain in primary care: an international comparison.�Spine.�2001;26:2504�2513. doi: 10.1097/00007632-200111150-00022.�[PubMed][Cross Ref]
110.�Konrad K, Tatrai T, Hunka A, Vereckei E, Korondi L. Controlled trial of balneotherapy in treatment of low back pain.�Ann Rheum Dis.�1992;51:820�822. doi: 10.1136/ard.51.6.820.�[PMC free article][PubMed][Cross Ref]
111.�Kuukkanen TM, Malkia EA. An experimental controlled study on postural sway and therapeutic exercise in subjects with low back pain.�Clin Rehabil.�2000;14:192�202. doi: 10.1191/026921500667300454.�[PubMed][Cross Ref]
112.�Lacey PH, Dodd GD, Shannon DJ. A double-blind placebo controlled study of piroxicam in the management of acute musculoskeletal disorders.�Eur J Rheumatol Inflamm.�1984;7:95�104.�[PubMed]
113.�Lankhorst GJ, Stadt RJ, Vogelaar TW, Korst JK, Prevo AJH. The effect of the Swedish back school in chronic idiopathic low-back pain.�Scand J Rehabil Med.�1983;15:141�145.�[PubMed]
114.�Larsson U, Ch�ler U, Lindstr�m A. Auto-traction for treatment of lumbago-sciatica. A multicenter controlled investigation.�Acta Orthop Scand.�1980;51:791�798. doi: 10.3109/17453678008990875.[PubMed][Cross Ref]
115.�Leclaire R, Esdaile JM, Suissa S, Rossignol M, Proulx R, Dupuis M. Back school in a first episode of compensated acute low back pain: a clinical trial to assess efficacy and prevent relapse.�Arch Phys Med Rehabil.�1996;77:673�679. doi: 10.1016/S0003-9993(96)90007-6.�[PubMed][Cross Ref]
116.�Lepisto P. A comparative trial of dS 103-282 and placebo in the treatment of acute skeletal muscle spasms due to disorders of the back.�Ther Res.�1979;26:454�459.
117.�Letchuman R, Deusinger RH. Comparison of sacrospinalis myoelectric activity and pain levels in patients undergoing static and intermittent lumbar traction.�Spine.�1993;18:1361�1365. doi: 10.1097/00007632-199308000-00017.�[PubMed][Cross Ref]
118.�Lidstrom A, Zachrisson M. Physical therapy on low back pain and sciatica.�Scand J Rehabil Med.�1970;2:37�42.�[PubMed]
119.�Lindequist SL, Lundberg B, Wikmark R, Bergstad B, Loof G, Ottermark AC. Information and regime at low-back pain.�Scand J Rehabil Med.�1984;16:113�116.�[PubMed]
120.�Lindstrom I, Ohlund C, Eek C, Wallin L, Peterson LE, Fordyce WE. The effect of graded activity on patients with subacute low back pain: a randomized prospective clinical study with an operant-conditioning behavioural approach.�Phys Ther.�1992;72:279�293.�[PubMed]
121.�Linton SJ, Bradley LA, Jensen I, Spangfort E, Sundell L. The secondary prevention of low back pain: a controlled study with follow-up.�Pain.�1989;36:197�207. doi: 10.1016/0304-3959(89)90024-9.�[PubMed][Cross Ref]
122.�Ljunggren E, Weber H, Larssen S. Autotraction versus manual traction in patients with prolapsed lumbar intervertebral discs.�Scand J Rehabil Med.�1984;16:117�124.�[PubMed]
123.�Loisel P, Abenhaim L, Durand P, Esdaile J, Suissa S, Gosselin L, Simard R, Turcotte J, Lemaire J. A population-based, randomized clinical trial on back pain management.�Spine.�1997;22:2911�2918. doi: 10.1097/00007632-199712150-00014.�[PubMed][Cross Ref]
124.�L�nn JH, Glomsr�d B, Soukup MG, B� K, Larsen S. Active back school: prophylactic management for low back pain. A randomized controlled 1-year follow-up study.�Spine.�1999;24:865�871. doi: 10.1097/00007632-199905010-00006.�[PubMed][Cross Ref]
125.�Lukinmaa�Kansanelakelaitoksen julkaisuja.�1989;ML:90.
126.�McGill SM. Abdominal belts in industry: a position paper on their assets, liabilities and use.�Am Ind Hyg Assoc.�1993;54:752�754.�[PubMed]
127.�Malmivaara A, H�kkinen U, Aro T, Heinrichs M-L, Koskenniemi L, Kuosma E, Lappi S, Paloheimo R, Servo C, Vaaranen V, Hernberg S. The treatment of acute low back pain�bed rest, exercises, or ordinary activity.�N Eng J Med.�1995;332:351�355. doi: 10.1056/NEJM199502093320602.�[PubMed][Cross Ref]
128.�Marchand S, Charest J, Li J, Chenard JR, Lavignolle B, Laurencelle L. Is TENS purely a placebo effect? A controlled study on chronic low back pain.�Pain.�1993;54:99�106. doi: 10.1016/0304-3959(93)90104-W.�[PubMed][Cross Ref]
129.�Mathews JA, Hickling J. Lumbar traction: a double-blind controlled study for sciatica.�Rheumatol Rehabil.�1975;14:222�225. doi: 10.1093/rheumatology/14.4.222.�[PubMed][Cross Ref]
130.�Mathews JA, Mills SB, Jenkins VM. Back pain and sciatica: controlled trials of manipulation, traction, sclerosant and epidural injections.�Br J Rheumatol.�1987;26:416�423. doi: 10.1093/rheumatology/26.6.416.�[PubMed][Cross Ref]
131.�Mathews W, Morkel M, Mathews J. Manipulation and traction for lumbago and sciatica: physiotherapeutic techniques used in two controlled trials.�Physiother Pract.�1988;4:201�206.
132.�Mellin G, Hurri H, H�rk�p�� K, J�rvikoski A. A controlled study on the outcome of inpatient and outpatient treatment of low back pain. Part II.�Scand J Rehabil Med.�1989;21:91�95.�[PubMed]
133.�Mellin G, H�rk�p�� K, Hurri H, J�rvikoski A. A controlled study on the outcome of inpatient and outpatient treatment of low back pain. Part IV.�Scand J Rehabil Med.�1990;22:189�194.�[PubMed]
134.�Milgrom C, Finestone A, Lev B, Wiener M, Floman Y. Overexertional lumbar and thoracic back pain among recruits: a prospective study of risk factors and treatment regimens.�J Spinal Disord.�1993;6:187�193. doi: 10.1097/00002517-199306030-00001.�[PubMed][Cross Ref]
135.�Milne S, Welch V, Brosseau L (2004) Transcutaneous electrical nerve stimulation (TENS) for chronic low back pain. In: The Cochrane Library, Issue 4. Update Software, Oxford
136.�Mitchell RI, Carmen GM. The functional restoration approach to the treatment of chronic pain in patients with soft tissue and back injuries.�Spine.�1994;19:633�642. doi: 10.1097/00007632-199403001-00001.�[PubMed][Cross Ref]
137.�Moll W. Zur therapie akuter lumbovertebraler syndrome durch optimale medikamentose muskelrelaxation mittels diazepam.�Med Welt.�1973;24:1747�1751.�[PubMed]
138.�Moseley L. Combined physiotherapy and education is efficacious for chronic low back pain.�Aust J Physiother.�2002;48:297�302.�[PubMed]
139.�Newton-John TR, Spence SH, Schotte D. Cognitive�behavioural therapy versus EMG biofeedback in the treatment of chronic low back pain.�Behav Res Ther.�1995;33:691�697. doi: 10.1016/0005-7967(95)00008-L.�[PubMed][Cross Ref]
140.�Niemist� L, Lahtinen-Suopanki T, Rissanen P, Lindgren K-A, Sarna S, Hurri H. A randomized trial of combined manipulation, stabilizing exercises, and physician consultation compared to physician consultation alone for chronic low back pain.�Spine.�2003;28:2185�2191. doi: 10.1097/01.BRS.0000085096.62603.61.�[PubMed][Cross Ref]
141.�Nicholas MK, Wilson PH, Goyen J. Operant�behavioural and cognitive�behavioural treatment for chronic low back pain.�Behav Res Ther.�1991;29:225�238. doi: 10.1016/0005-7967(91)90112-G.[PubMed][Cross Ref]
142.�Nicholas MK, Wilson PH, Goyen J. Comparison of cognitive�behavioral group treatment and an alternative non-psychological treatment for chronic low back pain.�Pain.�1992;48:339�347. doi: 10.1016/0304-3959(92)90082-M.�[PubMed][Cross Ref]
143.�Nouwen A. EMG biofeedback used to reduce standing levels of paraspinal muscle tension in chronic low back pain.�Pain.�1983;17:353�360. doi: 10.1016/0304-3959(83)90166-5.�[PubMed][Cross Ref]
144.�Oliphant D. Safety of spinal manipulation in the treatment of lumbar disk herniations: a systematic review and risk assessment.�J Manipulative Physiol Ther.�2004;27:197�210. doi: 10.1016/j.jmpt.2003.12.023.�[PubMed][Cross Ref]
145.�Ongley MJ, Klein RG, Dorman TA, Eek BC, Hubert LJ. A new approach to the treatment of chronic low back pain.�Lancet.�1987;2:143�146. doi: 10.1016/S0140-6736(87)92340-3.�[PubMed][Cross Ref]
146.�Ostelo RW, van Tulder MW, Vlaeyen JW, Linton SJ, Morley SJ, Assendelft WJ (2005) Behavioural treatment for chronic low-back pain. In: The Cochrane Library, Issue 1. Update Software, Oxford[PubMed]
147.�Pal P, Mangion P, Hossian MA, Diffey L. A controlled trial of continuous lumbar traction in the treatment of back pain and sciatica.�Br J Rheumatol.�1986;25:181�183. doi: 10.1093/rheumatology/25.2.181.�[PubMed][Cross Ref]
148.�Pallay RM, Seger W, Adler JL, Ettlinger RE, Quaidoo EA, Lipetz R, O�Brien K, Mucciola L, Skalky CS, Petruschke RA, Bohidar NR, Geba GP. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial.�Scand J Rheumatol.�2004;33:257�266. doi: 10.1080/03009740410005728.�[PubMed][Cross Ref]
149.�Penrose KW, Chook K, Stump JL. Acute and chronic effects of pneumatic lumbar support on muscular strength, flexibility, and functional impairment index.�Sports Train Med Rehabil.�1991;2:121�129.
150.�Penttinen J, Nevala-Puranen N, Airaksinen O, Jaaskelainen M, Sintonen H, Takala J. Randomized controlled trial of back school with and without peer support.�J Occup Rehabil.�2002;12:21�29. doi: 10.1023/A:1013594103133.�[PubMed][Cross Ref]
151.�Pheasant H, Bursk A, Goldfarb J, Azen SP, Weiss JN, Borelli L. Amitriptyline and chronic low back pain: a randomised double-blind crossover study.�Spine.�1983;8:552�557. doi: 10.1097/00007632-198307000-00012.�[PubMed][Cross Ref]
152.�Postacchini F, Facchini M, Palieri P. Efficacy of various forms of conservative treatment in low-back pain. A comparative study�. Neuro-Orthopedics.�1988;6:28�35.
153.�Pratzel HG, Alken R-G, Ramm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial.�Pain.�1996;67:417�425. doi: 10.1016/0304-3959(96)03187-9.�[PubMed][Cross Ref]
154.�Preyde M. Effectiveness of massage therapy for subacute low-back pain: a randomized controlled trial.�Can Med Assoc J.�2000;162:1815�1820.�[PMC free article][PubMed]
155.�Rasmussen GG. Manipulation in treatment of low back pain: a randomized clinical trial.�Man Med.�1979;1:8�10.
156.�Rasmussen-Barr E, Nilsson-Wikmar L, Arvidsson I. Stabilizing training compared with manual treatment in sub-acute and chronic low-back pain.�Man Ther.�2003;8:233�241. doi: 10.1016/S1356-689X(03)00053-5.�[PubMed][Cross Ref]
157.�Reust P, Chantraine A, Vischer TL. Traitement par tractions mecaniques des lombosciatalgies avec ou sans d�ficit neurologique.�Schweiz Med Wochenschr.�1988;118:271�274.�[PubMed]
158.�Risch SV, Norvell NK, Pollock Ml, Risch ED, Langer H, Fulton M. Lumbar strengthening in chronic low back pain patients: physiologic and psychological benefits.�Spine.�1993;18:232�238. doi: 10.1097/00007632-199302000-00010.�[PubMed][Cross Ref]
159.�Rozenberg S, Delval C, Rezvani Y. Bed rest or normal activity for patients with acute low back pain: a randomized controlled trial.Spine.�2002;27:1487�1493. doi: 10.1097/00007632-200207150-00002.[PubMed][Cross Ref]
160.�Sackett D (1997) Evidence based medicine. Churchill Livingstone
161.�Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment in chronic back pain: a meta-analysis.�Arch Intern Med.�2002;162:19�24. doi: 10.1001/archinte.162.1.19.�[PubMed][Cross Ref]
162.�Salzmann E, Pforringer W, Paal G, Gierend M. Treatment of chronic low-back syndrome with tetrazepam in a placebo controlled double-blind trial.�J Drug Dev.�1992;4:219�228.
163.�Schonstein E, Kenny D, Keating J, Koes B, Herbert RD. Physical conditioning programs for workers with back and neck pain: a Cochrane systematic review.�Spine.�2003;28:E391�E395. doi: 10.1097/01.BRS.0000092482.76386.97.�[PubMed][Cross Ref]
164.�Serferlis T, Lindholm L, Nemeth G. Cost-minimization analysis of three conservative treatment programmes in 180 patients sick-listed for acute low-back pain.�Scand J Prim Health Care.�2000;18:53�57. doi: 10.1080/02813430050202578.�[PubMed][Cross Ref]
165.�Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib long-term arthritis safety study.�JAMA.�2000;284:1247�1255. doi: 10.1001/jama.284.10.1247.�[PubMed][Cross Ref]
166.�Skargren EI, Oberg BE, Carlsson PG, Gade M. Cost and effectiveness analysis of chiropractic and physiotherapy treatment for low back and neck pain.�Six-month follow-up. Spine.�1997;22:2167�2177.[PubMed]
167.�Soukup MG, Glomsrod B, Lonn JH, Bo K, Larsen S, Fordyce WE. The effect of a Mensendieck exercise program as secondary prophylaxis for recurrent low back pain: a randomized, controlled trial with 12-month follow-up.�Spine.�1999;24:1585�1592. doi: 10.1097/00007632-199908010-00013.�[PubMed][Cross Ref]
168.�Soukup M, Lonn J, Glomsrod B, Bo K, Larsen S. Exercises and education as secondary prevention for recurrent low back pain.�Physiother Res Int.�2001;6:27�39. doi: 10.1002/pri.211.�[PubMed][Cross Ref]
169.�Staal JB, Hlobil H, Twisk JWR, Smid T, K�ke AJA. Graded activity for low back pain in occupational health care: a randomized controlled trial.�Ann Intern Med.�2004;140:77�84.�[PubMed]
170.�Staiger O, Barak G, Sullivan MD, Deyo RA. Systematic review of antidepressants in the treatment of chronic low back pain.�Spine.�2003;28:2540�2545. doi: 10.1097/01.BRS.0000092372.73527.BA.[PubMed][Cross Ref]
171.�Stankovic R, Johnell O. Conservative treatment of acute low back pain. A prospective randomized trial: McKenzie method of treatment versus patient education in �Mini Back School��Spine.�1990;15:120�123. doi: 10.1097/00007632-199002000-00014.�[PubMed][Cross Ref]
172.�Stankovic R, Johnell O. Conservative treatment of acute low-back pain: a 5-year follow-up study of two methods of treatment.�Spine.�1995;20:469�472. doi: 10.1097/00007632-199502001-00010.�[PubMed][Cross Ref]
173.�Storheim K, Brox JI, Holm I, Koller AK, Bo K. Intensive group training versus cognitive intervention in sub-acute low back pain: short-term results of a single-blind randomized controlled trial.�J Rehabil Med.�2003;35:132�140. doi: 10.1080/16501970310010484.�[PubMed][Cross Ref]
174.�Stuckey SJ, Jacobs A, Goldfarb J. EMG biofeedback training, relaxation training, and placebo for the relief of chronic back pain.�Percept Mot Skills.�1986;63:1023�1036.�[PubMed]
175.�Sweetman BJ, Baig A, Parsons DL. Mefenamic acid, chlormezanone-paracetamol, ethoheptazine-aaspirin-meprobamate: a comparative study in acute low back pain.�Br J Clin Pract.�1987;41:619�624.[PubMed]
176.�Sweetman BJ, Heinrich I, Anderson JAD. A randomized controlled trial of exercises, short wave diathermy, and traction for low back pain, with evidence of diagnosis-related response to treatment.�J Ortho Rheumatol.�1993;6:159�166.
177.�Szpalski M, Hayez JP. How many days of bed rest for acute low back pain? Objective assessment of trunk function.�Eur Spine J.�1992;1:29�31. doi: 10.1007/BF00302139.�[PubMed][Cross Ref]
178.�Szpalski M, Hayez JP. Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain: a double blind placebo-controlled study.�Br J Rheumatol.�1994;33:74�78. doi: 10.1093/rheumatology/33.1.74.�[PubMed][Cross Ref]
179.�Tesio L, Merlo A. Autotraction versus passive traction: an open controlled study in lumbar disc herniation.�Arch Phys Med Rehabil.�1993;74:871�876. doi: 10.1016/0003-9993(93)90015-3.�[PubMed][Cross Ref]
180.�Topol EJ. Failing the public health�rofecoxib, Merck, and the FDA.�N Engl J Med.�2004;351:1707�1709. doi: 10.1056/NEJMp048286.�[PubMed][Cross Ref]
181.�Torstensen TA, Ljunggren AE, Meen HD, Odland E, Mowinckel P, Geijerstam SA. Efficiency and costs of medical exercise therapy, conventional physiotherapy, and self-exercise in patients with chronic low back pain: a pragmatic, randomized, single-blinded, controlled trial with 1-year follow-up.�Spine.�1998;23:2616�2624. doi: 10.1097/00007632-199812010-00017.�[PubMed][Cross Ref]
182.�Triano JJ, McGregor M, Hondras MA, Brennan PC. Manipulative therapy versus education in chronic low back pain.�Spine.�1995;20:948�955. doi: 10.1097/00007632-199504150-00013.�[PubMed][Cross Ref]
183.�Turner JA. Comparison of group progressive-relaxation training and cognitive�behavioral group therapy for chronic low back pain.�J Consult Clin Psychol.�1982;50:757�765. doi: 10.1037/0022-006X.50.5.757.�[PubMed][Cross Ref]
184.�Turner JA, Clancy S. Comparison of operant�behavioral and cognitive�behavioral group treatment for chronic low back pain.�J Consult Clin Psychol.�1988;56:261�266. doi: 10.1037/0022-006X.56.2.261.[PubMed][Cross Ref]
185.�Turner JA, Jensen MP. Efficacy of cognitive therapy for chronic low back pain.�Pain.�1993;52:169�177. doi: 10.1016/0304-3959(93)90128-C.�[PubMed][Cross Ref]
186.�Turner JA, Clancy S, McQuade KJ, Cardenas DD. Effectiveness of behavioral therapy for chronic low back pain: a component analysis.�J Consult Clin Psychol.�1990;58:573�579. doi: 10.1037/0022-006X.58.5.573.�[PubMed][Cross Ref]
187.�Underwood MR, Morgan J. The use of a back class teaching extension exercises in the treatment of acute low back pain in primary care.�Fam Pract.�1998;15:9�15. doi: 10.1093/fampra/15.1.9.�[PubMed][Cross Ref]
188.�Valle-Jones JC, Walsh H, O�Hara J, O�Hara H, Davey NB, Hopkin-Richards H. Controlled trial of a back support in patients with non-specific low back pain.�Curr Med Res Opin.�1992;12:604�613.[PubMed]
189.�Heijden GJMG, Beurskens AJHM, Dirx MJM, Bouter LM, Lindeman E. Efficacy of lumbar traction: a randomised clinical trial.�Physiotherapy.�1995;81:29�35. doi: 10.1016/S0031-9406(05)67032-0.[Cross Ref]
190.�Tulder MW, Scholten RJPM, Koes BW, Deyo RA. Non-steroidal anti-inflammatory drugs for low back pain: a systematic review within the framework of the Cochrane Collaboration.�Spine.�2000;25:2501�2513. doi: 10.1097/00007632-200010010-00013.�[PubMed][Cross Ref]
191.�Tulder M, Furlan A, Bombardier C, Bouter L. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group.�Spine.�2003a;28:1290�1299. doi: 10.1097/00007632-200306150-00014.�[PubMed][Cross Ref]
192.�Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the Cochrane Collaboration.�Spine.�2003b;28:1978�1992. doi: 10.1097/01.BRS.0000090503.38830.AD.�[PubMed][Cross Ref]
193.�Tulder M, Furlan A, Gagnier J. Complementary and alternative therapies for low back pain.�Ballieres Best Pract Rheumatol.�2005;19:639�654. doi: 10.1016/j.berh.2005.03.006.�[PubMed][Cross Ref]
194.�Videman T, Heikkila J, Partanen T. Double-blind parallel study of meptazinol versus diflunisal in the treatment of lumbago.�Curr Med Res Opin.�1984;9:246�252.�[PubMed]
195.�Vollenbroek-Hutten MMR, Hermens HJ, Wever D, Gorter M, Rinket J, IJzerman MJ. Differences in outcome of a multidisciplinary treatment between subgroups of chronic low back pain patients defined using two multiaxial assessment instruments: the multidimensional pain inventory and lumbar dynamometry.�Clin Rehabil.�2004;18:566�579. doi: 10.1191/0269215504cr772oa.�[PubMed][Cross Ref]
196.�Vroomen PJAJ, Marc CTFM, Wilmink JT, Kester ADM, Knottnerus JA. Lack of effectiveness of bed rest for sciatica.�N Engl J Med.�1999;340:418�423. doi: 10.1056/NEJM199902113400602.�[PubMed][Cross Ref]
197.�Waagen GN, Haldeman S, Cook G, Lopez D, DeBoer KF. Short term trial of chiropractic adjustments for the relief of chronic low back pain.�Manual Med.�1986;2:63�67.
198.�Waddell G. A new clinical model for the treatment of low-back pain.�Spine.�1987;12:632�644. doi: 10.1097/00007632-198709000-00002.�[PubMed][Cross Ref]
199.�Walker L, Svenkerud T, Weber H. Traksjonsbehandling ved lumbago-ischias. En kontrollert undersolske med Spina-trac.�Fysioterapeuten.�1982;49:161�163.
200.�Ward N, Bokan JA, Phillips M, Benedetti C, Butler S, Spengler D. Antidepressants in concomitant chronic back pain and depression: doxepin and desipramine compared.�J Clin Psychiatry.�1984;45:54�57.[PubMed]
201.�Waterworth RF, Hunter A. An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain.�N Z Med J.�1985;95:372�375.�[PubMed]
202.�Weber H. Traction therapy in sciatica due to disc prolapse.�J Oslo City Hosp.�1973;23:167�176.[PubMed]
203.�Weber H, Aasand G. The effect of phenylbutazone on patients with acute lumbago-sciatica: a double blind trial.�J Oslo City Hosp.�1980;30:69�72.�[PubMed]
204.�Weber H, Ljunggren E, Walker L. Traction therapy in patients with herniated lumbar intervertebral discs.�J Oslo City Hosp.�1984;34:61�70.�[PubMed]
205.�Weber H, Holme I, Amlie E. The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam.�Spine.�1993;18:1433�1438. doi: 10.1097/00007632-199312000-00021.�[PubMed][Cross Ref]
206.�Werners R, Pynsent PB, Bulstrode CJK. Randomized trial comparing interferential therapy with motorized lumbar traction and massage in the management of low back pain in a primary care setting.�Spine.�1999;24:1579�1584. doi: 10.1097/00007632-199908010-00012.�[PubMed][Cross Ref]
207.�Wiesel SW, Cuckler JM, Deluca F, Jones F, Zeide MS, Rothman RH. Acute low back pain: an objective analysis of conservative therapy.�Spine.�1980;5:324�330. doi: 10.1097/00007632-198007000-00006.�[PubMed][Cross Ref]
208.�Wilkinson MJ. Does 48 hours� bed rest influence the outcome of acute low back pain?�Br J Gen Pract.�1995;45:481�484.�[PMC free article][PubMed]
209.�W�rz R, Bolten W, Heller J, Krainick U, Pergande G. Flupirtin im vergleich zu chlormezanon und placebo bei chronische muskuloskelettalen ruckenschmerzen.�Fortschritte der Therapie.�1996;114(35�36):500�504.�[PubMed]
210.�Wreje U, Nordgren B, Aberg H. Treatment of pelvic joint dysfunction in primary care�a controlled study.�Scand J Prim Health Care.�1992;10:310�315. doi: 10.3109/02813439209014080.�[PubMed][Cross Ref]
211.�Yelland MJ, Glasziou PP, Bogduk N, Schluter PJ, McKernon M. Prolotherapy injections, saline injections, and exercises for chronic low-back pain: a randomized trial.�Spine.�2004;29:9�16. doi: 10.1097/01.BRS.0000105529.07222.5B.�[PubMed][Cross Ref]
212.�Zachrisson Forsell M. The back school.�Spine.�1981;6:104�106. doi: 10.1097/00007632-198101000-00022.�[PubMed][Cross Ref]
213.�Zylbergold RS, Piper MC. Lumbar disc disease: comparative analysis of physical therapy treatments.�Arch Phys Med Rehabil.�1981;62:176�179.�[PubMed]
Close Accordion
Respiratory Health And Nutrition

Respiratory Health And Nutrition

Respiratory Health Abstract: Diet and nutrition may be important modifiable risk factors for the development,
progression and management of obstructive lung diseases such as asthma and chronic
obstructive pulmonary disease (COPD). This review examines the relationship between
dietary patterns, nutrient intake and weight status in obstructive lung diseases, at different
life stages, from in-utero influences through childhood and into adulthood. In vitro and
animal studies suggest important roles for various nutrients, some of which are supported by
epidemiological studies. However, few well-designed human intervention trials are available
to definitively assess the efficacy of different approaches to nutritional management of
respiratory diseases. Evidence for the impact of higher intakes of fruit and vegetables is
amongst the strongest, yet other dietary nutrients and dietary patterns require evidence from
human clinical studies before conclusions can be made about their effectiveness.

Keywords: respiratory disease; asthma; COPD; dietary patterns; antioxidants; vitamin C;
vitamin E; flavonoids; vitamin D; obesity; adipokines; undernutrition

1. Introduction:�Respiratory Health

Diet and nutrition are increasingly becoming recognized as modifiable contributors to chronic disease development and progression. Considerable evidence has emerged indicating the importance of dietary intake in obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) in both early life and disease development [1,2] and management of disease progression [3,4]. These�respiratory diseases are characterized by airway and systemic inflammation, airflow obstruction, deficits in lung function and significant morbidity and mortality, as well as being costly economic burdens [5,6]. Pharmacological management remains the mainstay for treatment of respiratory diseases, and while treatment options are advancing, dietary intake modification could be an important adjuvant to disease management and an important consideration for disease prevention. Dietary patterns as well as intake of individual nutrients have been evaluated in observational and experimental studies throughout life stages and disease stages to elucidate their role in respiratory diseases. This review concentrates on evidence regarding the role of dietary patterns, individual nutrients, weight status and adipokines in asthma and COPD.

2. Dietary Intake And Respiratory Diseases

2.1. Dietary Patterns:�Respiratory Health

Various dietary patterns have been linked to the risk of respiratory disease [7]. The Mediterranean diet has been found to have protective effects for allergic respiratory diseases in epidemiological studies [8]. This dietary pattern consists of a high intake of minimally processed plant foods, namely; fruit, vegetables, breads, cereals, beans, nuts and seeds, low to moderate intake of dairy foods, fish, poultry and wine and low intake of red meat. High intakes of olive oil result in a dietary composition that is low in saturated fat though still moderate in total fat. In children, several studies showed that adherence to the Mediterranean diet is inversely associated with atopy and has a protective effect on atopy, wheezing and asthma symptoms [9�11]. The Mediterranean diet may also be important for maternal diet, as a study in Spain found that a high Mediterranean diet score during pregnancy was protective for persistent wheeze and atopic wheeze in children at 6.5 years of age [12]. Though one cross-sectional study in Japan reported a strong association between the adherence to the Mediterranean diet and asthma control [13], there is less evidence available to support this dietary pattern in adults. The �western� dietary pattern, prevalent in developed countries, is characterised by high consumption of refined grains, cured and red meats, desserts and sweets, french fries, and high-fat dairy products [2,14]. This pattern of intake has been associated with increased risk of asthma in children [15,16]. Furthermore, in children, increased intake of fast food such as hamburgers and related eating behaviours, for example salty snack eating and frequent take away consumption, are correlated with the presence of asthma, wheezing and airway hyperresponsiveness (AHR) [17,18]. In adults, a western diet has been shown to be positively associated with increased frequency of asthma exacerbation [19], but not related to asthma risk. In addition, an acute challenge with a high fat fast food meal has been shown to worsen airway inflammation [20]. While this dietary pattern appears to be deleterious in children and adults with asthma, studies examining the effect of this dietary pattern in maternal diets have found no relationship with a consumption of a �western� style diet in pregnancy and risk of asthma in offspring [21]. Cross-sectional studies have also found that the �western� diet is associated with an increased risk of COPD [2]. In summary the Mediterranean diet appears to be protective in children, though there is less evidence for benefits in the maternal diet and in adults. There is evidence to suggest that a �western� style dietary pattern increases risk of asthma in children, has worse outcomes for adults with asthma and is related to COPD risk.

2.2. Fruit And Vegetables:�Respiratory Health

Fruit and vegetable intake has been investigated for potential benefits in association with respiratory conditions due to their nutrient profile consisting of antioxidants, vitamins, minerals, fibre and phytochemicals. The mechanisms by which the nutrients in fruit and vegetables exert beneficial effects in respiratory conditions are discussed in the sections below. Epidemiological evidence reviewed by Saadeh et al. [7] showed that fruit intake was associated with a low prevalence of wheezing and that cooked green vegetable intake was associated with a low prevalence of wheezing and asthma in school children aged 8�12 years old. Furthermore low vegetable intake in children was related to current asthma [7]. In adults, Grieger et al. [22] discusses the heterogeneous nature of the data describing fruit and vegetable intake and lung function, with one study showing no effect on lung function of higher fruit and vegetable intake over 10 years [23], yet in another study, increased fruit intake over 2 years was associated with increased FEV1 [23], while another study showed that a large decrease in fruit intake over 7 years was associated with decreased FEV1 [24]. We recently conducted an intervention in adults with asthma and found that subjects who consumed a high fruit and vegetable diet for 3 months, had a decreased risk of asthma exacerbation, compared to subjects who consumed a low fruit and vegetable diet [25]. A recent meta-analysis of adults and children, which analysed 12 cohorts, 4 population-based case-control studies, and 26 cross-sectional studies provides important new evidence showing that a high intake of fruit and vegetables reduces the risk of childhood wheezing, and that fruit and vegetable intake is negatively associated with asthma risk in adults and children [26]. While some studies of maternal diet have found no relationship with fruit and vegetable intake and asthma in children [27], other studies have found that increased fruit and vegetable intake were related to a decreased risk of asthma in children [21,28]. Increased fruit and vegetable intake may be protective against COPD development, with consumption of a �prudent� diet including increased fruit and vegetables being protective against lung function decline [3]. Two randomized controlled trials (RCT�s) manipulating fruit and vegetable intake have been conducted in COPD. A 12 week study showed no effect of a high fruit and vegetable intake on FEV1, systemic inflammation or airway oxidative stress [29]. However, a 3-year study in 120 COPD patients revealed an improvement in lung function in the high fruit and vegetable group compared to the control group [30], suggesting that longer term intervention is needed to provide a therapeutic effect. There is considerable evidence to suggest that a high intake of fruit and vegetables is favourable for all life stages of asthma and evidence is emerging which suggests the same in COPD.

2.3. Omega-3 Fatty Acids And Fish:�Respiratory Health

Omega-3 polyunsaturated fatty acids (PUFA) from marine sources and supplements have been shown to be anti-inflammatory through several cellular mechanisms including their incorporation into cellular membranes and resulting altered synthesis of eicosanoids [31]. Experimental studies have shown that long chain omega-3 PUFA�s decrease inflammatory cell production of pro-inflammatory prostaglandin (PG) E2, leukotriene (LT) B4 [32] and activity of nuclear factor-kappaB (NF-?B), a potent inflammatory transcription factor [33]. Long chain omega-3 PUFA�s also down regulate pro-inflammatory cell cytokine production (interleukin-1? (IL-1?), tumor necrosis factor-? (TNF-?)) by monocytes and macrophages, decrease expression of cellular adhesion molecules on monocytes and endothelial cells and reduce�production of ROS in neutrophils [34]. Saddeh et al. [7] reported that the evidence describing the relationship between omega-3 PUFA�s or fish consumption and respiratory conditions in childhood is contradictory. Some observational studies show that intake of oily fish is negatively associated with AHR and asthma [35,36]. However, evidence from Japan suggests that frequency of fish consumption is positively related to asthma risk [37] and in Saudi Arabia fish intake was not related to the presence of asthma or wheezing at all [18]. Similarly in adults, the data is heterogeneous, with omega-3 PUFAs or fish being associated with improved lung function [38] and decreased risk of asthma [39], AHR [35] and wheeze [36] in some, but not all studies [40]. Maternal dietary intake of oily fish was found to be protective of asthma in children 5 years of age if born to mothers with asthma [41] and a recent systematic review of omega-3 fatty acid supplementation studies in women during pregnancy found that the risk of asthma development in children was reduced [42]. The data examining the possible benefits of dietary omega-3 fatty acid supplementation in asthma are heterogeneous and as summarized by a 2002 Cochrane review [43], to date there is insufficient evidence to recommend omega-3 PUFA supplementation in asthma. Omega-3 PUFA may have positive effects in COPD, as higher levels of DHA in serum were found to decrease the risk of developing COPD [44]. Experimental studies in humans with COPD including supplementation with omega-3 found lower levels of TNF-? [45] and improved rehabilitation outcomes [46], though no improvements were seen in FEV1. Several studies using omega-3 PUFA supplementation in COPD are currently underway and will provide important new information to inform the field [47�49]. Consumption of oily fish or supplementation with omega-3 PUFA�s may have positive effects in asthma and COPD, though strong evidence to support the experimental and epidemiological data is not yet available.

3. Nutrients And Respiratory Disease

3.1. Antioxidants And Oxidative Stress

Dietary antioxidants are an important dietary factor in protecting against the damaging effects of oxidative stress in the airways, a characteristic of respiratory diseases [50]. Oxidative stress caused by reactive oxygen species (ROS), is generated in the lungs due to various exposures, such as air pollution, airborne irritants and typical airway inflammatory cell responses [51]. Also, increased levels of ROS generate further inflammation in the airways via activation of NF-?B and gene expression of pro-inflammatory mediators [52]. Antioxidants including vitamin C, vitamin E, flavonoids and carotenoids are abundantly present in fruits and vegetables, as well as nuts, vegetable oils, cocoa, red wine and green tea. Dietary antioxidants may have beneficial effects on respiratory health, from influences of the maternal diet on the fetus, and intake in children through to adults and pregnant women with asthma and adults with COPD. ?-tocopherol is a form of vitamin E, which helps maintain integrity of membrane fatty acids, by inhibiting lipid peroxidation [22]. Carotenoids are plant pigments and include; ?- and ?-carotene, lycopene, lutein and ?-cryptoxanthin. This group of fat soluble antioxidants have been shown to benefit respiratory health due to their ability to scavenge ROS and reduce oxidative stress [22]. The antioxidant lycopene, present predominantly in tomatoes, may be beneficial in respiratory conditions, indeed lycopene intake has been positively correlated with FEV1 in both asthma and COPD [53] and an�intervention study in asthma showed that lycopene supplementation could suppress neutrophilic airway inflammation [54]. Antioxidants may also be important in asthma during pregnancy, as while oxidative stress commonly increases during normal pregnancies, in women with asthma oxidative stress is heightened [55]. During pregnancy there is a compensatory increase in circulating and placental antioxidants in asthma versus women without asthma, to protect the foetus against damaging effects of oxidative stress [55,56]. Improving antioxidant intake in pregnant women with asthma may be beneficial as poor fetal growth outcomes are associated with low levels of circulating antioxidants and dietary antioxidants are the first defense mechanism against ROS [22]. Maternal intake of vitamin E, vitamin D, milk, cheese and calcium during pregnancy are negatively associated, while vitamin C is positively associated, with wheezing in early childhood [57,58]. Antioxidants including lycopene appear to have positive influences in respiratory conditions, further detail is provided below on evidence for vitamin C, vitamin E and flavonoids and their role in the maternal diet, diets of children and adults with asthma and adults with COPD.

3.2. Vitamin C:�Respiratory Health

Vitamin C has been enthusiastically investigated for benefits in asthma and links to asthma prevention. In vitro data from endothelial cell lines showed that vitamin C could inhibit NF-?B activation by IL-1, TNF-? and block production of IL-8 via mechanisms not dependent on the antioxidant activity of vitamin C [59]. Anti-inflammatory and anti-asthmatic effects of vitamin C supplementation in vivo, have been shown through allergic mouse models of asthma. Jeong et al. [60] reported decreased AHR to methacholine and inflammatory cell infiltration of perivascular and peribronchiolar spaces when vitamin C was supplemented during allergen challenge. While Chang et al. [61] found that high dose Vitamin C supplementation in allergen challenged mice decreased eosinophils in BALF and increased the ratio of Th1/Th2 cytokine production shifting the inflammatory pattern to Th1 dominant. Observational studies in children showed consumption of fruit, a rich source of vitamin C, was related to reduced wheezing [62] and vitamin C intake was negatively associated with wheezing [63], while another study reported no relationship between vitamin C intake and lung function [64]. Grieger et al. [22] also reported conflicting evidence for effects of vitamin C intake in adults, with epidemiological studies showing a positive association between vitamin C intake and lung function in some [65], but not all studies [23,66]. Despite the observational data linking vitamin C to lung health, supplementation with vitamin C has not been shown to reduce the risk of asthma [66] which may be related to the interdependence of nutrients found in foods, resulting in lack of efficacy when supplementing with isolated nutrients. Evidence from experimental and observational studies suggests that Vitamin C might be important in COPD pathogenesis and management. Koike et al. [67] reported that in knock out mice unable to synthesize vitamin C, vitamin C supplementation was able to prevent smoke induced emphysema and also to restore damaged lung tissue and decrease oxidative stress caused by smoke induced emphysema. A case control study in Taiwan reported that subjects with COPD had lower dietary intake and lower serum levels of vitamin C than healthy controls [68]. Indeed an epidemiological study in the United Kingdom of over 7000 adults aged 45�74 years found that increased plasma vitamin C concentration was associated with a decreased risk of obstructive airways disease, suggestive of a protective effect [69]. Thus, in summary, while observational data has suggested that vitamin C is important for lung health, intervention trials�showing efficacy are lacking and it appears that supplementation with vitamin C-rich whole foods, such
as fruit and vegetables may be more effective.

3.3. Vitamin E:�Respiratory Health

The vitamin E family comprises of 4 tocopherols and 4 tocotrienols, with the most plentiful in the diet or in tissues being ?-tocopherol and ?-tocopherol [70]. Vitamin E works synergistically with vitamin C, as following neutralisation of ROS, oxidised vitamin E isoforms can be processed back into their reduced form by vitamin C [71]. Abdala-Valencia et al. [72] discuss the evidence for the roles of ?-tocopherol and ?-tocopherol in allergic lung inflammation in mechanistic animal studies and clinical trials. Supplementation of mice with ?-tocopherol reduced allergic airway inflammation and AHR [73], while ?-tocopherol was pro-inflammatory and augmented AHR, negating the positive effects of ?-tocopherol [74]. Other animal studies report that ?-tocopherol may assist in resolving inflammation caused by ozone exposure and endotoxin induced neutrophilic airway inflammation, owing to its ability to oxidize reactive nitrogen species [75,76]. A study in humans showed that both ? and ?-tocopherol may be effective in decreasing LPS induced neutrophilic inflammation [77]. The conflicting results from these supplementation studies are likely to be influenced by baseline tissue levels of vitamin E [72], with ?-tocopherol supplementation leading to improved lung function and wheeze in Europe, where ?-tocopherol levels are low [78�80], but not in the US, where ?-tocopherol intake is high due to soybean oil consumption [81�83]. As a result, meta-analysis of vitamin E effects on asthma outcomes is equivocal; it is likely that supplementation with physiological concentrations of ?-tocopherol in the context of a background diet low in ?-tocopherol, may be most beneficial in asthma and further research testing this hypothesis is required. In COPD, serum levels of vitamin E have been shown to be decreased during exacerbation, which suggests increased intake may be helpful to improve vitamin E concentrations [84]. Vitamin E has been shown to reduce biomarkers of oxidative stress in adults with COPD in one RCT [85], but not another [86]. In the Women�s Health Study (n = 38,597), the risk of developing chronic lung disease over a 10 year supplementation period was reduced by 10% in women using vitamin E supplements (600 IU on alternate days) [87]. Dietary intake of vitamin E lower than recommended dietary intakes has been reported in pregnant women with a family history of allergic disease [88] and recent work in animal models has highlighted ?-tocopherol may be important for allergic mothers in pregnancy. Allergic female mice were supplemented with ?-tocopherol prior to mating and following allergen challenge the offspring showed reduced response to allergen challenge with decreased eosinophils in BALF [89]. The offspring also showed reduced development of lung dendritic cells, necessary for producing allergic responses. Evidence from observational studies also suggests that reduced maternal dietary intake of vitamin E is related to an increased risk of childhood asthma and wheeze [90�92] and increased in vitro proliferative responses in cord blood mononuclear cells (CBMC) [93]. A mechanistic study by Wassall et al. [94] examined the effect of ?-tocopherol and vitamin C on CBMC and maternal peripheral blood mononuclear cells (PBMC). ?-tocopherol was mostly anti-inflammatory, although increased proliferation and increased TGF-? were seen with some allergens. However, the addition of vitamin C to the system had inflammatory actions, with increased production of pro-inflammatory cytokines, combined with reduced production of IL-10 and TGF-?. This study by Wassall et al. [94] demonstrates that supplementation�with these antioxidants does modulate immune responses in pregnancy, however several of the results are unexpected, highlighting the complex nature of the relationships between dietary nutrients and disease. In asthma the experimental data for vitamin E are compelling, yet supplementation benefits are not well described. In COPD there is currently not enough evidence to make conclusions about vitamin E supplementation.

3.4. Flavonoids:�Respiratory Health

Flavonoids are potent antioxidants and have anti-inflammatory as well as anti-allergic actions due in part, to their ability to neutralise ROS [95]. There are 6 classes of flavonoids including flavones, flavonols, flavanones, isoflavones and flavanols [96], which are widely distributed throughout the diet and found in fruit, vegetables, nuts, seeds, stems, flowers, roots, bark, dark chocolate, tea, wine and coffee [96]. Tanaka et al. [95] present the evidence for the benefits of dietary flavonoids in asthma development and progression. In addition to reducing oxidative stress, in vitro experiments have found that many individual flavonoids have inhibitory effects on IgE mediated immune responses such as histamine secretion by mast cells, shift in cytokine production from Th-2 to Th-1 production and decreased NF-?B activation and inhibition of TNF-? [97�100]. Experimental studies of flavonoids in animal models of allergic asthma have shown reduced airway and peripheral blood inflammation, decreased bronchoconstriction and AHR and lower eosinophils in BALF, blood and lung tissue [101�104]. In humans, evidence from a case control study in adults showed that apple and red wine consumption, rich sources of flavonoids, was associated with reduced asthma prevalence and severity [66]. However a follow-up study investigating intake of 3 subclasses of flavonoids did not find any associations with asthma prevalence or severity [105]. There are a limited number of experimental studies using flavonoid supplements in humans with asthma. Three RCT�s in adults with asthma using a product called pycnogenol, which contains a mixture of bioflavonoids, reported benefits including increased lung function, decreased symptoms and reduced need for rescue inhalers [106]. There is a paucity of evidence for the effects of flavonoids in the maternal diet and respiratory outcomes in children. One study which found a positive association of maternal apple intake and asthma in children at 5 years, suggests that the flavonoid content of apples may be responsible for the beneficial relationship [107]. Evidence for the effects of flavonoids in respiratory conditions is emerging and promising. Though like vitamin C, it may be difficult to disentangle the effects of flavonoids from other nutrients in flavonoid-rich foods. Supplementation of individual flavonoids in experimental animal studies has provided evidence to suggest that intervention trials in humans may be warranted.

3.5. Vitamin D:�Respiratory Health

Epidemiological studies show promising associations between vitamin D and lung health; however the mechanisms responsible for these effects are poorly understood. Vitamin D can be obtained from dietary sources or supplementation; however sun exposure is the main contributor to vitamin D levels [108]. While vitamin D has beneficial effects independent of UV exposure [109], it can be difficult to separate this potential confounder from direct effects of vitamin D on lung health [110]. The review by Foong and Zosky [111] presents the current evidence for the role of vitamin D deficiency in disease onset, progression and exacerbation in respiratory infections, asthma and COPD. Respiratory infections contribute to disease progression and exacerbation in both COPD and asthma. Vitamin D appears to have a protective role against the susceptibility to and severity of these infections [111], as active vitamin D (1,25 (OH)2D) modifies production of antimicrobial cathelicidins and defensins that kill bacteria and induce wound repair [112]. Activated vitamin D also decreases the expression of rhinovirus receptors in endothelial cell cultures and PBMC�s [113]. In vitro studies also support the link between vitamin D and airway remodelling as active vitamin D inhibits airway smooth muscle (ASM) cell proliferation [114] and deficiency impairs normal lung development [115]. Furthermore, animal models suggest that vitamin D can inhibit Th1 and Th2 cell cytokine production [116]. Epidemiological evidence links low levels of vitamin D with wheeze and respiratory infections, though evidence for the link with asthma onset is weak and inconsistent [111]. In children, low circulating vitamin D was related to lower lung function, increased corticosteroid use and exacerbation frequency [117]. Also in children with steroid resistant asthma, low vitamin D was related to increased ASM thickness [117]. Other observational studies report that in children, low levels of vitamin D are associated with asthma exacerbation [118]. Several observational studies support the role of vitamin D for protection against respiratory conditions in children. Zosky et al. [119] found that vitamin D deficiency at 18 weeks gestation was associated with lower lung function and current wheeze in children 6 years of age and an increased risk of asthma in boys. The role for vitamin D in enhancing steroid responsiveness suggested by observational studies [120] is supported by mechanistic studies [121], and in concert with the actions of vitamin D in infection, may explain the effect of vitamin D in reducing asthma exacerbations [111]. Only one intervention trial has been conducted using vitamin D in adults with asthma, which found that rate of first exacerbation was reduced in subjects who demonstrated an increase in circulating vitamin D3 following supplementation [122]. Data for the role of vitamin D in COPD onset is limited, though several cross-sectional studies have reported an association between low vitamin D levels, or deficiency, with COPD incidence [123]. Blood vitamin D levels have also been correlated with lung function in COPD patients [124,125]. Experimental data suggest that vitamin D may be important in COPD for its effect on normal lung growth and development, though human data to support this is not available. It is possible that COPD onset may also be impacted by cellular responses to cigarette smoke exposure which inhibits the protective immunomodulatory effects of vitamin D [126]. There is research suggesting a genetic link between vitamin D and COPD pathogenesis. In an observational study single nucleotide polymorphisms in the vitamin D binding protein (VDBP) predicted vitamin D levels in COPD patients and were found to be a risk factor for COPD [123]. The VDBP is also involved in macrophage activation as high levels of airway VDBP are related to increased macrophage activation, also high levels of serum VDBP were found to be related to lower lung function [127]. COPD progression may also be affected by vitamin D status through absence of the vitamin D receptor and parenchyma degradation [128]. COPD exacerbations are generally caused by viral or bacterial lung infections, and though vitamin D has a positive role in reducing infection, there is no evidence to support that vitamin D is associated with ameliorating exacerbations in COPD patients [129]. The extra-skeletal effects of vitamin D are well documented in both asthma and COPD, and deficiency is associated with negative respiratory and immune outcomes. At this stage however, more evidence from supplementation interventions is needed before widespread adoption of supplementation can be recommended.

3.6. Minerals:�Respiratory Health

Some minerals have also been found to be protective in respiratory conditions. In children, increased intake of magnesium, calcium and potassium is inversely related to asthma prevalence [7]. While several observational and experimental trials have been performed with conflicting results [130], a randomised controlled trial concluded that a low sodium diet had no therapeutic benefit for bronchial reactivity in adults with asthma [131]. Dietary magnesium may have beneficial bronchodilator effects in asthma [132]. Low dietary magnesium intake has been associated with negative effects on bronchial smooth muscle in severe asthma [133] and with lower lung function in children [134]. However further evidence of positive therapeutic effects are required before its importance in asthma and recommendations can be determined [135]. Dietary intake of selenium has been shown to be lower in asthmatics compared to non-asthmatics [136] and maternal plasma selenium levels were reported to be inversely associated with risk of asthma in children [137]. However case control studies in children have not found a relationship with selenium levels or intake with asthma related outcomes [18,138]. Furthermore, results from a large well designed RCT in adults with asthma showed no positive benefit of selenium supplementation [139]. Investigation of minerals in cord blood imply the importance of adequate intake during pregnancy, as levels of cord blood selenium were negatively associated with persistent wheeze, and levels of iron were negatively associated with later onset wheeze in children [140]. Studies on dietary intake of minerals and associations with COPD are sparse. A small study in Sweden found that in older subjects with severe COPD, intakes of folic acid and selenium were below recommended levels, and although intake of calcium was adequate, serum calcium levels were low, likely related to their vitamin D status as intake was lower than recommended [141]. Mineral intake may be important in respiratory diseases, yet evidence for supplementation is weak. It is likely that adequate intake of these nutrients in a whole diet approach is sufficient.

4. Obesity, Adipokines And Respiratory Disease

Overnutrition and resulting obesity are clearly linked with asthma, though the mechanisms involved are still under investigation. The review by Periyalil et al. [142] describes how immunometabolismadipose tissue derived immunological changes causing metabolic effects [143] contributes to the link between asthma and obesity. In the obese state dietary intake of lipids leads to increased circulating free fatty acids [144], which activate immune responses, such as activation of TLR4, leading to increased inflammation, both systemically and in the airways [20]. Adipose tissue also secretes adipokines and asthmatic subjects have higher concentrations of circulating leptin than healthy controls [14] which are further increased in females, though leptin is associated with BMI in both males and females [145]. Leptin receptors are present in the bronchial and alveolar epithelial cells and leptin has been shown to induce activation of alveolar macrophages [146] and have indirect effects on neutrophils [147]. Also leptin promotes Th1 proliferation inducing increased activation of neutrophils by TNF-? [148]. In vitro, leptin also activates alveolar macrophages taken from obese asthmatics, which induces airway inflammation through production of pro-inflammatory cytokines [149]. However, a causal role for leptin in the obese asthma relationship is yet to be established. Adiponectin, an anti-inflammatory adipokine, has beneficial effects in animal models of asthma [150], however, positive associations in human studies have only been seen in women [151]. In obesity, macrophage and mast cell infiltration into adipose tissue is upregulated [142]. Neutrophils also appear to dominate airway inflammation in the obese asthma phenotype [152], particularly in females [153], which may explain why inhaled corticosteroids are less effective in achieving control in obese asthma [154]. While the mechanisms are yet to be understood, a recent review reports that obesity in pregnancy is associated with higher odds of asthma in children, with increased risk as maternal BMI increases [155].

COPD is characterised not only by pulmonary deficits but also by chronic systemic inflammation and co-morbidities which may develop in response to the metabolic dysregulation that occurs with excess adipose tissue [156]. A recent meta-analysis of leptin levels in COPD reported a correlation with body mass index (BMI) and fat mass percent in stable COPD though absolute levels were not different to healthy controls [157]. During exacerbation, leptin levels increased and were positively associated with circulating TNF-? [157]. Bianco et al. [158] describes the role of adiponectin and its effect on inflammation in COPD. Adiponectin has anti-inflammatory effects and is present in high concentrations in serum of healthy subjects [159]. Adiponectin exists in several isoforms, which have varied biological effects [160] and interact with two receptors present in the lungs (AdipoR1 and AdipoR2) that have opposing effects on inflammation [161]. Single nucleotide polymorphisms in the gene encoding adiponectin are associated with cardiovascular disease, obesity and the metabolic syndrome [162]. The role of adiponectin in COPD however is not well understood. In COPD, serum adiponectin is increased and directly relates to disease severity and lung function decline [163]. There is an alteration in the oligomerisation of adiponectin in COPD resulting in increased concentrations of the anti-inflammatory higher-molecular weight isoform [164], and the expression of adiponectin receptors in the lung is also altered in comparison to healthy subjects [165]. Animal models have shown anti-inflammatory effects of adiponectin in the lung through the increased expression of TNF-? in alveolar macrophages in adiponectin deficient mice [166]. Further mechanistic studies have also shown the anti-inflammatory potential of adiponectin by reducing the effects of TNF-?, IL-1? and NF-?B and increasing expression of IL-10 through interaction with AdipoR1 [161]. However under certain conditions in cell lines and animal models adiponectin has been shown to have pro-inflammatory effects [167,168]. As both detrimental and protective effects have been seen, the complex modulation of adiponectin isoforms and receptors in COPD requires further exploration. Obesity, the resulting systemic inflammation and alterations in adipokines have significant negative effects in both asthma and COPD. While work examining the mechanisms of effect is extensive, evidence for interventions to improve the course of disease are limited to weight loss interventions in asthma at this stage.

5. Undernutrition And Respiratory Disease

Though underweight has not been well studied in asthma, an observational study in Japan reported that subjects with asthma who were underweight had poorer asthma control than their normal weight counterparts [169]. While there is widespread acknowledgement that malnutrition in pregnant women adversely effects of the lung development of the fetus [170], a recent review reported that the offspring of mothers who were underweight did not have an increased risk of asthma. Amongst the obstructive lung diseases, undernutrition is most commonly recognized as a feature of COPD. Itoh et al. [171] present a review on undernutrition in COPD and the evidence for nutritional therapy in management�of the disease. Weight loss, low body weight and muscle wasting are common in COPD patients with advanced disease and are associated with reduced survival time and an increased risk of exacerbation [172]. The causes of undernutrition in COPD are multifactorial and include reduced energy intake due to decreased appetite, depression, lower physical activity and dyspnoea while eating [173]. In addition, resting energy expenditure is increased in COPD, likely due to higher energy demands from increased work of breathing [174]. Also, systemic inflammation which is a hallmark of COPD, may influence energy intake and expenditure [175]. Cigarette smoke may also have deleterious effects on body composition in addition to the systemic effects of COPD. Smoking causes muscle fibre atrophy and decreased muscle oxidative capacity shown in cohorts of non-COPD smokers [176,177] and in animal models of chronic smoke exposure [178,179]. The mechanisms underlying muscle wasting in COPD are complex and multifaceted [180]. Increased protein degradation occurs in the whole body, though it is enhanced in the diaphragm [181]. Protein synthesis pathways are altered, indeed insulin like growth factor-1 (IGF-1) which is essential for muscle synthesis is decreased in cachectic COPD patients [182] and is lower in COPD patients during acute exacerbation, compared to healthy controls [183]. Increased oxidative stress, due to increased mitochondrial ROS production, occurs both systemically and in muscle tissue in cachectic COPD patients and is negatively associated with fat free mass (FFM) and muscle strength in COPD patients [184]. Furthermore myostatin induces muscle atrophy by inhibiting proliferation of myoblasts and mRNA expression of myostain is increased in cachectic COPD patients and is related to muscle mass [185]. Systemic inflammatory mediators such as TNF-? and NF-?B are also implicated in COPD muscle atrophy [186,187]. Nutritional supplementation therapy in undernourished COPD patients has been shown to induce weight gain, increase fat free mass, increase grip strength and exercise tolerance as well as improve quality of life [188]. Further studies point out the importance of not only high energy content, but also macronutrient composition of the nutritional supplement and inclusion of low intensity respiratory rehabilitation exercise [189,190]. Other dietary nutrients have been investigated for the benefits in COPD. Creatinine, found in meat and fish, did not have additive effects to rehabilitation, while sulforaphane, found in broccoli and wasabi, and curcumin, the pigment in turmeric, may have beneficial antioxidant properties [191�193]. Branched chain amino acid supplementation in COPD is associated with positive results including increases in whole body protein synthesis, body weight, fat free mass and arterial blood oxygen levels [194,195]. Undernutrition is not a significant problem in asthma, though is a major debilitating feature of COPD. There is promising evidence that nutritional supplementation in COPD is important and can help to alleviate some of the adverse effects of the disease, particularly muscle wasting and weight loss.

6. Conclusions: Respiratory Health

Dietary intake appears to be important in both the development and management of respiratory diseases, shown through epidemiological and cross-sectional studies and supported by mechanistic studies in animal models. Although more evidence is needed from intervention studies in humans, there is a clear link for some nutrients and dietary patterns. The dietary patterns associated with benefits in respiratory diseases include high fruit and vegetable intake, Mediterranean style diet, fish and omega-3 intake, while fast food intake and westernized dietary�patterns have adverse associations. Figure 1 shows a diagrammatic representation of the relationships of nutrition and obstructive lung diseases.

respiratory

Respiratory Health

Though antioxidants are associated with positive effects on inflammation, clinical outcomes and respiratory disease prevention, intervention studies of individual antioxidants do not indicate widespread adoption of supplementation [196]. Differences in results from individual studies including whole foods such as fruit and vegetables and fish could be influenced by the nutritional profile owing to the region it was grown or produced. In considering studies using single nutrients it is also important to acknowledge that nutrients in the diet are consumed as whole foods that contain other micronutrients, fibre and compounds with both known and unknown anti and pro-inflammatory potential. Furthermore investigations of single nutrients should ideally control for other antioxidants and dietary sources of pro-inflammatory nutrients. While this limitation is common, it is a significant challenge to control for dietary intake of other nutrients in clinical trials. A whole foods approach to nutrient supplementation�for example, increasing intake of fruit and vegetables, has the benefit of increasing intake of multiple nutrients, including vitamin C, vitamin E, carotenoids and flavonoids and shows more promise in respiratory diseases in terms of reducing risk of COPD [3] and incidence of asthma exacerbations [25].

The evidence for mechanisms of vitamin D in lung development and immune function are yet to be fully established. It appears that vitamin D is important in respiratory diseases and infections, however the temporal role of vitamin D deficiency in disease onset, pathogenesis and exacerbations and whether supplementation is indicated is yet to be clarified.

Overnutrition in respiratory disease is clearly associated with adverse effects, highlighted by detrimental effects induced by immunometabolism. Further understanding of the relationship between mediators of immunometabolism and respiratory diseases and their mechanisms may provide therapeutic options. Undernutrition still poses risk in some respiratory conditions. Appropriate nutritional supplementation in advanced COPD is indicated, and several nutrients appear to be beneficial in COPD development and exacerbation.

The field of nutrition and respiratory disease continues to develop and expand, though further work is required in the form of randomized controlled dietary manipulation studies using whole foods to enable provision of evidence based recommendations for managing respiratory conditions.

Bronwyn S. Berthon and Lisa G. Wood *

Centre for Asthma and Respiratory Diseases, Level 2, Hunter Medical Research Institute,
University of Newcastle, Lot 1 Kookaburra Circuit, New Lambton Heights, NSW 2305, Australia;
E-Mail: bronwyn.berthon@newcastle.edu.au

* Author to whom correspondence should be addressed; E-Mail: lisa.wood@newcastle.edu.au;
Tel.: +61-2-4042-0147; Fax: +61-2-4042-0046.

Author Contributions

Bronwyn Berthon and Lisa Wood contributed to the study concept and design and were both involved in the preparation and completion of the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

� 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/4.0/).

blank
References:

1. Nurmatov, U.; Devereux, G.; Sheikh, A. Nutrients and foods for the primary prevention of asthma
and allergy: Systematic review and meta-analysis. J. Allergy Clin. Immunol. 2011, 127,
724�733.e30.
2. Varraso, R.; Fung, T.T.; Barr, R.G.; Hu, F.B.; Willett, W.; Camargo, C.A.J. Prospective study of
dietary patterns and chronic obstructive pulmonary disease among US women. Am. J. Clin. Nutr.
2007, 86, 488�495.
3. Shaheen, S.O.; Jameson, K.A.; Syddall, H.E.; Aihie Sayer, A.; Dennison, E.M.; Cooper, C.;
Robinson, S.M.; Hertfordshire Cohort Study Group. The relationship of dietary patterns with adult
lung function and COPD. Eur. Respir. J. 2010, 36, 277�284.
4. Scott, H.A.; Jensen, M.E.; Wood, L.G. Dietary interventions in asthma. Curr. Pharm. Des. 2014,
20, 1003�1010.
5. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention
2012 (update). Available online: http://www.ginasthma.org (accessed on 30 July 2013).
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the
Diagnosis, Management and Prevention of COPD. Available online: http://www.goldcopd.org/
(accessed on 3 December 2014).
7. Saadeh, D.; Salameh, P.; Baldi, I.; Raherison, C. Diet and allergic diseases among population aged
0 to 18 years: Myth or reality? Nutrients 2013, 5, 3399�3423.
8. Willett, W.C.; Sacks, F.; Trichopoulou, A.; Drescher, G.; Ferro-Luzzi, A.; Helsing, E.;
Trichopoulos, D. Mediterranean diet pyramid: A cultural model for healthy eating. Am. J. Clin.
Nutr. 1995, 61, 1402S�1406S.
9. Arvaniti, F.; Priftis, K.N.; Papadimitriou, A.; Papadopoulos, M.; Roma, E.; Kapsokefalou, M.;
Anthracopoulos, M.B.; Panagiotakos, D.B. Adherence to the Mediterranean type of diet is associated
with lower prevalence of asthma symptoms, among 10�12 years old children: The PANACEA
study. Pediatr. Allergy Immunol. 2011, 22, 283�289.
10. Chatzi, L.; Kogevinas, M. Prenatal and childhood Mediterranean diet and the development of
asthma and allergies in children. Public Health Nutr. 2009, 12, 1629�1634.
11. De Batlle, J.; Garcia-Aymerich, J.; Barraza-Villarreal, A.; Ant�, J.M.; Romieu, I. Mediterranean
diet is associated with reduced asthma and rhinitis in Mexican children. Allergy 2008, 63,
1310�1316.
12. Chatzi, L.; Torrent, M.; Romieu, I.; Garcia-Esteban, R.; Ferrer, C.; Vioque, J.; Kogevinas, M.;
Sunyer, J. Mediterranean diet in pregnancy is protective for wheeze and atopy in childhood. Thorax
2008, 63, 507�513.
13. Barros, R.; Moreira, A.; Fonseca, J.; de Oliveira, J.F.; Delgado, L.; Castel-Branco, M.G.; Haahtela,
T.; Lopes, C.; Moreira, P. Adherence to the Mediterranean diet and fresh fruit intake are associated
with improved asthma control. Allergy 2008, 63, 917�923.
14. Wood, L.G.; Gibson, P.G. Dietary factors lead to innate immune activation in asthma. Pharmacol.
Ther. 2009, 123, 37�53.
15. Carey, O.J.; Cookson, J.B.; Britton, J.; Tattersfield, A.E. The effect of lifestyle on wheeze, atopy,
and bronchial hyperreactivity in Asian and white children. Am. J. Respir. Crit. Care Med. 1996, 154,
537�540.
16. Huang, S.L.; Lin, K.C.; Pan, W.H. Dietary factors associated with physician-diagnosed asthma and
allergic rhinitis in teenagers: Analyses of the first Nutrition and Health Survey in Taiwan. Clin.
Exp. Allergy 2001, 31, 259�264.
17. Wickens, K.; Barry, D.; Friezema, A.; Rhodius, R.; Bone, N.; Purdie, G.; Crane, J. Fast foods�
Are they a risk factor for asthma? Allergy 2005, 60, 1537�1541.
18. Hijazi, N.; Abalkhail, B.; Seaton, A. Diet and childhood asthma in a society in transition: A study
in urban and rural Saudi Arabia. Thorax 2000, 55, 775�779.
19. Varraso, R.; Kauffmann, F.; Leynaert, B.; Le Moual, N.; Boutron-Ruault, M.C.; Clavel-Chapelon,
F.; Romieu, I. Dietary patterns and asthma in the E3N study. Eur. Respir. J. 2009, 33, 33�41.
20. Wood, L.G.; Garg, M.L.; Gibson, P.G. A high-fat challenge increases airway inflammation and
impairs bronchodilator recovery in asthma. J. Allergy Clin. Immunol. 2011, 127, 1133�1140.
21. Netting, M.J.; Middleton, P.F.; Makrides, M. Does maternal diet during pregnancy and lactation
affect outcomes in offspring? A systematic review of food-based approaches. Nutrition 2014, 30,
1225�1241.
22. Grieger, J.; Wood, L.; Clifton, V. Improving asthma during pregnancy with dietary antioxidants:
The current evidence. Nutrients 2013, 5, 3212�3234.
23. Butland, B.K.; Fehily, A.M.; Elwood, P.C. Diet, lung function, and lung function decline in
a cohort of 2512 middle aged men. Thorax 2000, 55, 102�108.
24. Carey, I.M.; Strachan, D.P.; Cook, D.G. Effects of changes in fresh fruit consumption on
ventilatory function in healthy British adults. Am. J. Respir. Crit. Care Med. 1998, 158, 728�733.
25. Wood, L.G.; Garg, M.L.; Smart, J.M.; Scott, H.A.; Barker, D.; Gibson, P.G. Manipulating
antioxidant intake in asthma: A randomized controlled trial. Am. J. Clin. Nutr. 2012, 96, 534�543.
26. Seyedrezazadeh, E.; Moghaddam, M.P.; Ansarin, K.; Vafa, M.R.; Sharma, S.; Kolahdooz, F. Fruit
and vegetable intake and risk of wheezing and asthma: A systematic review and meta-analysis. Nutr.
Rev. 2014, 72, 411�428.
27. Erkkola, M.; Nwaru, B.I.; Kaila, M.; Kronberg-Kippil�, C.; Ilonen, J.; Simell, O.; Veijola, R.;
Knip, M.; Virtanen, S.M. Risk of asthma and allergic outcomes in the offspring in relation to
maternal food consumption during pregnancy: A Finnish birth cohort study. Pediatr. Allergy
Immunol. 2012, 23, 186�194.
28. Fitzsimon, N.; Fallon, U.; O�Mahony, D.; Loftus, B.G.; Bury, G.; Murphy, A.W.; Kelleher, C.C.;
Lifeways Cross Generation Cohort Study Steering Group. Mother�s dietary patterns during
pregnancy and risk of asthma symptoms in children at 3 years. Ir. Med. J. 2007, 100, 27�32.
29. Baldrick, F.R.; Elborn, J.S.; Woodside, J.V.; Treacy, K.; Bradley, J.M.; Patterson, C.C.;
Schock, B.C.; Ennis, M.; Young, I.S.; McKinley, M.C. Effect of fruit and vegetable intake on
oxidative stress and inflammation in COPD: A randomised controlled trial. Eur. Respir. J. 2012, 39,
1377�1384.
30. Keranis, E.; Makris, D.; Rodopoulou, P.; Martinou, H.; Papamakarios, G.; Daniil, Z.; Zintzaras, E.;
Gourgoulianis, K.I. Impact of dietary shift to higher-antioxidant foods in COPD: A randomised
trial. Eur. Respir. J. 2010, 36, 774�780.
31. Thies, F.; Miles, E.A.; Nebe-von-Caron, G.; Powell, J.R.; Hurst, T.L.; Newsholme, E.A.;
Calder, P.C. Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty
acids on blood inflammatory cell populations and functions and on plasma soluble adhesion
molecules in healthy adults. Lipids 2001, 36, 1183�1193.
32. Kelley, D.S.; Taylor, P.C.; Nelson, G.J.; Schmidt, P.C.; Ferretti, A.; Erickson, K.L.; Yu, R.;
Chandra, R.K.; Mackey, B.E. Docosahexaenoic acid ingestion inhibits natural killer cell activity
and production of inflammatory mediators in young healthy men. Lipids 1999, 34, 317�324.
33. Lo, C.J.; Chiu, K.C.; Fu, M.; Chu, A.; Helton, S. Fish oil modulates macrophage P44/P42 mitogenactivated
protein kinase activity induced by lipopolysaccharide. J. Parenter. Enter. Nutr. 2000, 24,
159�163.
34. Calder, P.C. n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin.
Nutr. 2006, 83, 1505S�1519S.
35. Peat, J.K.; Salome, C.M.; Woolcock, A.J. Factors associated with bronchial hyperresponsiveness
in Australian adults and children. Eur. Respir. J. 1992, 5, 921�929.
36. Tabak, C.; Wijga, A.H.; de Meer, G.; Janssen, N.A.; Brunekreef, B.; Smit, H.A. Diet and asthma
in Dutch school children (ISAAC-2). Thorax 2006, 61, 1048�1053.
37. Takemura, Y.; Sakurai, Y.; Honjo, S.; Tokimatsu, A.; Tokimatsu, A.; Gibo, M.; Hara, T.; Kusakari,
A.; Kugai, N. The relationship between fish intake and the prevalence of asthma: The Tokorozawa
childhood asthma and pollinosis study. Prev. Med. 2002, 34, 221�225.
38. De Luis, D.A.; Armentia, A.; Aller, R.; Asensio, A.; Sedano, E.; Izaola, O.; Cuellar, L. Dietary
intake in patients with asthma: A case control study. Nutrition 2005, 21, 320�324.
39. Laerum, B.N.; Wentzel-Larsen, T.; Gulsvik, A.; Omenaas, E.; Gislason, T.; Janson, C.; Svanes, C.
Relationship of fish and cod oil intake with adult asthma. Clin. Exp. Allergy 2007, 37, 1616�1623.
40. McKeever, T.M.; Lewis, S.A.; Cassano, P.A.; Ocke, M.; Burney, P.; Britton, J.; Smit, H.A.
The relation between dietary intake of individual fatty acids, FEV1 and respiratory disease in Dutch
adults. Thorax 2008, 63, 208�214.
41. Salam, M.T.; Li, Y.F.; Langholz, B.; Gilliland, F.D. Maternal fish consumption during pregnancy
and risk of early childhood asthma. J. Asthma 2005, 42, 513�518.
42. Klemens, C.M.; Berman, D.R.; Mozurkewich, E.L. The effect of perinatal omega-3 fatty acid
supplementation on inflammatory markers and allergic diseases: A systematic review. BJOG 2011,
118, 916�925.
43. Thien, F.C.K.; Woods, R.; De Luca, S.; Abramson, M.J. Dietary marine fatty acids (fish oil) for
asthma in adults and children (Cochrane Review). In The Cochrane Library; John Wiley & Sons,
Ltd.: Chichester, UK, 2002 (updated 2010).
44. Shahar, E.; Boland, L.L.; Folsom, A.R.; Tockman, M.S.; McGovern, P.G.; Eckfeldt, J.H.
Docosahexaenoic acid and smoking-related chronic obstructive pulmonary disease. Am. J. Respir.
Crit. Care Med. 1999, 159, 1780�1785.
45. De Batlle, J.; Sauleda, J.; Balcells, E.; G�mez, F.P.; M�ndez, M.; Rodriguez, E.; Barreiro, E.;
Ferrer, J.J.; Romieu, I.; Gea, J.; et al. Association between ?3 and ?6 fatty acid intakes and serum
inflammatory markers in COPD. J. Nutr. Biochem. 2012, 23, 817�821.
46. Broekhuizen, R.; Wouters, E.F.; Creutzberg, E.C.; Weling-Scheepers, C.A.; Schols, A.M.
Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease.
Thorax 2005, 60, 376�382.
47. Fulton, A.S.; Hill, A.M.; Williams, M.T.; Howe, P.R.; Frith, P.A.; Wood, L.G.; Garg, M.L.;
Coates, A.M. Feasibility of omega-3 fatty acid supplementation as an adjunct therapy for people
with chronic obstructive pulmonary disease: Study protocol for a randomized controlled trial.
Trials 2013, 14, 107.
48. Texas A&M University, USA. Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism
in Chronic Obstructive Pulmonary Disease (COPD): Aim 2 NLM Identifier: NCT01624792.
Available online: https://clinicaltrials.gov/ct2/show/NCT01624792 (accessed on 29 September 2014).
49. National Institute of Environmental Health Sciences; Columbia University, USA. The Chronic
Obstructive Pulmonary Disease Fish Oil Pilot Trial (COD-Fish). Available online:
http://clinicaltrials.gov/show/NCT00835289 (accessed on 29 September 2014).
50. Wood, L.G.; Gibson, P.G.; Garg, M.L. Biomarkers of lipid peroxidation, airway inflammation and
asthma. Eur. Respir. J. 2003, 21, 177�186.
51. Kelly, F.J. Vitamins and respiratory disease: Antioxidant micronutrients in pulmonary health and
disease. Proc. Nutr. Soc. 2005, 64, 510�526.
52. Rahman, I. Oxidative stress, chromatin remodeling and gene transcription in inflammation and
chronic lung diseases. J. Biochem. Mol. Biol. 2003, 36, 95�109.
53. Ochs-Balcom, H.M.; Grant, B.J.; Muti, P.; Sempos, C.T.; Freudenheim, J.L.; Browne, R.W.;
McCann, S.E.; Trevisan, M.; Cassano, P.A.; Iacoviello, L.; et al. Antioxidants, oxidative stress,
and pulmonary function in individuals diagnosed with asthma or COPD. Eur. J. Clin. Nutr. 2006, 60,
991�999.
54. Wood, L.G.; Garg, M.L.; Powell, H.; Gibson, P.G. Lycopene-rich treatments modify
noneosinophilic airway inflammation in asthma: Proof of concept. Free Radic. Res. 2008, 42,
94�102.
55. Clifton, V.L.; Vanderlelie, J.; Perkins, A.V. Increased anti-oxidant enzyme activity and biological
oxidation in placentae of pregnancies complicated by maternal asthma. Placenta 2005, 26, 773�779.
56. McLernon, P.C.; Wood, L.G.; Murphy, V.E.; Hodyl, N.A.; Clifton, V.L. Circulating antioxidant
profile of pregnant women with asthma. Clin. Nutr. 2012, 31, 99�107.
57. Miyake, Y.; Sasaki, S.; Tanaka, K.; Hirota, Y. Dairy food, calcium and vitamin D intake in
pregnancy, and wheeze and eczema in infants. Eur. Respir. J. 2010, 35, 1228�1234.
58. Kumar, R. Prenatal factors and the development of asthma. Curr. Opin. Pediatr. 2008, 20,
682�687.
59. Bowie, A.G.; O�Neill, L.A. Vitamin C inhibits NF-kappa B activation by TNF via the activation
of p38 mitogen-activated protein kinase. J. Immunol. 2000, 165, 7180�7188.
60. Jeong, Y.-J.; Kim, J.-H.; Kang, J.S.; Lee, W.J.; Hwang, Y. Mega-dose vitamin C attenuated lung
inflammation in mouse asthma model. Anat. Cell Biol. 2010, 43, 294�302.
61. Chang, H.-H.; Chen, C.-S.; Lin, J.-Y. High Dose Vitamin C Supplementation Increases the
Th1/Th2 Cytokine Secretion Ratio, but Decreases Eosinophilic Infiltration in Bronchoalveolar
Lavage Fluid of Ovalbumin-Sensitized and Challenged Mice. J. Agric. Food Chem. 2009, 57,
10471�10476.
62. Forastiere, F.; Pistelli, R.; Sestini, P.; Fortes, C.; Renzoni, E.; Rusconi, F.; Dell�Orco, V.; Ciccone,
G.; Bisanti, L. The SIDRIA Collaborative Group, I. Consumption of fresh fruit rich in vitamin C
and wheezing symptoms in children. Thorax 2000, 55, 283�288.
63. Emmanouil, E.; Manios, Y.; Grammatikaki, E.; Kondaki, K.; Oikonomou, E.; Papadopoulos, N.;
Vassilopoulou, E. Association of nutrient intake and wheeze or asthma in a Greek pre-school
population. Pediatr. Allergy Immunol. 2010, 21, 90�95.
64. Cook, D.G.; Carey, I.M.; Whincup, P.H.; Papacosta, O.; Chirico, S.; Bruckdorfer, K.R.; Walker, M.
Effect of fresh fruit consumption on lung function and wheeze in children. Thorax 1997, 52,
628�633.
65. Schwartz, J.; Weiss, S.T. Relationship between dietary vitamin C intake and pulmonary function
in the First National Health and Nutrition Examination Survey (NHANES I). Am. J. Clin. Nutr.
1994, 59, 110�114.
66. Shaheen, S.O.; Sterne, J.A.; Thompson, R.L.; Songhurst, C.E.; Margetts, B.M.; Burney, P.G.
Dietary antioxidants and asthma in adults: Population-based case-control study. Am. J. Respir. Crit.
Care Med. 2001, 164, 1823�1828.
67. Koike, K.; Ishigami, A.; Sato, Y.; Hirai, T.; Yuan, Y.; Kobayashi, E.; Tobino, K.; Sato, T.; Sekiya,
M.; Takahashi, K.; et al. Vitamin C Prevents Cigarette Smoke�Induced Pulmonary Emphysema in
Mice and Provides Pulmonary Restoration. Am. J. Respir. Cell Mol. Biol. 2013, 50, 347�357.
68. Lin, Y.C.; Wu, T.C.; Chen, P.Y.; Hsieh, L.Y.; Yeh, S.L. Comparison of plasma and intake levels
of antioxidant nutrients in patients with chronic obstructive pulmonary disease and healthy people
in Taiwan: A case-control study. Asia Pac. J. Clin. Nutr. 2010, 19, 393�401.
69. Sargeant, L.A.; Jaeckel, A.; Wareham, N.J. Interaction of vitamin C with the relation between
smoking and obstructive airways disease in EPIC Norfolk. European Prospective Investigation into
Cancer and Nutrition. Eur. Respir. J. 2000, 16, 397�403.
70. Brigelius-Flohe, R.; Traber, M.G. Vitamin E: Function and metabolism. FASEB J. 1999, 13,
1145�1155.
71. Huang, J.; May, J.M. Ascorbic acid spares ?-tocopherol and prevents lipid peroxidation in cultured
H4IIE liver cells. Mol. Cell. Biochem. 2003, 247, 171�176.
72. Abdala-Valencia, H.; Berdnikovs, S.; Cook-Mills, J. Vitamin E isoforms as modulators of lung
inflammation. Nutrients 2013, 5, 4347�4363.
73. Mabalirajan, U.; Aich, J.; Leishangthem, G.D.; Sharma, S.K.; Dinda, A.K.; Ghosh, B. Effects of
vitamin E on mitochondrial dysfunction and asthma features in an experimental allergic murine
model. J. Appl. Physiol. 2009, 107, 1285�1292.
74. McCary, C.A.; Abdala-Valencia, H.; Berdnikovs, S.; Cook-Mills, J.M. Supplemental and highly
elevated tocopherol doses differentially regulate allergic inflammation: Reversibility of ?-tocopherol
and ?-tocopherol�s effects. J. Immunol. 2011, 186, 3674�3685.
75. He, Y.; Franchi, L.; Nunez, G. The protein kinase PKR is critical for LPS-induced iNOS production
but dispensable for inflammasome activation in macrophages. Eur. J. Immunol. 2013, 43, 1147�1152.
76. Fakhrzadeh, L.; Laskin, J.D.; Laskin, D.L. Ozone-induced production of nitric oxide and TNF-?
and tissue injury are dependent on NF-kappaB p50. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004,
287, L279�L285.
77. Hernandez, M.L.; Wagner, J.G.; Kala, A.; Mills, K.; Wells, H.B.; Alexis, N.E.; Lay, J.C.; Jiang, Q.;
Zhang, H.; Zhou, H.; et al. Vitamin E, ?-tocopherol, reduces airway neutrophil recruitment after
inhaled endotoxin challenge in rats and in healthy volunteers. Free Radic. Biol. Med. 2013, 60,
56�62.
78. Dow, L.; Tracey, M.; Villar, A.; Coggon, D.; Margetts, B.M.; Campbell, M.J.; Holgate, S.T. Does
dietary intake of vitamins C and E influence lung function in older people? Am. J. Respir. Crit.
Care Med. 1996, 154, 1401�1404.
79. Smit, H.A.; Grievink, L.; Tabak, C. Dietary influences on chronic obstructive lung disease and
asthma: A review of the epidemiological evidence. Proc. Nutr. Soc. 1999, 58, 309�319.
80. Tabak, C.; Smit, H.A.; Rasanen, L.; Fidanza, F.; Menotti, A.; Nissinen, A.; Feskens, E.J.; Heederik,
D.; Kromhout, D. Dietary factors and pulmonary function: A cross sectional study in middle aged
men from three European countries. Thorax 1999, 54, 1021�1026.
81. Weiss, S.T. Diet as a risk factor for asthma. Ciba Found. Symp. 1997, 206, 244�257.
82. Troisi, R.J.; Willett, W.C.; Weiss, S.T.; Trichopoulos, D.; Rosner, B.; Speizer, F.E. A prospective
study of diet and adult-onset asthma. Am. J. Respir. Crit. Care Med. 1995, 151, 1401�1408.
83. Devereux, G.; Seaton, A. Diet as a risk factor for atopy and asthma. J. Allergy Clin. Immonol.
2005, 115, 1109�1117.
84. Tug, T.; Karatas, F.; Terzi, S.M. Antioxidant vitamins (A, C and E) and malondialdehyde levels in
acute exacerbation and stable periods of patients with chronic obstructive pulmonary disease. Clin.
Investig. Med. 2004, 27, 123�128.
85. Daga, M.K.; Chhabra, R.; Sharma, B.; Mishra, T.K. Effects of exogenous vitamin E supplementation
on the levels of oxidants and antioxidants in chronic obstructive pulmonary disease. J. Biosci.
2003, 28, 7�11.
86. Wu, T.C.; Huang, Y.C.; Hsu, S.Y.; Wang, Y.C.; Yeh, S.L. Vitamin E and vitamin C supplementation
in patients with chronic obstructive pulmonary disease. Int. J. Vitam. Nutr. Res. 2007, 77,
272�279.
87. Agler, A.H.; Kurth, T.; Gaziano, J.M.; Buring, J.E.; Cassano, P.A. Randomised vitamin E
supplementation and risk of chronic lung disease in the Women�s Health Study. Thorax 2011, 66,
320�325.
88. West, C.E.; Dunstan, J.; McCarthy, S.; Metcalfe, J.; D�Vaz, N.; Meldrum, S.; Oddy, W.H.;
Tulic, M.K.; Prescott, S.L. Associations between maternal antioxidant intakes in pregnancy and
infant allergic outcomes. Nutrients 2012, 4, 1747�1758.
89. Abdala-Valencia, H.; Berdnikovs, S.; Soveg, F.W.; Cook-Mills, J.M. ?-Tocopherol Supplementation
of Allergic Female Mice Inhibits Development of CD11c+CD11b+ Dendritic Cells in Utero and
Allergic Inflammation in Neonates. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014, 307, L482�L496.
90. Litonjua, A.A.; Rifas-Shiman, S.L.; Ly, N.P.; Tantisira, K.G.; Rich-Edwards, J.W.;
Camargo, C.A., Jr.; Weiss, S.T.; Gillman, M.W.; Gold, D.R. Maternal antioxidant intake in
pregnancy and wheezing illnesses in children at 2 year of age. Am. J. Clin. Nutr. 2006, 84, 903�911.
91. Miyake, Y.; Sasaki, S.; Tanaka, K.; Hirota, Y. Consumption of vegetables, fruit, and antioxidants
during pregnancy and wheeze and eczema in infants. Allergy 2010, 65, 758�765.
92. Devereux, G.; Turner, S.W.; Craig, L.C.; McNeill, G.; Martindale, S.; Harbour, P.J.; Helms, P.J.;
Seaton, A. Low maternal vitamin E intake during pregnancy is associated with asthma in 5-year-old
children. Am. J. Respir. Crit. Care Med. 2006, 174, 499�507.
93. Devereux, G.; Barker, R.N.; Seaton, A. Antenatal determinants of neonatal immune responses to
allergens. Clin. Exp. Allergy 2002, 32, 43�50.
94. Wassall, H.; Devereux, G.; Seaton, A.; Barker, R. Complex effects of vitamin E and vitamin C
supplementation on in vitro neonatal mononuclear cell responses to allergens. Nutrients 2013, 5,
3337�3351.
95. Tanaka, T.; Takahashi, R. Flavonoids and asthma. Nutrients 2013, 5, 2128�2143.
96. Manach, C.; Scalbert, A.; Morand, C.; Remesy, C.; Jimenez, L. Polyphenols: Food sources and
bioavailability. Am. J. Clin. Nutr. 2004, 79, 727�747.
97. Hirano, T.; Higa, S.; Arimitsu, J.; Naka, T.; Shima, Y.; Ohshima, S.; Fujimoto, M.; Yamadori, T.;
Kawase, I.; Tanaka, T. Flavonoids such as luteolin, fisetin and apigenin are inhibitors of
interleukin-4 and interleukin-13 production by activated human basophils. Int. Arch. Allergy
Immunol. 2004, 134, 135�140.
98. Kawai, M.; Hirano, T.; Higa, S.; Arimitsu, J.; Maruta, M.; Kuwahara, Y.; Ohkawara, T.; Hagihara,
K.; Yamadori, T.; Shima, Y.; et al. Flavonoids and related compounds as anti-allergic substances.
Allergol. Int. 2007, 56, 113�123.
99. Nair, M.P.; Mahajan, S.; Reynolds, J.L.; Aalinkeel, R.; Nair, H.; Schwartz, S.A.; Kandaswami, C.
The flavonoid quercetin inhibits proinflammatory cytokine (tumor necrosis factor alpha) gene
expression in normal peripheral blood mononuclear cells via modulation of the NF-kappa beta
system. Clin. Vaccine Immunol. 2006, 13, 319�328.
100. Nair, M.P.N.; Kandaswami, C.; Mahajan, S.; Chadha, K.C.; Chawda, R.; Nair, H.; Kumar, N.;
Nair, R.E.; Schwartz, S.A. The flavonoid, quercetin, differentially regulates Th-1 (IFN?) and Th-2
(IL4) cytokine gene expression by normal peripheral blood mononuclear cells. Biochim. Biophys.
Acta Mol. Cell Res. 2002, 1593, 29�36.
101. Leemans, J.; Cambier, C.; Chandler, T.; Billen, F.; Clercx, C.; Kirschvink, N.; Gustin, P.
Prophylactic effects of omega-3 polyunsaturated fatty acids and luteolin on airway
hyperresponsiveness and inflammation in cats with experimentally-induced asthma. Vet. J.
2010, 184, 111�114.
102. Li, R.R.; Pang, L.L.; Du, Q.; Shi, Y.; Dai, W.J.; Yin, K.S. Apigenin inhibits allergen-induced
airway inflammation and switches immune response in a murine model of asthma.
Immunopharmacol. Immunotoxicol. 2010, 32, 364�370.
103. Wu, M.Y.; Hung, S.K.; Fu, S.L. Immunosuppressive effects of fisetin in ovalbumin-induced
asthma through inhibition of NF-kB activity. J. Agric. Food Chem. 2011, 59, 10496�10504.
104. Rogerio, A.P.; Kanashiro, A.; Fontanari, C.; da Silva, E.V.G.; Lucisano-Valim, Y.M.; Soares, E.G.;
Faccioli, L.H. Anti-inflammatory activity of quercetin and isoquercitrin in experimental murine
allergic asthma. Inflamm. Res. 2007, 56, 402�408.
105. Garcia, V.; Arts, I.C.; Sterne, J.A.; Thompson, R.L.; Shaheen, S.O. Dietary intake of flavonoids
and asthma in adults. Eur. Respir. J. 2005, 26, 449�452.
106. Belcaro, G.; Luzzi, R.; Cesinaro di Rocco, P.; Cesarone, M.R.; Dugall, M.; Feragalli, B.;
Errichi, B.M.; Ippolito, E.; Grossi, M.G.; Hosoi, M.; et al. Pycnogenol improvements in asthma
management. Panminerva Med. 2011, 53, 57�64.
107. Willers, S.M.; Devereux, G.; Craig, L.C.A.; McNeill, G.; Wijga, A.H.; Abou El-Magd, W.; Turner,
S.W.; Helms, P.J.; Seaton, A. Maternal food consumption during pregnancy and asthma,
respiratory and atopic symptoms in 5-year-old children. Thorax 2007, 62, 773�779.
108. Holick, M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357, 266�281.
109. Hart, P.H.; Lucas, R.M.; Walsh, J.P.; Zosky, G.R.; Whitehouse, A.J.O.; Zhu, K.; Allen, K.L.;
Kusel, M.M.; Anderson, D.; Mountain, J.A. Vitamin D in Fetal Development: Findings From
a Birth Cohort Study. Pediatrics 2014, doi:10.1542/peds.2014-1860.
110. Hart, P.H.; Gorman, S.; Finlay-Jones, J.J. Modulation of the immune system by UV radiation:
More than just the effects of vitamin D? Nat. Rev. Immunol. 2011, 11, 584�596.
111. Foong, R.; Zosky, G. Vitamin D deficiency and the lung: Disease initiator or disease modifier?
Nutrients 2013, 5, 2880�2900.
112. Hiemstra, P.S. The role of epithelial ?-defensins and cathelicidins in host defense of the lung. Exp.
Lung Res. 2007, 33, 537�542.
113. Martinesi, M.; Bruni, S.; Stio, M.; Treves, C. 1,25-Dihydroxyvitamin D3 inhibits tumor necrosis
factor-?-induced adhesion molecule expression in endothelial cells. Cell Biol. Int. 2006, 30,
365�375.
114. Song, Y.; Qi, H.; Wu, C. Effect of 1,25-(OH)2D3 (a vitamin D analogue) on passively sensitized
human airway smooth muscle cells. Respirology 2007, 12, 486�494.
115. Zosky, G.R.; Berry, L.J.; Elliot, J.G.; James, A.L.; Gorman, S.; Hart, P.H. Vitamin D deficiency
causes deficits in lung function and alters lung structure. Am. J. Respir. Crit. Care Med. 2011, 183,
1336�1343.
116. Pichler, J.; Gerstmayr, M.; Szepfalusi, Z.; Urbanek, R.; Peterlik, M.; Willheim, M. 1?,25(OH)2D3
inhibits not only Th1 but also Th2 differentiation in human cord blood T cells. Pediatr. Res. 2002,
52, 12�18.
117. Gupta, A.; Sjoukes, A.; Richards, D.; Banya, W.; Hawrylowicz, C.; Bush, A.; Saglani, S.
Relationship between serum vitamin D, disease severity and airway remodeling in children with
asthma. Am. J. Respir. Crit. Care Med. 2011, 184, 1342�1349.
118. Brehm, J.M.; Schuemann, B.; Fuhlbrigge, A.L.; Hollis, B.W.; Strunk, R.C.; Zeiger, R.S.; Weiss,
S.T.; Litonjua, A.A. Serum vitamin D levels and severe asthma exacerbations in the Childhood
Asthma Management Program study. J. Allergy Clin. Immonol. 2010, 126, 52�58.
119. Zosky, G.R.; Hart, P.H.; Whitehouse, A.J.; Kusel, M.M.; Ang, W.; Foong, R.E.; Chen, L.; Holt, P.G.;
Sly, P.D.; Hall, G.L. Vitamin D deficiency at 16 to 20 weeks� gestation is associated with impaired
lung function and asthma at 6 years of age. Ann. Am. Thorac. Soc. 2014, 11, 571�577.
120. Searing, D.A.; Zhang, Y.; Murphy, J.R.; Hauk, P.J.; Goleva, E.; Leung, D.Y. Decreased serum
vitamin D levels in children with asthma are associated with increased corticosteroid use. J. Allergy
Clin. Immonol. 2010, 125, 995�1000.
121. Xystrakis, E.; Kusumakar, S.; Boswell, S.; Peek, E.; Urry, Z.; Richards, D.F.; Adikibi, T.;
Pridgeon, C.; Dallman, M.; Loke, T.K.; et al. Reversing the defective induction of IL-10 secreting
regulatory T cells in glucocorticoid-resistant asthma patients. J. Clin. Investig. 2006, 116,
146�155.
122. Castro, M.; King, T.S.; Kunselman, S.J.; Cabana, M.D.; Denlinger, L.; Holguin, F.; Kazani, S.D.;
Moore, W.C.; Moy, J.; Sorkness, C.A.; et al. Effect of vitamin D3 on asthma treatment failures in
adults with symptomatic asthma and lower vitamin D levels: The VIDA randomized clinical trial.
JAMA 2014, 311, 2083�2091.
123. Janssens, W.; Bouillon, R.; Claes, B.; Carremans, C.; Lehouck, A.; Buysschaert, I.; Coolen, J.;
Mathieu, C.; Decramer, M.; Lambrechts, D. Vitamin D deficiency is highly prevalent in COPD
and correlates with variants in the vitamin D-binding gene. Thorax 2010, 65, 215�220.
124. Black, P.N.; Scragg, R. Relationship between serum 25-hydroxyvitamin D and pulmonary function
survey. Chest 2005, 128, 3792�3798.
125. Persson, L.J.; Aanerud, M.; Hiemstra, P.S.; Hardie, J.A.; Bakke, P.S.; Eagan, T.M. Chronic
obstructive pulmonary disease is associated with low levels of vitamin D. PLoS One 2012,
7, e38934.
126. Uh, S.T.; Koo, S.M.; Kim, Y.K.; Kim, K.U.; Park, S.W.; Jang, A.S.; Kim, D.J.; Kim, Y.H.;
Park, C.S. Inhibition of vitamin D receptor translocation by cigarette smoking extracts. Tuberc.
Respir. Dis. 2012, 73, 258�265.
127. Wood, A.M.; Bassford, C.; Webster, D.; Newby, P.; Rajesh, P.; Stockley, R.A.; Thickett, D.R.
Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax
2011, 66, 205�210.
128. Sundar, I.K.; Hwang, J.W.; Wu, S.; Sun, J.; Rahman, I. Deletion of vitamin D receptor leads to
premature emphysema/COPD by increased matrix metalloproteinases and lymphoid aggregates
formation. Biochem. Biophys. Res. Commun. 2011, 406, 127�133.
129. Lehouck, A.; Mathieu, C.; Carremans, C.; Baeke, F.; Verhaegen, J.; Van Eldere, J.; Decallonne,
B.; Bouillon, R.; Decramer, M.; Janssens, W. High doses of vitamin D to reduce exacerbations in
chronic obstructive pulmonary disease: A randomized trial. Ann. Intern. Med. 2012, 156, 105�114.
130. Baker, J.C.; Ayres, J.G. Diet and asthma. Respir. Med. 2000, 94, 925�934.
131. Pogson, Z.E.K.; Antoniak, M.D.; Pacey, S.J.; Lewis, S.A.; Britton, J.R.; Fogarty, A.W.
Does a low sodium diet improve asthma control? A randomized controlled trial. Am. J. Respir.
Crit. Care Med. 2008, 178, 132�138.
132. Matthew, R.; Altura, B. The role of magnesium in lung diseases: Asthma, allergy, and pulmonary
hypertension. Magnes. Trace Elem. 1991, 10, 220�228.
133. Baker, J.; Tunnicliffe, W.; Duncanson, R.; Ayres, J. Dietary antioxidants in type 1 brittle asthma:
A case control study. Thorax 1999, 54, 115�118.
134. Gilliand, F.; Berhane, K.; Li, Y.; Kim, D.; Margolis, H. Dietary magnesium, potassium, sodium
and childrens lung function. Am. J. Epidemiol. 2002, 155, 125�131.
135. Kim, J.-H.; Ellwood, P.; Asher, M.I. Diet and asthma: Looking back, moving forward. Respir. Res.
2009, 10, 49�55.
136. Kadrabova, J.; Mad�aric, A.; Kovacikova, Z.; Podiv�nsky, F.; Ginter, E.; Gazd�k, F. Selenium
status is decreased in patients with intrinsic asthma. Biol. Trace Elem. Res. 1996, 52, 241�248.
137. Devereux, G.; McNeill, G.; Newman, G.; Turner, S.; Craig, L.; Martindale, S.; Helms, P.; Seaton,
A. Early childhood wheezing symptoms in relation to plasma selenium in pregnant mothers and
neonates. Clin. Exp. Allergy 2007, 37, 1000�1008.
138. Burney, P.; Potts, J.; Makowska, J.; Kowalski, M.; Phillips, J.; Gnatiuc, L.; Shaheen, S.; Joos, G.;
Van Cauwenberge, P.; van Zele, T.; et al. A case control study of the relation between plasma
selenium and asthma in European populations: A GAL2EN project. Allergy 2008, 63, 865�871.
139. Shaheen, S.O.; Newson, R.B.; Rayman, M.P.; Wong, A.P.; Tumilty, M.K.; Phillips, J.M.;
Potts, J.F.; Kelly, F.J.; White, P.T.; Burney, P.G. Randomised, double blind, placebo controlled
trial of selenium supplementation in adult asthma. Thorax 2007, 62, 483�490.
140. Shaheen, S.O.; Newson, R.B.; Henderson, A.J.; Emmett, P.M.; Sherriff, A.; Cooke, M.; Team, A.S.
Umbilical cord trace elements and minerals and risk of early childhood wheezing and eczema. Eur.
Respir. J. 2004, 24, 292�297.
141. Andersson, I.; Gr�nberg, A.; Slinde, F.; Bosaeus, I.; Larsson, S. Vitamin and mineral status in
elderly patients with chronic obstructive pulmonary disease. Clin. Respir. J. 2007, 1, 23�29.
142. Periyalil, H.; Gibson, P.; Wood, L. Immunometabolism in obese asthmatics: Are we there yet?
Nutrients 2013, 5, 3506�3530.
143. Mathis, D.; Shoelson, S.E. Immunometabolism: An emerging frontier. Nat. Rev. Immunol.
2011, 11, 81.
144. Medzhitov, R. Origin and physiological roles of inflammation. Nature 2008, 454, 428�435.
145. Berthon, B.S.; Macdonald-Wicks, L.K.; Gibson, P.G.; Wood, L.G. Investigation of the association
between dietary intake, disease severity and airway inflammation in asthma. Respirology 2013, 18,
447�454.
146. Procaccini, C.; Jirillo, E.; Matarese, G. Leptin as an immunomodulator. Mol. Aspects Med.
2012, 33, 35�45.
147. Caldefie-Chezet, F.; Poulin, A.; Vasson, M.P. Leptin regulates functional capacities of
polymorphonuclear neutrophils. Free Radic. Res. 2003, 37, 809�814.
148. Zarkesh-Esfahani, H.; Pockley, A.G.; Wu, Z.; Hellewell, P.G.; Weetman, A.P.; Ross, R.J.
Leptin indirectly activates human neutrophils via induction of TNF-alpha. J. Immunol. 2004, 172,
1809�1814.
149. Lugogo, N.L.; Hollingsworth, J.W.; Howell, D.L.; Que, L.G.; Francisco, D.; Church, T.D.;
Potts-Kant, E.N.; Ingram, J.L.; Wang, Y.; Jung, S.H.; et al. Alveolar macrophages from
overweight/obese subjects with asthma demonstrate a proinflammatory phenotype. Am. J. Respir.
Crit. Care Med. 2012, 186, 404�411.
150. Shore, S.A.; Terry, R.D.; Flynt, L.; Xu, A.; Hug, C. Adiponectin attenuates allergen-induced
airway inflammation and hyperresponsiveness in mice. J. Allergy Clin. Immonol. 2006, 118,
389�395.
151. Wood, L.G.; Gibson, P.G. Adiponectin: The link between obesity and asthma in women? Am. J.
Respir. Crit. Care Med. 2012, 186, 1�2.
152. Wood, L.G.; Baines, K.J.; Fu, J.; Scott, H.A.; Gibson, P.G. The neutrophilic inflammatory
phenotype is associated with systemic inflammation in asthma. Chest 2012, 142, 86�93.
153. Scott, H.A.; Gibson, P.G.; Garg, M.L.; Wood, L.G. Airway inflammation is augmented by obesity
and fatty acids in asthma. Eur. Respir. J. 2011, 38, 594�602.
154. Telenga, E.D.; Tideman, S.W.; Kerstjens, H.A.; Hacken, N.H.; Timens, W.; Postma, D.S.;
van den Berge, M. Obesity in asthma: More neutrophilic inflammation as a possible explanation
for a reduced treatment response. Allergy 2012, 67, 1060�1068.
155. Forno, E.; Young, O.M.; Kumar, R.; Simhan, H.; Celed�n, J.C. Maternal Obesity in Pregnancy,
Gestational Weight Gain, and Risk of Childhood Asthma. Pediatrics 2014, 134, e535�e546.
156. Franssen, F.M.; O�Donnell, D.E.; Goossens, G.H.; Blaak, E.E.; Schols, A.M. Obesity and the lung:
5. Obesity and COPD. Thorax 2008, 63, 1110�1117.
157. Zhou, L.; Yuan, C.; Zhang, J.; Yu, R.; Huang, M.; Adcock, I.M.; Yao, X. Circulating Leptin
Concentrations in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review
and Meta-Analysis. Respiration 2014, 86, 512�522.
158. Bianco, A.; Mazzarella, G.; Turchiarelli, V.; Nigro, E.; Corbi, G.; Scudiero, O.; Sofia, M.; Daniele,
A. Adiponectin: An attractive marker for metabolic disorders in chronic obstructive pulmonary
disease (COPD). Nutrients 2013, 5, 4115�4125.
159. Daniele, A.; de Rosa, A.; de Cristofaro, M.; Monaco, M.L.; Masullo, M.; Porcile, C.; Capasso, M.;
Tedeschi, G.; Oriani, G.; di Costanzo, A. Decreased concentration of adiponectin together with
a selective reduction of its high molecular weight oligomers is involved in metabolic complications
of myotonic dystrophy type 1. Eur. J. Endocrinol. 2011, 165, 969�975.
160. Kadowaki, T.; Yamauchi, T. Adiponectin and adiponectin receptors. Endocr. Rev. 2005, 26,
439�451.
161. Nigro, E.; Scudiero, O.; Sarnataro, D.; Mazzarella, G.; Sofia, M.; Bianco, A.; Daniele, A.
Adiponectin affects lung epithelial A549 cell viability counteracting TNFa and IL-1? toxicity
through AdipoR1. Int. J. Biochem. Cell Biol. 2013, 45, 1145�1153.
162. Gable, D.R.; Matin, J.; Whittall, R.; Cakmak, H.; Li, K.W.; Cooper, J.; Miller, G.J.; Humphries, S.E.;
HIFMECH investigators. Common adiponectin gene variants show different effects on risk of
cardiovascular disease and type 2 diabetes in European subjects. Ann. Hum. Genet. 2007, 71,
453�466.
163. Yoon, H.I.; Li, Y.; Man, S.F.; Tashkin, D.; Wise, R.A.; Connett, J.E.; Anthonisen, N.A.; Churg, A.;
Wright, J.L.; Sin, D.D. The complex relationship of serum adiponectin to COPD outcomes COPD
and adiponectin. Chest 2012, 142, 893�899.
164. Daniele, A.; de Rosa, A.; Nigro, E.; Scudiero, O.; Capasso, M.; Masullo, M.; de Laurentiis, G.;
Oriani, G.; Sofia, M.; Bianco, A. Adiponectin oligomerization state and adiponectin receptors
airway expression in chronic obstructive pulmonary disease. Int. J. Biochem. Cell Biol. 2012, 44,
563�569.
165. Petridou, E.T.; Mitsiades, N.; Gialamas, S.; Angelopoulos, M.; Skalkidou, A.; Dessypris, N.;
Hsi, A.; Lazaris, N.; Polyzos, A.; Syrigos, C.; et al. Circulating adiponectin levels and expression
of adiponectin receptors in relation to lung cancer: Two case-control studies. Oncology 2007, 73,
261�269.
166. Ajuwon, K.M.; Spurlock, M.E. Adiponectin inhibits LPS-induced NF-kappaB activation and
IL-6 production and increases PPARgamma2 expression in adipocytes. Am. J. Physiol. Regul.
Integr. Comp. Physiol. 2005, 288, R1220�R1225.
167. Cheng, X.; Folco, E.J.; Shimizu, K.; Libby, P. Adiponectin induces pro-inflammatory programs in
human macrophages and CD4+ T cells. J. Biol. Chem. 2012, 287, 36896�36904.
168. Miller, M.; Pham, A.; Cho, J.Y.; Rosenthal, P.; Broide, D.H. Adiponectin-deficient mice are
protected against tobacco-induced inflammation and increased emphysema. Am. J. Physiol. Lung
Cell. Mol. Physiol. 2010, 299, L834�L842.
169. Furukawa, T.; Hasegawa, T.; Suzuki, K.; Koya, T.; Sakagami, T.; Youkou, A.; Kagamu, H.;
Arakawa, M.; Gejyo, F.; Narita, I.; et al. Influence of underweight on asthma control. Allergol. Int.
2012, 61, 489�496.
170. Harding, R.; Maritz, G. Maternal and fetal origins of lung disease in adulthood. Semin. Fetal.
Neonatal Med. 2012, 17, 67�72.
171. Itoh, M.; Tsuji, T.; Nemoto, K.; Nakamura, H.; Aoshiba, K. Undernutrition in patients with COPD
and its treatment. Nutrients 2013, 5, 1316�1335.
172. Hallin, R.; Koivisto-Hursti, U.K.; Lindberg, E.; Janson, C. Nutritional status, dietary energy intake
and the risk of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Respir. Med. 2006, 100, 561�567.
173. Gr�nberg, A.M.; Slinde, F.; Engstr�m, C.P.; Hulth�n, L.; Larsson, S. Dietary problems in patients
with severe chronic obstructive disease. J. Hum. Nutr. Diet. 2005, 18, 445�452.
174. Wilson, D.O.; Donahoe, M.; Rogers, R.M.; Pennock, B.E. Metabolic rate and weight loss in
chronic obstructive lung disease. J. Parenter. Enter. Nutr. 1990, 14, 7�11.
175. Gan, W.Q.; Man, S.F.; Senthilselvan, A.; Sin, D.D. Association between chronic obstructive
pulmonary disease and systemic inflammation: A systematic review and a meta-analysis. Thorax
2004, 59, 574�580.
176. Orlander, J.; Kiessling, K.H.; Larsson, L. Skeletal muscle metabolism, morphology and function
in sedentary smokers and nonsmokers. Acta Physiol. Scand. 1979, 107, 39�46.
177. Kok, M.O.; Hoekstra, T.; Twisk, J.W.R. The Longitudinal Relation between Smoking and Muscle
Strength in Healthy Adults. Eur. Addict. Res. 2012, 18, 70�75.
178. Gosker, H.R.; Langen, R.C.J.; Bracke, K.R.; Joos, G.F.; Brusselle, G.G.; Steele, C.; Ward, K.A.;
Wouters, E.F.M.; Schols, A.M.W.J. Extrapulmonary Manifestations of Chronic Obstructive
Pulmonary Disease in a Mouse Model of Chronic Cigarette Smoke Exposure. Am. J. Respir. Cell
Mol. Biol. 2009, 40, 710�716.
179. Nakatani, T.; Nakashima, T.; Kita, T.; Ishihara, A. Effects of exposure to cigarette smoke at
different dose levels on extensor digitorum longus muscle fibres in Wistar-Kyoto and spontaneously
hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2003, 30, 671�677.
180. Remels, A.H.; Gosker, H.R.; Langen, R.C.; Schols, A.M. The mechanisms of cachexia underlying
muscle dysfunction in COPD. J. Appl. Physiol. (1985) 2013, 114, 1253�1262.
181. Caron, M.A.; Debigare, R.; Dekhuijzen, P.N.; Maltais, F. Comparative assessment of the
quadriceps and the diaphragm in patients with COPD. J. Appl. Physiol. (1985) 2009, 107,
952�961.
182. Vogiatzis, I.; Simoes, D.C.; Stratakos, G.; Kourepini, E.; Terzis, G.; Manta, P.; Athanasopoulos, D.;
Roussos, C.; Wagner, P.D.; Zakynthinos, S. Effect of pulmonary rehabilitation on muscle
remodelling in cachectic patients with COPD. Eur. Respir. J. 2010, 36, 301�310.
183. Kythreotis, P.; Kokkini, A.; Avgeropoulou, S.; Hadjioannou, A.; Anastasakou, E.; Rasidakis, A.;
Bakakos, P. Plasma leptin and insulin-like growth factor I levels during acute exacerbations of
chronic obstructive pulmonary disease. BMC Pulm. Med. 2009, 9, 11.
184. Barreiro, E.; Rabinovich, R.; Marin-Corral, J.; Barbera, J.A.; Gea, J.; Roca, J. Chronic endurance
exercise induces quadriceps nitrosative stress in patients with severe COPD. Thorax 2009, 64,
13�19.
185. Plant, P.J.; Brooks, D.; Faughnan, M.; Bayley, T.; Bain, J.; Singer, L.; Correa, J.; Pearce, D.;
Binnie, M.; Batt, J. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease.
Am. J. Respir. Cell Mol. Biol. 2010, 42, 461�471.
186. Langen, R.C.; Haegens, A.; Vernooy, J.H.; Wouters, E.F.; de Winther, M.P.; Carlsen, H.; Steele, C.;
Shoelson, S.E.; Schols, A.M. NF-kappaB activation is required for the transition of pulmonary
inflammation to muscle atrophy. Am. J. Respir. Cell Mol. Biol. 2012, 47, 288�297.
187. Sharma, R.; Anker, S.D. Cytokines, apoptosis and cachexia: The potential for TNF antagonism.
Int. J. Cardiol. 2002, 85, 161�171.
188. Ferreira, I.M.; Brooks, D.; White, J.; Goldstein, R. Nutritional supplementation for stable chronic
obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012, 12, CD000998.
189. Planas, M.; Alvarez, J.; Garc�a-Peris, P.A.; de la Cuerda, C.; de Lucas, P.; Castell�, M.; Canseco, F.;
Reyes, L. Nutritional support and quality of life in stable chronic obstructive pulmonary disease
(COPD) patients. Clin. Nutr. 2005, 24, 433�441.
190. Sugawara, K.; Takahashi, H.; Kasai, C.; Kiyokawa, N.; Watanabe, T.; Fujii, S.; Kashiwagura, T.;
Honma, M.; Satake, M.; Shioya, T. Effects of nutritional supplementation combined with
low-intensity exercise in malnourished patients with COPD. Respir. Med. 2010, 104, 1883�1889.
191. Al-Ghimlas, F.; Todd, D.C. Creatine supplementation for patients with COPD receiving
pulmonary rehabilitation: A systematic review and meta-analysis. Respirology 2010, 15, 785�795.
192. Morimitsu, Y.; Nakagawa, Y.; Hayashi, K.; Fujii, H.; Kumagai, T.; Nakamura, Y.; Osawa, T.;
Horio, F.; Itoh, K.; Iida, K.; et al. A sulforaphane analogue that potently activates the Nrf2-
dependent detoxification pathway. J. Biol. Chem. 2002, 277, 3456�3463.
193. Meja, K.K.; Rajendrasozhan, S.; Adenuga, D.; Biswas, S.K.; Sundar, I.K.; Spooner, G.;
Marwick, J.A.; Chakravarty, P.; Fletcher, D.; Whittaker, P.; et al. Curcumin restores corticosteroid
function in monocytes exposed to oxidants by maintaining HDAC2. Am. J. Respir. Cell Mol. Biol.
2008, 39, 312�323.
194. Engelen, M.P.; Rutten, E.P.; de Castro, C.L.; Wouters, E.F.; Schols, A.M.; Deutz, N.E.
Supplementation of soy protein with branched-chain amino acids alters protein metabolism in
healthy elderly and even more in patients with chronic obstructive pulmonary disease. Am. J. Clin.
Nutr. 2007, 85, 431�439.
195. Dal Negro, R.W.; Aquilani, R.; Bertacco, S.; Boschi, F.M.C.; Tognella, S. Comprehensive effects of
supplemented essential amino acids in patients with severe COPD and sarcopenia. Monaldi Arch.
Chest Dis. 2010, 73, 25�33.
196. Varraso, R. Nutrition and asthma. Curr. Allergy Asthma Rep. 2012, 12, 201�210.

Close Accordion
Mastodon